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ABSTRACT

Background:
Studies from overseas, predominantly the USA, indicate that patients with severe
mental illness (SMI) have elevated risks for sexually transmitted infections (STIs)
and blood borne viruses (BBVs). Findings indicate a need for local research to
clarify whether there are similarly elevated risk factors, STI/BBV infections and
heightened risk for patients with SMI, in Western Sydney, Australia.

Objectives:
Identify the level of risk factors, prevalent STIs or BBVs, and correlates of infection
based on risk factor history, as well as explore the role of an SMI diagnosis. Describe
the practices and characteristics of psychiatrists caring for patients with SMI,
specifically their knowledge, attitudes, and behaviours (KAB) regarding STIs and
BBVs, as well as assess the determinants of STI/BBV testing behaviours to identify
the potential risk for patients.

Methods:
The thesis explored the risk regarding STIs or BBVs for patients with SMI with a
literature review and two studies. The systematic literature review identified potential
risk factors and aided the design of the subsequent studies.
Study One was based on structured interviews and biological samples from 95
participants with SMI, inpatients at a large psychiatric hospital, and referred to the
study by their attending psychiatrist. The study described and compared sexual and
substance use behaviours (including injecting drug use), risk partners, and other risks
(such as healthcare and incarceration), as well as the prevalence of STI and BBV
infections, based on self-report and/or biological sample result. Risks and infection
prevalence were compared to Australian population data. In addition, serology
testing and infection prevalence rates for all 1791 admitted Cumberland Hospital
patients during the study period were assessed. Descriptive, bivariate, and
multivariate analyses were conducted to assess predictors for infection risk.
Study Two, a KAB psychometric survey with Likert scales, evaluated 35
psychiatrists working in western Sydney, regarding STIs and BBVs. Descriptive
ii

comparisons with GPs and multivariate analyses of psychometric measures were
undertaken, exploring pathways to better behaviours assessing patients’ risk for
infection.

Results:
Study One found that patients with SMI had elevated risk factors (sexual, substance
use and incarceration), STI and BBV rates, and statistically significant elevated risk
compared to the Australian population, despite a small referred participant group.
Patients were at risk because of their own and their partners’ involvement in risk
behaviours. HIV (2.5%) was not as prominent, but self-reported STIs (49%), HCV
exposure (26%) and HBV exposure (16%) were significant findings. As well,
Cumberland Hospital data indicate low screening but with high overall
seroprevalence for HCV (5%) and HBV exposure (6%). Infections were not new but
many patients were unaware of past exposures or testing, indicating suboptimal
STI/BBV healthcare. HCV risk for injecting drug users was higher than injectors
from the Australian population, despite similar IDU risk activities. HCV rates and
risks were elevated for patients without an IDU history when compared to the
stratified Australian population. Elevated HCV risk was possibly associated with the
presence of SMI. At multivariate analysis HCV exposure was predicted by “IDU
ever” and “incarceration ever”. Self-reported STIs were predicted by “marijuana use
ever” or “sex ever with an IDU partner”. Patients with SMI and their partners (often
with SMI or met in hospital), may be a unique risk network, with frequent and riskier
sexual and drug use activities within this network. SMI risk may be because of
psychiatric factors, limited socialisation options and poorer access to healthcare.
Study Two, though a small KAB survey of psychiatrists, explained the poor referral
to Study One and confirmed the suboptimal STI/BBV healthcare for patients.
Participants were slightly older and specialist consultant psychiatrists compared to
the pool of available psychiatrists. Overall psychiatrists had good knowledge and
attitudes compared to general practitioners (GPs), but there was a lack of screening
behaviours for STIs or BBVs, particularly for HCV. Psychiatrists “newer” to the
specialty had better HCV knowledge and those “well-informed” reported better HCV
screening behaviours. The psychometric multivariate predictors for HCV screening
behaviours were HCV referral knowledge and attitudes to HCV patients.
iii

Conclusion:
Patients with SMI are at risk for STIs and BBVs and are likely part of a risk SMI
network with elevated risk behaviours, risk partners and STI/BBV infections. This
SMI network of inpatients may be a closed network and without current new
infections. The predominant risks in the network are substance use and incarceration
risks by individuals and their partners, and possibly an SMI diagnosis, though this
role requires further elucidation. Future studies should assess choices of IDU
partners and their risk as well as young people first diagnosed with SMI, who are at
risk for new STI or BBV diagnosis. Effective healthcare should include broader STI/
BBV education, prevention, screening and management for patients with SMI. Of
particular concern are the high HCV rates, which will add to patients’ health burden
with possible liver disease. SMI creates a unique risk network, deserving
consideration as a priority group and requiring targeted and holistic healthcare.

iv

RELEVANT MANUSCRIPTS AND CONFERENCE
PRESENTATIONS IN THE COURSE OF THE CANDIDATURE
Manuscripts:
1. Lagios K. Deane FP. Psychiatrists’ knowledge and practices in screening and
assessment of Hepatitis C for inpatients with severe mental illness. Australasian
Psychiatry2011; 19(2):156-9. (Comparative Study)

2. Lagios K. Deane FP. Severe mental illness is a new risk marker for blood-borne
viruses and sexually transmitted infections. Australian and New Zealand Journal of
Public Health2007; 31(6):562-6. (Comparative Study)
3. Lagios K. Deane FP. Response to “Blood borne viral and sexually transmissible
infections among psychiatric populations: what are we doing about them?”
Australian and New Zealand Journal of Psychiatry 2006; 40(9):815. (Letter)

Conference Presentations:
Lagios, K. and F.P. Deane, Sex at Cumberland: The Risk of Sexually Transmitted
Infections and Blood Borne Viruses For Patients With Severe Mental Illness.
POSTER in; Australasian Society of Infectious Diseases, 2012, Fremantle, Australia.

Lagios, K. and F.P. Deane, Sex at Cumberland: The Risk Of Sexually Transmitted
Infections And Blood Borne Viruses For Patients With Severe Mental Illness, ORAL
PRESENTATION in Australasian Sexual Health Conference 2009. Brisbane, Aus.
Lagios K. Deane FP. Mental Health Care Workers’ knowledge, attitude and practices
in screening and assessment for STIs and BBVs. POSTER, in Australasian Sexual
Health Conference 2009. Brisbane, Australia.

Lagios, K. and F.P. Deane, Sex at Cumberland: The Risk Of Sexually Transmitted
Infections And Blood Borne Viruses For Patients With Severe Mental Illness, ORAL
PRESENTATION in Australian and New Zealand Psychiatry Congress 2008.
Melbourne, Australia.
v

ACKNOWLEDGEMENTS

I would like to acknowledge with gratitude the contribution of the following people
and organizations that helped me make this study possible.

I wish to express gratitude to my supervisor, Professor Frank Deane, for his guidance
and support throughout my candidature, for his inspiration, critical powers and ongoing
encouragement. He has been an inspiring mentor, challenging my ability and capacity to
conduct research and produce academic writing.

Dr Karen Bythe-Wilson, epidemiologist, Division of Medicine, Westmead Hospital,
for immense help and evaluation of my statistical calculations.

Professor Tania Sorrell from Infectious Diseases Westmead Hospital and Dr Peter
Tucker and then Dr Mayur, from Cumberland Hospital, for peer support and
encouragement as well as financial support for pathology testing.

I would like to acknowledge the patients and staff at Cumberland Hospital who have
contributed and enabled this research project.

I wish to thank my parents Maria and Fotios Lagios, as well as my siblings Gina and
Peter, for providing spiritual and emotional support.

My special thanks and dedication are to my immediate family, my children Milica,
Nikolas and Hristofor who have had to endure the whole research process, and
hopefully may find that this is a challenge they too can achieve and enjoy in their
adult years. And lastly to my beloved husband Darko Kukic for his love,
understanding, tolerance, support and encouragement and unfailing confidence in my
capability, allowing completion of this thesis.

vi

TABLE OF CONTENTS
THESIS CERTIFICATION…………………………………………………………....……
ABSTRACT ……………………………………..………………………………….…..…..
RELEVANT MANUSCRIPT AND CONFERENCE PRESENTATION IN THE
COURSE OF THE CANDIDATURE………………………………………….….………..
ACKNOWLEDGEMENTS ………………………………………………………………....
TABLE OF CONTENTS……………………………………………………….….…….......
LIST OF APPENDICES……………………………………………………………….…....
LIST OF TABLES…………………………………………………………….……….....….
LIST OF FIGURES…………………………………………………………….………..…..
ABBREVIATIONS……………………………………………………….…………………

CHAPTER ONE
INTRODUCTION AND OVERVIEW OF THE RESEARCH……………….…..…..
CHAPTER TWO
SEXUAL AND MENTAL HEALTH IN AUSTRALIA………………………….....…....
2.1
2.2
2.3
2.4

2.5
2.6
2.7
2.8

INTRODUCTION…………………………………………………………………………………....…..
SEXUAL HEALTH IN AUSTRALIA……………………………………………………………...…....
SEXUALLY TRANSMISSIBLE INFECTIONS AND BLOOD BORNE VIRUSES……………...…...
RISK FACTORS FOR STIs AND BBVs…………………………………………………………....……
2.4.1
Risk at the Individual Level……………………………………………………………………..
2.4.1.1 Sexual risk behaviour…………………………………………………………...……
2.4.1.2 Substance use risk behaviour……………………………………………………..….
2.4.1.3 “Other” risk factors…………………………………………………………………..
2.4.2
Risk at the Partner Level………………………………………………………………….…..…
2.4.3
Risk at the Community Level ……………………………………………………………..……
MENTAL HEALTH IN AUSTRALIA…………………………………………………………..…….…
SEVERE MENTAL ILLNESS ………………………………………………………………….…….…
RISK FACTORS FOR SMI……………………………………………………………………….….….
RISKS FOR SMI AND RISKS FOR STIS AND BBVS……………………………………….…….….

CHAPTER THREE
LITERATURE REVIEW: STUDIES ASSESSING STI & BBV RISKS…………….
3.1
3.2
3.3

3.4

INTRODUCTION……………………………………………………………………………….….….
AIMS and OBJECTIVES……………………………………………………………………….….…..
REVIEW PROCEDURES………..…………………………………………………………………….
3.3.1 Review – The risk of STI and BBVs for patients with SMI………………………………….…..
3.3.2 Review - Healthcare Workers’ Assessment of STIs & BBVs………………………………..…..
FINDINGS THE RISK OF STI AND BBVS FOR PATIENTS WITH SMI ………………….………
3.4.1. Prevalence of STI and BBV risk factors for patients with SMI……………………………….
3.4.1.1 Sexual risk behaviours………………………………………………………………
3.4.1.2 Sexual risk partners…………………………………………………………….……

vii

i
ii
v
vi
vii
xi

xii
xiv
xv

1

5
5
5
7
13
14
14
15
15
16
20
21
22
24
25

28
28
28
29
29
31
32
32
33
33

3.4.1.3
3.4.1.4

37
37
39
39
41
42

FINDINGS - HEALTHCARE WORKERS RISK ASSESSMENT OF STIs AND BBVs………..…..…
DISCUSSION……………………………………………………………………………………..…..….
CONCLUSION……………………………………………………………………………………...…....

44
47
50

3.4.3

CHAPTER FOUR
STUDY ONE: THE RISK OF STIs & BBVs FOR INPATIENTS WITH SMI…….…..
4.1
4.2
4.3

51

OVERVIEW OF STUDY ONE………………………………………………………………………….
AIMS, OBJECTIVES AND HYPOTHESES…………………………………………………………....
METHOD…………………………………………………………………………………………………
4.3.1
Ethical Issues…………………………………………………………………………….…...…
4.3.2
Procedure…………………………………………………………………………………..……
4.3.3
Study Participants……………………………………………………………………………….

51
52
53
54
56
59

Measures……………………………………………………………………………………..….
4.3.4.1 Bias in Risk Behaviour Measurements…………………………………………..…..
4.3.4.2 Measuring Risk Factors………………………………………………………….…..
4.3.4.3 Measuring Partners and Networks………………………………………………..….
4.3.4.4 Measuring STIs and BBVs…………………………………………………………..
Statistical Issues…………………………………………………………………………….…..

61
63
65
67
68
69

RESULTS…………………………………………………………………………………………….…..
4.4.1
Comparison and representativeness of study participants………………………………….…..
4.4.2
Sexual Risk Behaviours……………………………………………………………………..….
4.4.2.1 Sexual Identity and Experience…………………………………………………..…..
4.4.2.2 Sexual Activities…………………………………………………………………….
4.4.2.3 Number of Sexual Partners Ever……………………………………………………..

72
72
73
73
75
76

4.4.2.4 Number of Sexual Partners in the last 12 months……………………………………
4.4.2.5 Sex after Drug or Alcohol Use…………………………………………….……..….
4.4.2.6 Sex and Condom Use……………………………………………………….…..……
Sexual Risk Partners………………………………………………………………….………....
4.4.3.1 Sex and Regular Relationship………………………………………………………..
4.4.3.2 Sex and Partner at Last Sexual Encounter.………………………..…………………
4.4.3.3 Sex with Partners at Risk ….………………………………………………………...
4.4.3.4 Sources of Sexual Contacts……………………………………………………….….
4.4.3.5 Sex for Favours or Payment ………………………………………….….……….….
4.4.3.6 Sexual Partner with Drug or Alcohol Issues ………………………….…….…..…..
4.4.3.7 Sexual Coercion…………………………… ………………………….…….…..….
Substance Use Risk Behaviours…………………………………………………………….….
4.4.4.1 Illicit Drug Use………………………………………………………………….……

77
78
78
78
79
79
80
81
81
82
82
83
83

4.3.4

4.3.5
4.4

34
34

Prevalence of STI and BBV infections for patients with SMI………………………….….…..
3.4.2.1 Prevalence of STIs and HCV…………………………………………………..……
3.4.2.2 Prevalence of HIV…………………………………………………………………..
The extent that patients with SMI are at risk for STIs and BBVs………………………..….…
3.4.3.1 Risk of HCV or HBV for patients with SMI stratified by IDU ………………..……
3.4.3.2 Risk of HIV for patients with SMI stratified by IDU and MSM……………………..

3.4.2

3.5
3.6
3.7

Substance use risk behaviours………………………………………………………
“Other” risk factors…………………………………………………………….……

4.4.3

4.4.4

viii

4.4.4.2 IDU and Blood Exposures…………………………………………………….…...…
“Other” Risk Factors – Screening, Vaccinations, Tattoos and Incarceration……………….…..

84
84

Prevalence of STIs and BBVs…………………………………………………………………..
4.4.6.1 STI and BBV Prevalence from Self-reported STI/BBV History……………..…..…
4.4.6.2 STI and BBV Prevalence from Biological Sample Tests…….……………..….....…
4.4.6.3 STI and BBV Results of all Cumberland Hospital patients……………………...…..
Stratification Analysis: Risk for HCV stratified by IDU risk history……………………..……
Bivariate Analysis: Prevalence of STIs and BBVs for patients according to risk history……...

85
85
86
87
89
91

4.4.9
Multivariable Analysis: Risks for HCV exposure and Self-reported STIs……………..…….…
DISCUSSION…………………………………………………………………………………………….
OVERALL STRENGTHS AND LIMITATIONS………………………………………………….….…
CONCLUSION………………………….………………………………………………………………..

95
97
99
100

4.4.5
4.4.6

4.4.7
4.4.8
4.5
4.6
4.7

CHAPTER FIVE
STUDY TWO: PSYCHIATRISTS’ KNOWLEDGE, ATTITUDES & BEHAVIOURS
IN ASSESSMENT & MANAGEMENT OF STIs & BBVs……………………………...
5.1
5.2
5.3

OVERVIEW OF STUDY TWO…………………………………………………………….…..……….
AIMS, OBJECTIVES and HYPOTHESES………………………………………………….…..…..….
METHOD……………………………………………………………………………………...….….….
5.3.1
Procedure…………………………………………………………………………….…..…..…

101
101
104
105
105

Study Participants ………………………………………………………………………….….
Measures………………………………………………………..…………………………...…
5.3.3.1 Demographics and Descriptive STI/BBV Domain……………………………..…..
5.3.3.2 Measuring Knowledge....…………………………………………………….….….
5.3.3.3 Measuring Attitude……………………………………………………………..…..
5.3.3.4 Measuring Behaviour………………………………………………………….……

106
107
109
109
111
112

5.3.3.5 Bias in KAB Surveys Assessing Doctors Psychiatrists………..……………………
5.3.4
Statistical Issues……………………………………………………………………………..…
RESULTS……………………………………………………………………………………….…..…..
5.4.1
Descriptive STI/BBV Domain Results………………………………………………….…..…
5.4.2
Knowledge Domain Results…………………………………………………………….….….
5.4.2.1 Knowledge STI/BBVs Asymptomatic ………………………………………..…….

113
115
116
116
117
117

5.4.2.2 Knowledge STI/BBVs Epidemiology ………………………………..…….….……
5.4.2.3 Knowledge HCV Epidemiology ………………………………………………..…..
5.4.2.4 Knowledge HCV Referral ……………………………………………….………....
5.4.2.5 Knowledge HCV Management ………………………………………………..……
5.4.2.6 Knowledge Domain Differences…………………………………………………….
Knowledge of Psychiatrists compared with other researched groups……………….………....
Attitudes Domain Results………………………………………………………………..…..…
5.4.4.1 Attitude Barriers STI/BBV History …………………….………………….……….
5.4.4.2 Attitude Treating Patients with HCV ……………….…………………….………..
5.4.4.3 Attitude Domain Differences…………………………………………………..…...
Attitudes of Psychiatrists compared with other researched groups…………………….…..….
Behaviour Domain Results……………………………………………..………………..…….
5.4.6.1 Behaviour STI/BBV History Taking…………………………………..…….….….

117
118
118
118
119
119
123
123
123
124
124
125
125

5.3.2
5.3.3

5.4

5.4.3
5.4.4

5.4.5
5.4.6

ix

5.4.6.2
5.4.6.3

5.4.7
5.4.8
5.4.9
5.5
5.6
5.7

Behaviour STI/BBV Post-test Management..…………………………………....…
Behaviour HIV Pre-test Screening ……………………………………..…………..

126
126

5.4.6.4 Behaviour HCV Pre-test Screening ………………………………………………..
126
5.4.6.5 Behaviour Domain Differences…………………………………………….……....
127
Behaviour of Psychiatrists compared to other researched groups…………………….….....…
127
Bivariate Analysis: The relationship between doctor characteristics and Knowledge, Attitudes and
Behaviours………………………………………………………………...………………….....
128
Multivariable Analysis: The relationship of Knowledge and Attitude to Behaviour………..….
129

DISCUSSION………………………………………………………………………………….….…..….
OVERALL STRENGTHS AND LIMITATIONS……………………….……………………….…....…
CONCLUSION……………………………………………………………………………………….…..

132
134
135

CHAPTER SIX
DISCUSSION………………………………………..…………………………………………….…...…..

136

INTRODUCTION………………………………………………………………………………………..
INTEGRATION OF STUDIES’ AIMS HYPOTHESES and FINDINGS ……………………........…..
UNDERSTANDING WHY PATIENTS WITH SMI ARE AT RISK …………………….…..………..
6.3.1 Risks for Patients with SMI at the Individual level……………………………………………..
6.3.1.1 Elevated Risk associated with Risk Factors..…………………………………………..
6.3.1.2 Elevated Risk associated with STI and BBV Infections.……………………………….

136
136
137
138
138
142

6.3.1.3 Elevated Risk associated with SMI……………………………………………….….....
6.3.2 Risks for Patients with SMI at the Partner and Community Level ………………………….….
6.3.2.1 SMI Risk Network………………………….……………………………………….….
6.3.2.2 SMI in the Community……………………..……………………………………….….
6.3.2.3 Patient Healthcare Provider Networks …………………………………………………
CONCLUSION…………………………………………………….. …………………….…..…….…..

144
145
145
147
147
147

6.1
6.2
6.3

6.4

CHAPTER SEVEN
CONCLUSIONS AND RECOMMENDATIONS………………………………………...…..
7.1 IMPORTANCE OF FINDINGS…………………………………………………………………….....
7.2 PUBLIC HEALTH IMPLICATIONS……………………………………………………….………...
7.3 RECOMMENDATIONS…………………………………….…………………………………………
7.3.1 Primary Prevention – Education and Harm Minimisation ………………………………………..
7.3.2 Secondary Prevention - Improved Patient Clinical Care……………..…………………………..
7.3.3 Tertiary Prevention - Integrated Clinical Care Services……………………..……………………
7.4 FUTURE RESEARCH……………………………………………………………………………...….
7.5 CONCLUSION…………………………………………………………………………...............…….

148
148
149
152
153
154
155
157
158

REFERENCES…………………………………………………………………………..

160

APPENDICES….…………………………………………………………………….…..

174

x

LIST OF APPENDICES
Appendix 1:
Study One: Ethics Approval - Risk of STIs & BBVs For Patients with SMI……………..174

Appendix 2:
Study One: Participant Information Sheets & Consent Forms………….............................179

Appendix 3:
Study One: Questionnaire……………………………………………………….……….…189

Appendix 4:
Study Two: Ethics Approval - Psychiatrists’ KAB of STIs and BBVs…………..….….....197

Appendix 5:
Study Two: Participant Information Sheet………………………………………...…….....200

Appendix 6:
Study Two: Questionnaire……………………………………………………….…………202

xi

LIST OF TABLES

Table 2.1

Descriptions of notifiable STIs and BBVs……………………………….….

Table 3.1

Risk Factors for patients with severe mental illness and the

12

general population…………………………………………………………...

35

Table 3.2

Prevalence of STIs and HCV in patients with severe mental illness………..

38

Table 3.3

Prevalence of HIV infection in patients with severe mental illness………..

40

Table 3.4

Rates of HCV exposure stratified by IDU history and groups - patients with
SMI and the US population, from Rosenberg et al (2001)…………………

Table 3.5

41

Rates of HBV exposure stratified by IDU history and groups - patients with
SMI and the US population, from Rosenberg et al (2001)………………….

42

Table 3.6

Risk of HIV according to Risk Behaviours for patients with SMI…………

43

Table 4.1

Comparison of Sexual Identity and Experiences……………………………

73

Table 4.2

Comparison of Sexual Activities……………………………………………

75

Table 4.3

Comparison of Number of Opposite-sex partners Ever (excludes sex work).

76

Table 4.4

Comparison of Number of Opposite-sex partners in the last 12m
(excludes sex work)………………………………..……………………….

77

Table 4.5

Comparison of rates of Condom Use ……………………………………….

78

Table 4.6

Comparison of Regular Relationships………………………………………

79

Table 4.7

Comparison of Partner at Last Sexual Encounter…………………….……..

80

Table 4.8

Description of Risk history of Sexual Contacts Ever……….…..…………

81

Table 4.9

Comparison of Experiences of Sex Work for Women……………….……

82

Table 4.10

Comparison of Experiences of Sexual Coercion Ever…………….……….

83

Table 4.11

Description of Drug usage ever and in the last 12 months…………………

83

Table 4.12

Comparison of IDU and Sharing Activities..……………………………….

84

Table 4.13

Comparison of “Other” Risk Factors – Tattoos, Body Piercing
and Incarceration…………………………………………………………….

85

Table 4.14

Comparison of Self-reported STI/BBV rates………………………………

86

Table 4.15

Description of Biological Sample - BBV and STI rates for study sample…

87

Table 4.16

Description of BBV and STI rates for study sample compared to
Cumberland Hospital………………………………………………………..

89

Table 4.17

Comparison of Drug Use in the last 12 months by Injecting Drug Users…...

90

Table 4.18

Comparison of HCV risk by IDU Risk Activities for Injecting Drug Users..

90

xii

Table 4.19

Risk for HCV stratified by IDU History and SMI……………….…………

91

Table 4.20

Bivariate Associations between HCV rates and Risk Factors………………

92

Table 4.21

Bivariate Associations between HBV rates and Risk Factors………………

93

Table 4.22

Bivariate Associations between self-report STI Rates and Risk Factors……

94

Table 4.23

Logistic regression to assess predictors of HCV exposure..………………..

95

Table 4.24

Logistic Regression to assess predictors of self-reported STI history……

96

Table 5.1

Summary of Knowledge Domain…………………………………………..

Table 5.2

Comparison of Knowledge Items with Correct Responses for different

117

participant groups……………………………………………………………

121

Table 5.3

Summary of Attitude Domain..……………………………………………..

124

Table 5.4

Comparison of Attitudes to Barriers re STI/BBV History…………………..

125

Table 5.5

Summary of Behaviour Domain……………………………………….……

126

Table 5.6

Comparison of Behaviours of Psychiatrists and GPs ……………………….

128

Table 5.7

Spearman’s Correlation coefficients and significance tests for

Table 5.8

STI/BBV subscales………………………………………………………….

130

Spearman’s Correlation coefficients and significance tests for HCV

130

Subscales…………………………………………………………………….
Table 5.9

Summary of standard multiple regression variables predicting self reported
Behaviour of HCV Pre-test Screening………………………………...…….

xiii

132

LIST OF FIGURES

Figure 2.1:
Conceptual model of the integration of population and individual level
factors in the study of epidemics of sexually transmitted infections and HIV……13

Figure 4.1:
Map Cumberland Hospital, Western Sydney, Australia…………………………..56

Figure 4.2:
Participant Flow Chart for Patient Involvement in Study One…………….………60

Figure 5.1:
Participant Flow Chart for Psychiatrist Involvement in Study Two……………….106

xiv

ABBREVIATIONS

AI

Anal Intercourse

AIDS

Acquired immuno-deficiency syndrome

AIVL

Australian Injecting and Illicit Drug Users League

ASHR

Australian Study of Health and Relationships: Sex in Australia

BBV

Blood Borne Virus

CATI

Computer assisted telephone survey

CDC

Centre for Disease Control and Prevention

D&A

Drug and Alcohol

GP

General Practitioner

ICPMR

Institute for Clinical Pathology and Medical Research

HAV

Hepatitis A virus

HBV

Hepatitis B virus

HCV

Hepatitis C virus

HIV

Human immunodeficiency virus

HPV

Human papilloma virus

HSV

Herpes simplex virus

Hx

History

KAB

Knowledge Attitude Behaviour

LSE

Last Sexual Encounter

MSM

Men-who-have-Sex with Men OR Male-to-Male Sex

NHMRC

National Health and Medical Research Council

NSP

Needle and Syringe Programme

NSW

New South Wales

OI

Oral Intercourse

RANZCP

Royal Australian and New Zealand College of Psychiatrists

SMI

Severe Mental Illness

STD

Sexually Transmitted Diseases

STI

Sexually Transmitted Infection

SWAHS

Sydney West Area Health Service

VI

Vaginal Intercourse

xv

CHAPTER ONE
Introduction and Overview of the Research
This thesis explores the risk of sexually transmitted infections (STIs) and blood
borne viruses (BBVs) for patients with severe mental illness (SMI), in an acute care
psychiatric inpatient setting of western Sydney, Australia.

There is a systematic literature review and two research studies comprising this
thesis. The literature review assesses the situation and sets the scene for the research.
Whereas Study One is an investigation of patients’ risks and Study Two investigates
the approach of doctors working in psychiatry, to this risk.

Severe mental illness is a significant health burden both directly and indirectly. An
Australian study concluded that for patients with severe mental illness, there is “…a
picture of excessive risks of all major physical illnesses in such a marginalised and
vulnerable group of our population, and (which) raise serious questions of equity in
healthcare provision for the mentally ill” (Lawrence, Holman, & Jablensky, 2001, p.
12). Severe mental illness has a serious impact on a person's ability to function
effectively over a long period, and contributes to a lack of autonomy and poor
socialisation. Psychiatric illness is associated with other significant physical ill health
as a consequence of lifestyle choices, such as smoking, or metabolic syndrome which
occurs with antipsychotic medication side effects as well as lifestyle choices (Cohn
& Sernyak, 2006a).

Patients with SMI, as a vulnerable group, may experience other significant health
disorders such as STI and BBV infections. Overseas studies have shown risks of
infections such as human immunodeficiency virus (HIV) and hepatitis C virus
(HCV) amongst people with SMI (Rosenberg, Goodman, Osher, Swartz, Essock et
al., 2001). Retrospective studies suggest that patients with SMI have had higher
levels of other sexually transmitted infections. Persons with SMI are at risk of
acquiring infections that are blood borne or contracted through sexual contact,
because of risk behaviours (Davidson et al., 2001; Lawrence et al., 2001; Thompson
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et al., 1997). Potential STI or BBV epidemics amongst the severely mentally ill
population can only add to their health burden (Hercus, Lubman, & Hellard, 2005;
Lawrence et al., 2001).

STI or BBV infections that may add to the health burden for patients with SMI
should be circumvented, with assessment and management of the potential risk.
Review of the extent and types of risk that patients with mental illness have for STI
and BBV infections is paramount for successful risk prevention. An appraisal and
analysis of the existing literature and published reports has identified key risk factor
issues, as well as provided guidance for the two research studies undertaken as part
of this thesis (Eagar, Garrett, & Lin, 2001; Lambert, Velakoulis, & Pantelis, 2003).
These key risk issues, such as risk behaviours, risk networks and prevalence of
infections, require an understanding of the epidemiology of STIs and BBVs and
associated risk factors, both globally and for Australia. The prevalence and effects of
mental health disorders need to be understood to appreciate the context of mental
illness for an individual and the impact the mental illness has for an individual’s
risky behaviour. Some of the effects, or sequelae, of mental health disorders, such as
illicit drug use, overlap with the risk factors for STIs and BBVs. There is also a need
to explore the associations between risk factors and infections for patients with
severe mental health disorders.

For inpatients with SMI, doctors working in psychiatry play a potentially critical role
in supporting their patients’ sexual health as well as mental health. Doctors working
in psychiatry are key healthcare providers in the hospital setting and a review of their
knowledge, attitudes and behaviour practices regarding STIs and BBVs would help
in planning better assessment, treatment and support for patients.

This thesis and research stems from the researcher providing monthly sexual health
clinical services to patients at a large urban psychiatric hospital, as a sexual health
physician. Anecdotal observations suggested a high frequency of both risk
behaviours and infections in this population and limited healthcare for such
problems. Research was needed to provide data that would guide the direction of
future planning of health services and prevention programmes.
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Study One of this thesis, aimed to identify the risks for STIs and BBVs for inpatients
with SMI. It was conducted in Australia, and is the first to explore rates of notifiable
STIs and BBVs. It explored a wide range of risk factors including risk partners, as
well as the prevalence of STIs and BBVs.

Study Two of this thesis, explored the knowledge, attitudes and behaviour of doctors
working in psychiatry toward assessment and management of STIs and BBVs, and
especially HCV. The study attempted to look at the factors involved in identification
of risks, if present, for patients.

This thesis has six chapters. Chapter One (this chapter) provides the introduction and
overview to the thesis and outlines the motivation and requirements for the research
study. In Chapter One, each chapter is briefly described to provide guidance through
the thesis.

Chapter Two, provides background information regarding sexual and mental health
issues in Australia. It describes STIs, BBVs and associated risks at various levels
including the role that risk factors and risk partnerings play in transmission
dynamics. Current public health problems such as specific infections and risk groups
may be important for patients with SMI, are described. Chapter Two, describes SMI
and relevant Australian epidemiology and provides an overview of the sequelae of
SMI, the environment of a psychiatric ward for patients and the role of the
psychiatrist in a hospital setting (Lelliott, 2006; Quirk, Lelliott, & Seale, 2006), that
may add to risk.

Chapter Three provides a literature review and analysis of prior research examining
(i) the risk of STIs and BBVs in patients with SMI and (ii) healthcare workers
assessment of STIs and BBVs for patients with SMI. It discusses previously
investigated risk behaviours, risk partnerings and levels of infections and explores
the extent of risk for an STI or BBV accompanying a diagnosis of SMI. The second
part of the review identifies from Knowledge, Attitude and Behaviour (KAB)
Surveys, the assessment practices of groups, such as GPs.
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Chapter Four provides aims, methods, results, discussion including strengths and
limitations for Study One. Study One is a cross-sectional-analytic study of risk for
STIs and BBVs for inpatients with SMI. This is the first Australian study to widely
assess risk factors and infection prevalence rates for patients with SMI. A
comparison of the findings for this small group with SMI, with Australian population
data is made for each set of results. The discussion summarises findings based on
objectives and compares findings with previous research. Discrepancies are
highlighted in order to help identify future recommendations in improving the health
for patients with SMI.

Chapter Five covers the aims, methods, results, discussion including strengths and
limitations for Study Two. This study explores the knowledge, attitudes and
assessment behaviours of doctors working in psychiatry, toward their patients with
respect to STI and BBV risk. There have not been prior Australian studies that
explore the knowledge, attitudes and behaviour of key healthcare workers, such as
psychiatrists, regarding STIs and BBVs and their perspective may be important
regarding risk for patients. Here too a summary of the objectives, including a
comparison of findings with other researched groups, is provided in the discussion.

Chapter Six integrates the findings across the two studies and links the aims of the
study and background literature. Major patterns, trends and generalizations,
including the likely mechanisms underlying these patterns are discussed. The chapter
concludes with implications of the present results for other unanswered questions
regarding healthcare requirements.

Chapter Seven concludes the thesis and provides recommendations regarding the
potential public health impact of findings. Suggestions for future research are made,
as well as applicability and extension of recommendations to psychiatric healthcare
settings.
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CHAPTER TWO

Sexual and Mental Health in Australia

2.1

INTRODUCTION

This chapter focuses on the sexual health disorders of sexually transmitted infections
(STIs) and Blood Borne Viruses (BBVs) and the mental health disorders termed
severe mental illness (SMI) in Australia. Definitions and epidemiology, including
risks, for these two groups of disorders are reviewed. At the end of this chapter there
is an exploration of the overlap for these two significant health problems as they may
occur in the hospital setting of the psychiatric ward, providing an understanding of
the ongoing risk for patients and the interest for this thesis.

2.2

SEXUAL HEALTH IN AUSTRALIA

To identify a sexual health disorder an understanding of sexual health is needed,
which has been defined as
“…a state of physical, emotional, mental and social well-being related to sexuality
(how people experience and express themselves as sexual beings); it is not merely
the absence of disease, dysfunction or infirmity. Sexual health requires a positive and
respectful approach to sexuality and sexual relationships, as well as the possibility of
having pleasurable and safe sexual experiences, free of coercion, discrimination and
violence. For sexual health to be attained and maintained, the sexual rights of all
persons must be respected, protected and fulfilled…” (WHO, 2002, p. 5).
Sexual health is a broad concept and refers not only to “the health of reproductive
organs but also to the psychological, emotional and relationship aspects of sexual
behaviour” (Australian Institute of Health and Welfare (AIHW), 2000, p. 38). An
individual’s ability to have safe, as well as satisfying sexual experiences can be
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impacted by sexual health disorders relating to infection, sexuality, sexual function
and relationships.

Sexual health disorders encompass a diverse number of pathological conditions as
well as infections. This includes infections such as STIs (e.g. chlamydia) or BBVs
(e.g. hepatitis C virus (HCV)) (Centers for Disease Control and Prevention, 2006b),
unintended pregnancy and abortion, pregnancy complications, infertility and chronic
pain or cancer resulting from STIs and BBVs. It is important to note that some
infections can affect sexual health, but may not usually be deemed sexually
transmitted, such as HCV (which is a BBV) and tuberculosis. One’s sexual health
can also be influenced by mental health problems, acute and chronic physical
illnesses, as well as psychological, social or economic problems, such as
experiencing violence (WHO, 2002). The issues of sexuality, sexual functioning,
gender, safety and autonomy must also be included when considering sexual health.
The ability to have safe and satisfying sex is impaired in the presence of an infection,
fear of acquisition of an infection, fear for safety or fear of possible complications
such as infertility and chronic pain. For persons with a mental illness these fears may
be compounded. Persons with mental illness have the dilemma of a chronic mental
health problem adversely affecting their autonomy, safety, social skills and
relationships. As well as the effects of their illness, their sexual health is affected by
associated psychiatric medical therapy, with ensuing sexual health problems such as
sexual dysfunction (Ross, 1999). As such some researchers have stated that sexual
activity for a person with a mental illness is infrequent (Akhtar & Thomson, 1980),
and impaired (Gupta, Andreason, Arndt, Flaum, Hubbard et al., 1997), and may not
be a prominent activity for patients with SMI. Part of this thesis is to explore such
assumptions of the level of sexuality. Although this thesis focuses on STI and BBV
infections, the researchers are mindful of the full impact that infections may have on
sexual health for patients with SMI.

6

2.3 SEXUALLY TRANSMITTED INFECTIONS and BLOOD BORNE
VIRUSES

Sexually Transmitted or Transmissible Infections (STI) and Blood Borne Viruses
(BBVs), are infections of human beings that can be acquired by sexual transmission,
blood contact or transmitted vertically from mother to child at birth. Infections that
can be sexually acquired and most often diagnosed in developed countries, such as
Australia, include gonorrhoea, chlamydia, hepatitis B (HBV), HIV, herpes simplex
virus (HSV), human papillomavirus (HPV) that causes genital warts, trichomoniasis,
scabies, pubic lice and molluscum (Centers for Disease Control and Prevention,
2010; Sexual Health Society of Victoria, 2008). Some infections transmitted by
contact with infected blood, which can occur with injecting drug-sharing situations,
are categorised as BBVs and include HIV, HBV and HCV. There can be overlap in
the modes of transmission and some infections are more effectively transmitted by
one mechanism compared to another. STI and BBV infections may be regarded as
those that are mostly derived from intimate social interactions such as sexual
intercourse or injecting drug use. Wasserheit and Aral (1996) have noted in regard to
STIs that “…(these) ... Pathogens that have been sufficiently diabolical to link their
transmission to an act that is essential to survival of the human species, sex...”
making control difficult. BBV infections occurring with illicit injecting drug use are
a relatively recent phenomenon of the 20th century, resulting from completely
nonessential behaviours and, theoretically should be more readily controllable.

Notifiable STI and BBV infections in New South Wales (NSW), Australia, are
chlamydia, gonorrhoea, syphilis, donovanosis (which is rare), HBV, HIV and HCV
as directed by legislation (NSW Parliament, 1991). This legislation requires deidentified notification of confirmed infections to NSW Health by all pathology
laboratories. In NSW, doctors report only clinical disease states of STI or BBV
infections such as acute hepatitis, early syphilis and acquired immunodeficiency
syndrome (AIDS). Other Australian states may have reports of confirmed infections
from both laboratories and doctors. Laboratory notifications, rather than doctor
notifications, overall provide a better surveillance of the epidemiology of STIs in the
different states of Australia (Blogg & Trent, 1998; Staff, Lawrence, Lui, Maywood,
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& Sathananadan, 2004). The notifiable STIs and BBVs are those most prevalent,
easily identified from a diagnostic pathology test and notification is considered
necessary for their prevention and control. As infections with public health
consequences they receive greater public health attention and public funds.
Surveillance of notifiable infections helps “…measure disease trends, assess the
effectiveness of control and prevention measures, identify populations or geographic
areas at high risk, allocate resources appropriately, formulate prevention strategies,
and develop public health policies”(Centers for Disease Control and Prevention,
2011b, p. 2). There are other STIs that are not notified either because they cannot be
easily identified in the laboratory, do not have an effective intervention or pose less
of a public health threat, despite being prevalent (e.g. HSV, HPV and trichomoniasis
infection). Study One of this thesis will examine the frequency of notifiable STIs and
BBVs for patients with SMI.

The epidemiology of STIs and BBVs describes the patterns and risks for these
infections and considers both the risk in acquiring and the risk in transmitting
infection. Inherent in determining epidemiology is transmission dynamics – the
description of how infections spread through the population influenced by risks at the
individual, partner and community levels and creating unique transmission dynamics
for each infection-population coupling (Garnett, 2008). Section 2.3 “Risk Factors for
STIs and BBVs”, expands on risks and transmission dynamics. Many of these STI
and BBV infections pose public health problems, occurring frequently and widely,
with significant morbidity and mortality. There are effective prevention measures
and therapies available that can minimise disease and the impact on patients and
society. Prevention may be at different levels, for example primary; avoiding initial
infection, such as with the use of condoms. Prevention may be secondary, with
treatment and elimination of infection prior to disease or transmission, as occurs with
screening. Lastly tertiary prevention, which attempts to eliminate or manage an
infection causing disease, may be the only measure available. An example is HIV
treatment to minimise HIV virus load and subsequent transmission risk.

In Australia, risk is unevenly distributed. Men-who-have-sex-with-men (MSM) have
had higher rates of STI and BBV infections as well as persons from an Indigenous
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background (Miller, Law, Torzillo, & Kaldor, 2001) (National Centre in HIV
Epidemiology and Clinical Research, 2007), though in recent years declining rates
have been reported for Indigenous groups (Huang, Torzillo, Hammond, S.T, &
Kirby, 2008). Other key groups with high prevalence rates of infection, depending on
the type of STI or BBV, include young people, injecting drug users (IDU), sex
workers and some heterosexual immigrants. MSM are at risk for HIV, gonorrhoea
and syphilis. Young people are at risk for chlamydia, IDUs are at risk for HCV, sex
workers may be at risk of all infections and heterosexuals who are immigrants from
some high prevalence countries are at risk for HIV or HBV (NSW Department of
Health, 2006a, 2006b, 2007).

Infections have biological differences that add to the risk picture and consideration
of the biology of the infecting organism and the immunology of the vulnerable
person, infection synergy and preventative health measures is needed to assess risk.
The biological risk factor of infection transmission is enhanced in the presence of
another infection or impaired immunity. Mayaud et al (2001) have proposed a model
explaining the relationship of STIs with HIV. HIV with immune suppression
modifies the duration and severity of other infections in an individual and adds to
transmission risk allowing a larger HIV inoculum to be present and transmitted and
for other infections to be readily acquired (Jin, Prestage, Matthews, Zablotska,
Rawstorne et al., 2010). Likewise STIs that cause ulceration and inflammation
enhance HIV acquisition at the mucosal surface. An illustrative example is the
extensive HIV epidemic in Sub-Saharan Africa which can be understood by the
combination of communities with high STI and BBV rates, immune suppression and
concurrent partnerships (Doherty, 2011). In recent years, many governments have
given some priority to STIs only because of their potential interaction with enhanced
transmission for HIV (Commonwealth of Australia, 2005; Renton, Whitaker, &
Riddlesdell, 1998). It seems that even HCV exposure may also facilitate the spread
of HIV, and both infections magnifying public health problems (Polis, Shah,
Johnson, & Gupta, 2007).

For some infections, the mode of exposure plays a biological role in transmission.
Though transmission dynamics of BBVs have been less studied, it has been
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documented that infections such as HCV and HBV, are more efficiently transmitted
by blood-to-blood contact than is HIV (MacDonald, Crofts, & Kaldor, 1996). The
risk of HIV acquisition by percutaneous mode is well under 1% whereas both HBV
and HCV may have a high risk of up to 30% (MacDonald et al., 1996). As HCV is
more efficiently transmitted through blood contamination it has not been deemed an
STI, as there is negligible transmission for penile vaginal sex and even for sexual
practices among HIV negative men (Jin, Prestage, Kippax, Kaldor, G.J. et al., 2005).
More recently, it has been recognised that HIV positive MSM, or contact with and
HIV positive MSM, are risk factors for HCV from sexual transmission. This may be
because of more traumatic, “bloody” sexual activities, a higher level of IDU and
HCV, as well as immune suppression in this subgroup (Centers for Disease Control
and Prevention, 2011a; Jin et al., 2010; Mahony, Donnan, Lester, Doyle, Knox et al.,
2013). Study One will review whether injecting drug use or HIV MSM are
prominent risks for patients with SMI.

Another biological factor determining STI epidemics are the unique populationpathogen interactions. Infections such as gonorrhoea and syphilis require multiple
partnerships either concurrent or of short duration to be maintained and hence are
present in unique very sexually active networks such MSM (Anderson, 1999;
Garnett, 2008). Other infections, such as chlamydia, do not require as many risk
partnerings and are more widely distributed in the community. Viral infections such
as HIV, HBV and HCV are long lasting infections and may only require as little as
two contacts over many years to maintain an epidemic (Anderson, 1999; Mann &
Roberts, 2011; Mathe, Van Dooren, Lemey, Van Damme, Buntinx et al., 2008;
Pybus, Cochrane, Holmes, & Simmonds, 2005).

Table 2.1 highlights the Australian situation regarding STIs and BBVs. As can be
seen chlamydia and Hepatitis C infections are the most common. Each infection has
a unique risk group in which prevalent infection is more likely to be diagnosed. It is
recognised that for some infections diagnosed such as Hepatitis B and C that
diagnoses can be of new infections or of existing infections that have only recently
been recognised. Australia, like many other countries, has had the profile of STIs and
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BBVs influenced by migration and travel to countries with high background STI or
BBV prevalence.

Study One, of this thesis will explore if patients with SMI have elevated rates of STI
or BBV infections and thus potentially at risk for other infections such as HIV.
Study One will assess the sexual and substance use activities of patients with SMI
that govern the extent that each infection is present in this group.

11

Table 2.1 Descriptions of notifiable STIs and BBVs
Infection

Cases in
2009

Rate in
2009 per
100 000

Transmission

Risk of
Transmission

Chronicity

Number
needed to
infect

Chlamydia

60,000

272

sexual

medium to
high

nil

1-3 q12m

- young people
- recent partner change

Gonorrhoea

8040

36

sexual

high

nil

1-3 q6m

- MSM
- sex tourists

Syphilis

1300

5.8

sexual

high (early)

Latent
(if untreated)

4-7 q6m

- early syphilis - MSM
- latent
- immigrants from high prevalence

Hepatitis B

7340
238

32.9
1.2

newly diagnosed
new infection

sexual
blood
non-specific

high

5% Adult onset
90% Neonatal
onset

1-2 lifetime

- IDU
- ATSI
- immigrants from high prevalence

Hepatitis C

11468
401

51.9
2

newly diagnosed
new infection

blood

high

75%

2-4 q10y

sex (HIV+ve
MSM)

low to med

- IDU
- immigrants from high prevalence
- HIV+ve MSM risk

sexual
blood

low

HIV

1050

5.7

12

Not known

100%

2 lifetime

Australian Risk groups

- MSM
- Heterosexual contact
- immigrants from high prevalence

2.4 RISK FACTORS FOR STIs AND BBVs

The risk of STI and BBV infection is a complex interplay at many levels of
individuals’ and their partners’ characteristics and behavioural choices within a
broader context of their communities. The term “risk” gauges the probability of
encountering an infected partner, or the probability of acquiring infection if exposed,
the probability of disease if infected, risk of transmitting disease and risk of being
infected. The multiple levels of sexual risks are depicted in Figure 2.1 from
Blanchard and Aral (2010).

Figure 2.1 Conceptual model of the integration of population and individual level
factors in the study of epidemics of sexually transmitted infections and HIV
(Blanchard & Aral, 2010).

Risk at the individual level is mostly determined by sexual and substance use
behaviours and the biological conditions necessary for transmission or acquisition of
each infection (Garnett, 2008). Risks at the partner level are determined by partner
dynamics and network structures, which have been recently recognised as crucial in
13

understanding STI and BBV transmission. Studies that have included analysis of
partner dynamics and networks have better predicted who may become infected and
the extent of an infection problem for the individual and the community (Blanchard
& Aral, 2010). Risks for STIs and BBVs also vary according to community level
characteristics such as social, economic and cultural factors. These community
factors influence the partnership dynamics and affect key areas such as condom use,
sexual practices (Gorbach & Holmes, 2003) and drug practices.

2.4.1 Risk at the Individual Level
Individual level “risk factors” are often based on individual sexual and substance use
behaviours. Individual level risks may also vary because of biological or “other” risk
factors, such as tattooing. Information and knowledge on risk factors has been
propagated because of the significant interest in HIV infection (Commonwealth of
Australia, 2005). Recent population studies, such as the “Sex in Australia: Australian
Study of Health and Relationships (ASHR)”, have surveyed sexual behaviour in the
general population and have fine-tuned and contributed to the assessment of risk (De
Visser, Smith, Rissel, Richters, & Grulich, 2003b). For example, it has been
recognised that use of condoms does not confer meaningful data about risk unless
condom use is specified along with type of partner, or type of sexual activity
(Peterman, Lin, Newman, Kamb, Bolan et al., 2000). This thesis will assess the
extent of such behaviours occurring for patients with SMI.

2.4.1.1 Sexual risk behaviour

Sexual risk behaviour ultimately is sex with one person infected and resulting
acquisition or transmission of infection. As this direct risk is mostly difficult to
measure, a review of surrogate sexual risk behaviours covering components such as
sexual experience, levels of sexual activity, current, concurrent and lifetime number
of sex partners, frequency of sexual intercourse, mode of recruitment of partners,
duration of sexual unions, types of sexual activity and condom use are explored (Aral
& Cates, 1989). Type of sexual activity, is an important question because risk will
differ depending on anatomical site of sex, level of trauma to the mucosa and the
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biological preference that each organism has in flourishing at a particular site. The
most risky sexual practice is anal receptive sex and this risk is enhanced with lack of
condom use or sex in a partnership with a higher background prevalence of infection.

2.4.1.2 Substance use risk behaviour

Risk behaviours related to substance or drug use, cover both injecting and noninjecting drugs. Injecting drug use is implicated in infection with sharing of any
injection equipment that may be contaminated with infected blood. All other forms
of substance abuse, be it alcohol, cannabis, heroin or inappropriate use of legal drugs
can place an individual at risk because of impaired decision making and impaired
ability to negotiate safe or consensual sex (Carey, Carey, Maisto, Gordon, &
Vanable, 2001) or safe injecting practices. Characteristics of substance use, such as
frequency of use, years of drug use and types of drugs play a role in risk. Substance
use and abuse creates other socio-economic risks such as involvement in sex work
and crime with the possibility of incarceration (Lankenau, Clatts, Welle, Goldsamt,
& Gwadz, 2005).
2.4.1.3 “Other” risk factors
“Other” risk factors to be explored as part of this thesis include healthcare risk
behaviours, skin penetration practices and incarceration. These risk factors modify
sexual and substance use risk behaviours. These “other” risk factors may provide
new situations or communities with risk behaviours and high STI or BBV prevalence
rates facilitating transmission or acquisition.

Healthcare behaviours are connected to community level risk considerations. The
availability of facilities and programmes, determined by community decisions,
reflect healthcare and behaviours. An individual may not seek healthcare because it
may be inaccessible or unavailable due to geography. Problematic healthcare
behaviours include, seeking medical attention late, non-compliance with therapy or
lack of notification of sexual contacts. Healthcare behaviours can be mixed risks with
patients choosing screening and treatment as means of minimising risk rather than
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primary preventative behaviours such as condom use. Other healthcare behaviour
may have a preventive care component such as vaccination for the prevention of a
sexually transmissible infection, or HCV therapy to eradicate HCV infection. Current
HCV therapy of weekly interferon injections and daily ribavirin tablets, is long and
arduous and may fail despite good efforts. As such, some patients recognise the
difficulty of a 24 or 48-week regime and choose not to commence therapy. At times
healthcare behaviours can be altered with the introduction of new and easier regimes
that allows a larger cohort to take up treatment and potentially be cured (Dore, 2012).
“Other BBV risk factors” include skin penetration practices such as the body arts of
tattooing and piercings. Tattooing is a significant risk for HCV exposure, more so in
the USA (Haley & Fischer, 2001), than Australia (Miller, Hellard, Bowden,
Bharadwaj, & Aitken, 2009). Piercings have a potential infection risk if not
performed under hygienic conditions and new body art techniques, such as
“branding”(Braverman, 2006), may add to the risk picture.

Incarceration is a risk for BBV (Miller et al., 2009; NSW Department of Health,
2007) and also a risk for STI infections (Templeton, 2006). It seems that
incarceration conditions create more risky behaviours, such as sex without condoms
and unclean injecting equipment in a sub-network with higher background infection
prevalence. Patients with SMI do have higher rates of incarceration in the USA and
may be exposed to risky behaviours whilst incarcerated (Baillargeon, Binswanger,
Penn, Williams, & Murray, 2009).
These particular “other” risk factors will be explored for patients with SMI, looking
at the extent that patients are involved in risk situations, such as tattooing, and in
preventative healthcare measures.

2.4.2 Risk at the Partner level

The essence of human existence is living in society with special connections within
the social networks. The network of sexual contacts through which STIs spread is a
sexual network and the contact with whom one shares drug activities is a drug
16

network involved in BBV transmission (Liljeros, Edling, & Nunes Amaral, 2003).
Mixing between individuals is a characteristic of partnerships or contacts, which
form within networks. “Partnership and network formation, and the chance of
acquiring and transmitting an infection sexually are not random; they are determined
by individual factors, cultural values, geography, demography, economics, health
service, and political and legal structures” (Low, Broutet, Adu-Sarkodie, Barton,
Hossain et al., 2006, p. 2003). Partnerings differ “by duration and sequence of
partnerships” for both sexual and drug networks (Morris, Goodreau, & Moody, 2008,
p. 117; Unger, Kipke, De Rosa, Hyde, Ritt-Olson et al., 2006) Networks are
important in the transmission dynamics of infections at the population level and
position in the network is important in the transmission and acquisition of infections
at the individual level. Concepts in understanding partnerings include assessing for
the number of concurrent partners and the degree of mixing between persons that
determines involvement in risk networks (Gorbach, Drumright, & K.K., 2005;
Gorbach & Holmes, 2003).

Persons with only one sexual or drug sharing partner at any time can still have
different risks. Exclusively long-term single partner relationships may not have any
risk nor be in a network. Some individuals have serial single partners, with the
duration of the relationship and the “gap” length of time between partnerings
important in transmission risk.

Others may have several concurrent sexual or drug sharing partners. Concurrent
partnerships play a big role in infection risk. The degree of risk for different
concurrent partners, who may be in different sexual networks, is based on the
prevalence of infections in each network and the degree of mixing (Aral &
Leichliter, 2010).
“Mixing” considers the choices of partners based on race, gender, age and other
variables. Understanding “mixing” helps explain some problems such as the
perpetuation of high STI and BBV rates for African Americans, despite similar or
even safer behaviours than Caucasian Americans (Centers for Disease Control and
Prevention, 2001). Explanation for this discrepancy is that their partner choices are
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usually with other African Americans within this tight and small network with a
background of high STI and BBV prevalence (Hallfors, Iritani, Miller, & Bauer,
2007). The larger Caucasian American group has a wider choice of partners,
broadening the network and lessening risk of encountering an infection. African
Americans choose similar partners by race, but partners are dissimilar by risk. In
contrast, Caucasian Americans are much more likely to find partners that are similar
by race and by risk (Laumann & Youm, 1999). Hallfors et al (2007, p. 130),
comment that “this combination of assortative (like with like) mixing by race and
disassortative mixing by risk group may create a ‘perfect storm’ effect for Blacks
that results in very high STD and HIV rates…”. Such mixing may explain the
Australian epidemiological profile of high STI and BBV rates for persons of
Indigenous background. Risks are based on both the individual’s and their partners’
risk behaviours, within the context of their sexual networks.

Risks for BBV infection can vary by network and is based on the pattern of drug use
and social structure of the involved drug network. In the USA, cocaine user’
networks differ from heroin user’ networks. Cocaine users are more likely to be
chaotic and more likely to be both HCV and HIV positive than heroin users, who
tend to be only HCV positive (De, Cox, Boivin, Platt, & Jolly, 2007).

In Australia, IDU networks have prevalent HCV exposure and not HIV. HIV from
IDU activities is relatively low at 3% of all new HIV diagnoses, during 2005-2009,
and at a 1% prevalence rate of all persons with an IDU history (National Centre in
HIV Epidemiology and Clinical Research, 2010, p. 11). In Australia, it has been
recognised that persons who have both HIV as well as HCV, are more likely to
report both IDU and MSM risk behaviours, and be a unique network with sexual and
drug risks (National Centre in HIV Epidemiology and Clinical Research, 2010, p.
22). MSM that also inject drugs are probably at risk because of risk sexual and
substance use behaviours. Studies of blood donors (Shev, Hermodsson, Lindholm,
Malm, Widell et al., 1995) and of injecting drug users (Latkin, Kuramoto, DaveyRothwell, & Tobin, 2010), have explored this issue with findings that those part of
more risky drug networks are more likely “to endorse both risky needle-sharing and
sex norms” (Latkin et al., 2010, p. 1159).
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Conversely, longitudinal studies have found that “over and above IDUs’ baseline
characteristics, changes in their personal networks are associated with changes in
individuals’ risky injection behaviours”, including reduction in drug behaviour risks
if new social contacts were not involved in IDU activities (Costenbader, Astone, &
Latkin, 2006, p. 1003).

Networks or subpopulations with a higher risk for STIs and BBVs based on high risk
behaviours and high risk partner choices may be identified or “marked” by particular
attributes. Most work defining risk networks are US based, with little work in
Australia apart from examining MSM groups. Such risk networks have previously
been termed “core groups”, “priority groups”, “risk markers” or “risk indicators”
(Huygens, Kajura, Seeley, & Barton, 1996; Johnson, Mercer, Erens, Copas,
McManus et al., 2001; Smith, Rissel, Richters, Grulich, & de Visser, 2003b). These
high-risk “marked” populations act as reservoirs of infection for STIs or BBVs
because they do not have symptoms, may not get treated, or, cannot always be cured
despite treatment, as is the case for HIV and HCV. This core group has important
variables perpetuating the risk, such as higher rates of sexual partnerships or
substance abuse. In addition, risk may be because of the social consequences of
marginalisation and inaccessibility to healthcare. It is argued that networks of core
groups have the potential to sustain the endemic and epidemic transmission of STIs
and BBVs (Thomas & Tucker, 1996). Being a member of the group is not sufficient
evidence that an individual has the infection in question. For example, being a young
person is a marker for STIs. The risk is not just being young because those who are
not yet sexually active will not have any risk. But for other young people, their new
found sexual expression and partner choices may mean experimentation and less
heed for sexual safety (Aral, 2004). The level of social networking or interaction of
this core group with the general population will influence the extent of transmission
and the epidemiology of STIs and BBVs (Mayaud & McCormick, 2001). For
sexually transmitted infections there can be significant interactions between core
groups, with high rates of risk behaviour or infection and general populations,
whereas blood borne virus infections tend to congregate in the core groups (Low et
al., 2006).
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Formally written strategies for addressing BBVs and STIs by NSW Health (NSW
Department of Health, 2006a, 2006b), term core groups, “priority groups”. NSW
Health defines these priority groups as; MSM, young people, persons who have ever
injected drugs, have HIV, are bisexual, are a sex worker, have multiple simultaneous
partners, are from an overseas country, or have ever been in gaol (NSW Department
of Health, 2006a, 2007; NSW Department of Health Sydney, 2006; UNAIDS,
2009).

In the current study, it is postulated that some patients with SMI may be a unique risk
group network - a core group that is important in the spread and perpetuation of
infection. This thesis will explicitly explore sexual risk partners. Such partners may
be part of any priority groups, as discussed in the previous paragraph. Risk
partnerings may include any sex of a commercial nature, such as sex with payment,
or be of a casual nature, or even coercive (Silverman, McCauley, Decker, Miller,
Reed et al., 2011). This thesis will evaluate any patterns of partnerings reported by
patients with SMI.

2.4.3 Risk at the Community level

Wider community and population factors contribute to the risk picture such as health
programmes, travel and political and economic situations of different populations.
“Social forces (can) affect the distribution of STIs through their effects on behaviour,
networks, and risk of exposure to infection” (Aral, Adimora, & Fenton, 2008, p.
337). African Americans’ risk is strongly influenced by poverty and violence that
create a sex ratio inequality, with fewer men than women overall, and fewer
financially secure men in the community.

In developed countries, some communities of individuals may be economically
forced by their circumstances to crime or prostitution (Aral & Holmes, 1999). This
may be because their potential productivity is too low for them to be employable.
Groups in such circumstances may be injecting drug users, new immigrants, the
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homeless, long-term unemployed, those in gaol, and all of these groups may include
patients with SMI (Aral & Holmes, 1999).

Community level variables have the potential to add to the risk of infection. This
thesis will tentatively examine the role community level risk creates for patients with
severe mental illness by starting to look at their position in various networks and
community.

2.5

MENTAL HEALTH IN AUSTRALIA

Assessment of patients with severe mental illness requires an overview of mental
health in Australia. Mental Health is not simply the absence of mental health
disorders - be it anxiety or severe mental illness. Mental Health describes the
capacity of individuals and groups to interact with one another and the environment,
in ways that promote subjective well being, optimal development, use of mental
abilities (cognitive, affective and relational) with achievement of individual and
collective goals.

WHO (2001) defines mental health as a state of emotional and social well-being, in
which the individual realises his or her own abilities, can cope with the normal
stresses of life, can work productively or fruitfully and is able to make a contribution
to his or her community. A person that does not have this well-being and autonomy,
and lacks good mental health, is more likely to suffer in their sexual as well as social
interactions (WHO, 2001). Mental health problems may be transient, or they may
meet criteria to constitute a mental disorder, requiring ongoing psychological or
medical care (Australian Health Ministers, 1991).
One of the main barriers to good “mental health” is having a mental health disorder.
Mental disorders refer to a spectrum of cognitive, emotional and behavioural
disorders that interfere with the lives and productivity of people. The more common,
but less debilitating disorders, such as depression and anxiety, have been termed
“high prevalence” disorders and affect 10-20% of the population (Andrews, Hall,
Teesson, & Henderson, 1999; Judd, Jackson, Komiti, Murray, Hodgins et al., 2002).
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The less common but more incapacitating disorders, have been called “low
prevalence” and “severe mental illness” with a significant and detrimental impact for
the 1- 2% of the population affected (Commonwealth Department of Health and
Aged Care, 2000). This thesis will study patients with severe mental illness.

2.6 SEVERE MENTAL ILLNESS
The low prevalence severe mental illnesses (SMI) are hallmarked by “psychotic
disorders” with deleterious effects. The main psychotic disorders are schizophrenia
spectrum disorders, bipolar disorder, severe depression with psychosis and other
psychosis. Jablensky et al (1999, p. 13) describe the main symptoms of psychotic
disorders; as delusions (incorrect beliefs out of keeping with the shared beliefs and
values in the culture), hallucinations (perceptions without external stimuli, e.g.
hearing voices), disorganised thought, speech and non-verbal communication and
loss of motivation and planning ability. “Psychotic disorders affect the most basic
functions that give a person a feeling of individuality, uniqueness and self-direction”
(WHO, 1994, p. 13), causing severe impairment and difficulties operating in society
(Lawrence et al., 2001). These conditions have been reviewed in Australia as part of
the National Survey of Mental Health and Well-being Report 4 (Jablensky, McGrath,
Herrman, Castle, Gureje et al., 1999). One to two percent of the general population is
affected and at any one time 3 to 5 out of every 1000 adults may have a psychotic
illness (Jablensky, McGrath, Herrman, & et al., 2000).

Severe mental illness is very incapacitating with a high likelihood of prolonged
hospitalisation. Jablensky et al (1999) found that just over 50% of Australian patients
with SMI had a hospital admission in the last 12 months, with over 70% spending
more than 2 weeks in hospital, with a mean length of stay of 13 weeks (median was 6
weeks). Patients with schizophrenia had longer stays than patients with mood
disorders. Despite the lower point prevalence of such problems they pose huge public
health and economic costs due to the severe disability. Almost half of the group with
SMI, surveyed by Jablensky (1999), was not able to work, socialise or perform daily
activities. Severe mental illness is a public health problem because of the magnitude
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and effect of the illness on patients and society. Schizophrenia and bipolar disorder
features are briefly described exemplifying severe mental illnesses.

Schizophrenia affects about 1% of the population and begins in the young adult years
(American Psychiatric Association, 1994). The incidence of new schizophrenia
diagnosis is about 1 per 100,000 of the population (American Psychiatric
Association, 1994). About half of all those afflicted will be disabled because of
repeated episodes of illness and difficulty in treating symptoms. Most people will
display a prodromal phase of altered, withdrawn and bizarre behaviour. Symptoms
for persons affected with schizophrenia include perceptions of reality that are
extremely different to others and usually frightening for them such as hearing voices
(auditory hallucinations), believing that people can read their minds or control their
thoughts. They may have disorganised speech and behaviour making them
incomprehensible or frightening to others. The signs for schizophrenia may include
social withdrawal, hostility or suspiciousness, deterioration of personal hygiene, flat
and expressionless gaze, inappropriate laughter or crying and strange use of words or
way of speaking.

Mood disorders such as bipolar and even severe depression can occur with psychosis
and be severe mental illnesses. Bipolar disorder is the well known mood disorder but
occurs less frequently than schizophrenia and less frequently than depression
(American Psychiatric Association, 1994; Baker, 2001), with a lifetime prevalence is
0.2%-0.4% as quoted by Perälä et al (2007). Symptoms for the patient developing
bipolar disorder may be feelings of hopelessness, sadness or emptiness, inability to
experience pleasure, irritability, fatigue or loss of energy, physical and mental
sluggishness, appetite or weight changes, concentration and memory problems,
feelings of worthlessness or guilt and thoughts of death or suicide. The classic
description of bipolar signs includes elevated but also labile mood, grandiosity, lack
of insight, disinhibition, flight of ideas (racy) and impulsivity associated with mania
– hypersexual or promiscuous behaviour (Saddock & Saddock, 2000) and other
excesses such as alcohol, gambling and risky business ventures.

23

The natural history of SMI is of a chronic health problem with slow deterioration and
frequent exacerbations. Patients develop additional medical problems along the way,
particularly metabolic syndrome, a combination of medical conditions that
predispose to cardiovascular disease and diabetes. Patients have a reduction in
average lifespan related to the risk of suicide, smoking, diet, accidents, poverty and
problems from use of both legal and illegal drugs. People with SMI may be
homeless, disorientated, disorganised, have poor judgement and unable to maintain
social or personal relationships (Hudson, 2005; Saddock & Saddock, 2000).

2.7

RISK FACTORS FOR SMI

There are many theories for the causation of mental illness but the factors
contributing to the development of a mental disorder are still not fully understood.
Currently it is recognised that a biological vulnerability with the interaction of
psychological, social and environment influences play a significant role (Brown,
2011; van Os & Kapur, 2009).

Biological risk factors in the interplay include; genetic propensity, biochemical
imbalance and perhaps infectious agents (van Os & Kapur, 2009). Psychological
risks can be a person’s upbringing, emotional experiences, and relationships with
others (Rutter & Sroufe, 2000). Social factors may be current life circumstances never married, unemployment, or life events - such as migration or poverty
(Goodyer, 2002; Rutter & Sroufe, 2000). Environmental factors which may be
involved include the effects of seasons or exposure to substance use (Kelly,
O’Callaghan, Lane, & Larkin, 2003).

Substance use, in particular, has had much written regarding its role in mental illness.
It has been considered as a cause for mental illness, as a precipitate for mental illness
in those predisposed, and also as a perpetuator of mental illness with a poorer
prognosis for those with a dual diagnosis of mental illness and substance use
(Siegfried, 1998). Batel (2000) from his review offered three hypotheses to explain
the high rate of substance abuse for patients with SMI. His review described (i) the
social-environmental hypothesis where drug use is linked to the social, economic and
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environmental deprivations associated with mental illness, (ii) the possible shared
biological vulnerability, such as common genetic determinants of schizophrenia and
abuse of psycho-active drugs and (iii) self-medication, whereby patients with SMI
use psycho-active substances to mediate the symptoms of their disorders.

Ultimately, risk for severe mental illness, such as schizophrenia, is complex and
multi-factorial. Often patients with severe mental illness remain at risk because
medical therapy fails to rehabilitate fully. Therapy does not address the biological
vulnerability that causes altered brain development, or the psychological, social or
environmental insults that trigger the illness. Whilst patients are on medication,
symptoms are controlled but relapse usually occurs if therapy is ceased (Hilty,
Brady, & Hales, 1999; van Os & Kapur, 2009). Lack of normal functioning and
quality support from the community, such as accommodation and rehabilitation, may
mean additional problems such as homelessness for patients with SMI (Thomas,
Romme, & Hamelijnck, 1996), and the likelihood of exposure to risk activities.

2.8

RISKS FOR SMI AND RISKS FOR STIs and BBVs

Theoretically, one can see the connection between the signs and symptoms of SMI,
as risk factors for STIs and BBVs. For example, impaired judgement, poor personal
relationship skills, disinhibition, sense of worthlessness may mean adverse choices in
sexual contacts or lead to risk behaviours such as illicit drug use. Sequelae of mental
illness, such as homelessness, substance abuse, poor relationships can be “markers”,
external recognisable indicators, of SMI and overlap as indicators of STI or BBV
risk.

This thesis will endeavour to assess the risk of STIs and BBVs amongst inpatients in
a psychiatric hospital and the extent that SMI and STI and BBV risks overlap. It may
be that despite being hospitalised, patients maintain risk behaviours and risk contacts.
Study One of this thesis focuses on patients and Study Two on the psychiatrists in a
psychiatric inpatient ward, and it is useful to have a portrayal of life in the ward for
patients with severe mental illness and the potential risks. Patients are hospitalised
when unwell with behaviours that are too difficult or dangerous to be managed as
25

outpatients. Once in hospital, patients will interact with many healthcare
professionals, the consultant psychiatrist, the ward registrars, mental healthcare
nurses, clinical nurse specialists, psychologists, social workers and many others. The
staff on the ward work as a team to observe, diagnose the illness, provide treatment
and rehabilitation activities - even if they may be perceived as tedious by patients.
The psychiatrist’s role for unwell patients in hospital settings is largely biological
psychiatry (Schwartz, 1987) and to provide “care leadership” (Sims & Sims, 1993),
diagnosing, treating and guiding the management for each patient to enable stability
and discharge.

Psychiatric inpatient settings in Australia encourage community living and care, but
this is not always possible for everyone and some patients have extended hospital
stays. The standard model of care for NSW hospitalised patients is admission under
the primary care of a psychiatrist. Care is provided by a multidisciplinary team,
which includes mental health nurses, social workers, psychologists and junior
medical staff. The psychiatrist is responsible for both mental health and physical
health problems including STIs and BBVs. Current psychiatric care often consists of
a “revolving door” environment with patients having short hospital stays but frequent
re-admissions (Haywood, Kravitz, Grossman, Cavanaugh Jr, Davis et al., 1995),
because many do not achieve sufficient wellness or control of symptoms.
An ethnographic study identified that this “revolving door” with revolution of
patients and visitors meant that “admission ward environments were permeable to the
adverse effects of local street life, including drug taking” (Lelliott, 2006, p. 92). The
researchers found “that ward membership was temporary and changed rapidly”
(patients had very short stays and staff turnover was high); patients maintained
contact with the outside world during their stay; and institutional identities were
blurred to the point where visitors or new patients could easily mistake staff and
patients for one another (Lelliott, 2006). Permeability had both positive
consequences, with a reduced risk of institutionalism, and negative consequences
such as unwanted troublemakers able to enter the hospital resulting in persistence of
adverse activities, such as illicit drug use, among patients.
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In addition to the ward permeability, problems of the psychiatric ward, such as a lack
of leisure activities, may be contributing to some risk behaviours of inpatients. Quirk
et al (2006) provided the opinion that today’s psychiatric wards are inadequately
designed with few therapeutic and leisure activities. This leads to inactivity,
boredom, aggression (Lelliott, 2006) and even sexual activity on the wards (Warner,
Pitts, Crawford, Serfaty, Prabhakaran et al., 2004). Patients may build poor social
contacts based on meeting other patients in hospital and continue socialising back in
their external environment. Boredom for patients coupled with ongoing contact with
the external environment can lead to unfavourable risk behaviours when hospitalised.
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CHAPTER THREE
Literature Review: Studies Assessing STI and BBV Risks 1

3.1

INTRODUCTION

Over the last two decades, there has been recognition that patients with severe mental
illness (SMI), are at an increased risk of human immunodeficiency virus infection
(HIV) because of high risk behaviours (Cournos & McKinnon, 1997). In 1997,
Cournos and McKinnon (1997) comprehensively reviewed many of the studies,
conducted up to 1995 exclusively in the USA, that had assessed this problem, and
calculated an elevated weighted HIV prevalence rate of 8% for patients with SMI.
The review emphasised the public health impact of such a problem and suggested
that recognising and addressing HIV risks for individuals would reduce the human
and economic cost of the "AIDS epidemic".

A more recent analysis of the literature looking at research exploring STI and BBV
risks for patients with severe mental illness was undertaken. This literature review
was necessary to provide the latest knowledge of risk factors, rates of prevalent
infections, associations and methodology thus guide both Study One and Study Two.

3.2

AIMS and OBJECTIVES

The aim of this literature review was to identify published findings that specify the
type and extent of risk for STIs and BBVs amongst patients with SMI. It aimed to
explore whether SMI constituted a risk factor for the acquisition of STIs and BBVs.
As well, the review aimed to explore the role of healthcare workers in the assessment
and recognition of STIs and BBVs, specifically Knowledge, Attitudes and
Behaviours as KAB surveys.
1
Specifically
Parts of this to:
chapter were published as Lagios & Deane (2007)
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i. To determine the prevalence of risk factors and prevalence of STI and BBV
infections, in people with SMI, in Australia and globally.
ii. To determine the extent that patients with SMI are at risk for STIs and BBVs, in
Australia and globally.
iii Describe findings from prior knowledge, attitudes and behaviour surveys on
healthcare workers regarding STIs and BBVs.

3.3

REVIEW PROCEDURES

This literature review elaborated on the work of Cournos and McKinnon (1997) and
examined publications since 1995, attempting to identify and include studies from
other countries as well as epidemiological studies examining associations. The
review process included updated Medline and PsycINFO searches. Identified articles
were scrutinised to locate key prevalence information and organised into groupings.

The role of healthcare workers regarding STI and BBV assessment was explored
descriptively. Review of the studies identified key areas for knowledge, attitudes and
behaviours.
3.3.1 Review – The risk of STIs and BBVs for patients with SMI

Searches of Medline and PsycINFO databases along with bibliographical review of
acquired publications were conducted. Variations of the following terms were used
in the search; "severe mental illness" and "HIV/BBV/STI" and "risk factors"; "severe
mental illness" and "HIV/BBV/STI" and "risk markers"; "severe mental illness" and
"STI/BBV" and "prevalence"; "severe mental illness" and "HIV" and "prevalence";
severe mental illness" and "HIV" and "prevalence" and "risk factors". The articles
that were included presented quantitative data for risk factors and notifiable STI or
BBV infections for populations with SMI and general populations. Only 51 articles
met inclusion criteria including 21 cross-sectional-descriptive studies determining
the prevalence of risk factors, 16 cross-sectional-descriptive studies on prevalence of
STIs and BBVs, 4 epidemiological studies, which had a cross-sectional-analytical
design, concurrently examining the association between risk behaviours and HIV as
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an outcome, and 10 review papers helpful as background but not part of any analysis.
National surveys were incorporated in the review to provide population prevalence
data for comparison purposes.

The cross-sectional studies’ prevalence information as well as national survey data
for the general population was grouped and presented in tables. Infection prevalence
data included HIV seroprevalence rates, STI and BBVs rates. Risk factors were
presented for sexual risk behaviours, risk partnerings, substance use behaviours and
“other” risk factors, such as community based preventative healthcare behaviours.
The tables included author, publication year, country, sample type and size, research
tools, percentage with schizophrenia/psychosis, participation rates and prevalence
rates.

Risk factors are depicted in Table 3.1 for patients with SMI (Carey et al., 2001;
Coverdale & Turbott, 2000; Davidson, Judd, Jolley, Hocking, Thompson et al., 2001;
Kalichman, Kelly, Johnson, & Bulto, 1994; Rosenberg et al., 2001; Thompson,
Checkley, Hocking, Crofts, Mijch et al., 1997). For comparison Table 3.1 has
Australian and US population data (Australian Institute of Health and Welfare, 2002;
De Visser, Smith et al., 2003b; Grulich, de Visser, Rissel, & Richters, 2003; Grulich,
de Visser, Smith, Rissel, & Richters, 2003a, 2003b; Grulich, de Visser, Smith,
Rissel, & Richters, 2003c; NHSDA, 2001).

STI or HCV prevalence rate estimated by self-reported or tested STIs or HCV are
reported in Table 3.2, (Banger, Olbrich, Fuchs, & Gastpar, 1995; Chang, Lin, Yen, &
Wu, 1993; Cividini, Pistorio, Regazzetti, Cerino, Tinelli et al., 1997; Coverdale &
Turbott, 2000; Dinwiddie, Shicker, & Newman, 2003; Klinkenberg, Caslyn, Morse,
Yonker, McCudden et al., 2003; Meyer, 2003; Nakamura, Koh, Miyoshi, Ida,
Morikawa et al., 2004; Rosenberg et al., 2001; Said, Saleh, & Jumaian, 2001;
Sitzman, Burch, Bartlett, & Urrutia, 1995).

The rate of HIV in groups with SMI are summarised in Table 3.3. Data is from 11
cross-sectional-descriptive sero-prevalence studies (Acuda & Sebit, 1996; Aday &
Cornelius, 2006; Ayuso-Mateos, Montanes, Lastra, Picazo de la Garza, & Ayuso30

Gutierrez, 1997; Chandra, Ravi, Puttaram, & Desai, 1996; Chen, 1994; Cournos,
Horwath, Guido, McKinnon, & Hopkins, 1994; Hutchinson & Simeon, 1999; Meyer,
2003; Naber, Pajonk, Perro, & Lohmer, 1994; Rosenberg et al., 2001; Tharyan,
Ramalingam, Kannangai, Sridharan, Muliyil et al., 2003). As well HIV matched
population data are shown (Burton & Mertens, 1998; New York City Department of
Health HIV Epidemiology Group & Thomas, 2001). HIV rate as a weighted mean
across all studies was calculated, i.e. total number HIV positive over total number in
all studies.

The extent of risk was reviewed by
i. comparison of risk factors for patients with SMI with the population data
ii. calculation and comparison of the weighted HIV mean for patients with SMI
with population data
iii. comparison of HCV, HBV and HIV rates stratified by risk factor history and
groups - patients with SMI and population groups

3.3.2 Review - Healthcare Workers’ Assessment of STIs & BBVs

Review of healthcare workers approach to assessing patients has been evaluated by
KAB surveys exploring Knowledge, Attitudes and Behaviours. Key words used to
identify articles were combinations of “general practice”, “heath care workers”
“STI”, “BBV”, “HCV”, “knowledge”, “attitudes” and behaviours”.

Prior KAB research had reviewed knowledge of STIs and BBVs in diverse groups,
for example one group has assessed the general public (Munoz Sastre, Bacq, Mullet,
& Clay Sorum, 2002) and another group of researchers, patients with SMI
(Goldberg, Tapscott, C.A., & Wolfe, 2009). Medical Practitioners have been the
most extensively studied (Coppola, Karakousis, Metz, Go, Mhokashi et al., 2004;
Dev & Sievert, 2002; Mulvey, Temple-Smith, & Keogh, 1997; Munoz Sastre et al.,
2002; Richmond, Dunning, & Desmond, 2007; Temple-Smith, Mulvey, & Keogh,
1999). Medical students (Anjum, Siddiqui, Ahmed, Rizvi, & Usman, 2005) as well
as other healthcare workers including complementary therapists, dentists, nurses,
pharmacists have also been researched (Richmond et al., 2007). Findings from these
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studies are presented descriptively, with key knowledge, attitude and behaviour areas
highlighted.
3.4 FINDINGS – THE RISK OF STIs AND BBVs FOR PATIENTS WITH
SMI

The 51 included studies were predominantly conducted in the USA but other
countries had researched HIV prevalence amongst their patients with SMI since the
1997 review by Cournos and McKinnon (1997). Most studies had been conducted on
convenience samples of referred patients and may have had selection bias. Australia
had six studies, one a HCV prevalence study (Lacey, Ellen, Devlin, Wright, & Mijch,
2007), two studies that evaluated self-reported STIs (Lacey et al., 2007; Shield,
Fairbrother, & Obmann, 2005) and four studies assessing risk behaviours in samples
of inpatients (Davidson et al., 2001; Lacey et al., 2007; Shield et al., 2005;
Thompson et al., 1997). Studies focused predominantly on risk behaviours and HIV
infection. None of the studies explicitly considered SMI as a risk and only a few
studies explored the level of other STIs or BBVs in patients with SMI.

3.4.1 Prevalence of STI and BBV risk factors for patients with SMI

Cross-sectional-descriptive studies mostly addressing HIV risk, which is similar for
STI and BBV acquisition, explored risk factors, particularly behaviours and
partnerings. Methodology between studies varied and limited comparison of the
study factors. Measurement was by clinical records review or structured interview
but each study used a unique interview tool. The risk behaviour questions were often
broad. For example, most asked about male-to-male sex, such as Thompson et al
(1997), but few asked participants specifically about receptive anal intercourse and
then neglected to ask about condom usage. Lack of definitions and differences in
terminology also hindered comparisons. Use of the term “sexual activity”, for
example, had several definitions - vaginal sex only, vaginal and anal sex, any sexual
activity with the opposite sex, or just stated as heterosexual sex. This was further
complicated by variations in reporting timeframes. Such factors required some
results to be recalculated in order to obtain comparable data.
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Table 3.1 presents data for six, of the 21 cross-sectional-descriptive studies, that
reported a wide range of risk factors over similar time-periods. Other studies, not
reported in the table, had analogous patterns of findings. The last 3 columns in the
table summarise results from recent US surveys, Australian drug use household
surveys and the ASHR, Australia-wide telephone survey, (Australian Institute of
Health and Welfare, 2002; de Visser, Smith, Rissel, Richters, & Grulich, 2003a;
Grulich, de Visser, Rissel et al., 2003; Grulich, de Visser et al., 2003a, 2003b;
Grulich, de Visser et al., 2003c; NHSDA, 2001). There is a wide range of risk
behaviours described but none of the studies asked all possible relevant questions.

3.4.1.1 Sexual risk behaviours

Only about half of patients with SMI were having sex compared with the general
population. When sex did occur, there were more occasions of risky sexual
behaviour for patients with SMI. Behaviours such as having two or more sexual
partners in the last 12 months and sex with casual sexual partners were reported more
frequently by patients with SMI. Reports of Men-who have-sex with-men (MSM)
were 4% in a 12 month time period (Coverdale & Turbott, 2000; Davidson et al.,
2001) and 22% ever (Kalichman et al., 1994) considerably higher than the ASHR
survey figure of 5% ever (Grulich, de Visser, Rissel et al., 2003). Similarly, having
sex, after the use of drugs or alcohol, was also reported at seemingly high rates for
patients with SMI. Positively, one protective behaviour, such as condom use at last
sexual exposure, was reported more frequently by those with SMI (Kalichman et al.,
1994; Thompson et al., 1997).

3.4.1.2 Sexual risk partners

Sexual contact with partners that had a risk history appeared high for patients with
SMI. As reported in sexual risk behaviour, patients with SMI were more likely to
have multiple partners, casual partners and choose partners with risk, such as a
history of sex work or injecting drug use. Many reported sex with partners met at the
psychiatric hospital, indicating sex with others that had an SMI. The various forms of
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exchange for sex, such as participation in sex work or trading sex for favours had too
many definitions and direct comparison between studies was not possible.

3.4.1.3 Substance use risk behaviours

Many of the substance use behaviours related to injecting and non-injecting drugs
were reported as more prevalent for patients with SMI than the general population
(Australian Institute of Health and Welfare, 2002; Carey et al., 2001; NHSDA,
2001). Injecting drug use (IDU) activity for patients with SMI was present in up to
17% of patients (Rosenberg et al., 2001) whereas less than 4% of the general
population reported any IDU history ever (Grulich, de Visser et al., 2003a). The
reporting of needle sharing compared to any of the population figures was also very
high. Even drug behaviours were not easily comparable as some studies used
different terms such as non-IDU or illicit drug use and some surveys described
marijuana and cocaine use.
3.4.1.4 “Other” risk factors

Access to community programmes indicative of good healthcare behaviours, such as
past healthcare attendance resulting in HIV testing, and possibly discussion of AIDS,
appeared similar for patients with SMI and the general population in most studies, at
about 40%. Few studies explored the extent of STI or BBV screening for patients.
One Australian study reported HCV screening uptake at 9% (Lacey et al., 2007).
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Table 3.1. Risk Factors for patients with severe mental illness and the general population
Author
Year
Country
N=

Kalichman
1994
US
95
Unique

Coverdale
2000
NZ
92
Unique

Interview Tool
Schizophrenia/
Psychotic
Participation rate

82%

69%

Carey
2001
US
1558
AUDIT/
DAST
19%

98% a

66% a

96%

77% a

80% a

87%

having sex last 12m
2+ partners 12m
condom use LSE
casual partners recent
sex coercion

54%
53%
24%
53%
43%

49%
14%
16%
5%

69%
19%
-

52%
21%
34%
-

46%
17%
23%
-

52%
21%
-

6m
6m

MSM
MSM anal sex

22%
-

-

13%
9%

21%
-

ever

sex with sex worker
sex with IDU 12m
sex with HIV ever
sex with bisexual
sex met psych. hosp.
sex met bar

18%
8%
6%
7%
40%
48%

6%
-

-

23%
3%
19%
-

sex after D & A use

36%

36%

-

-

ever

ever

12m

4%
-

12m
12m

Thompson
1997
Aus
145
13
item
55%

10y
10y

10y

Davidson
2001
Aus
229
10 item

NHSDA
2001
US
68929
Unique

AIHW
2001
Aus
26744
Unique

ASHR
2003
Aus
18591
Tel.

79%

Rosenberg
2001
US
931
ARI/
DALI
65%

Gen

Gen

Gen

NA

NA

NA

-

-

88%
13%
17%
3%
13%

-

-

5%
-

-

-

-

16%
-

-

-

-

-

4%
4%
<1%
1%
-
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12m

12m

ever
ever

IDU ever
IDU 12m
share needles ever
share needles 12m
heroin ever
heroin 12m
non IDU 12m
illicit ever
alcohol use 12m
marijuana
cocaine

4%
21%
58%
21%
11%

12m
12m

14%
-

1%
<1%
-

16%
8%
58%
-

14%
7%
7%
2%
5%
-

past HIV tests ever
45%
35%
37%
AIDS discussed ever
28%
17%
Notes:
‘a’
= of patients referred
MSM = Male-to-male-sex,
IDU = injecting drug use,
LSE = last sexual encounter,
NA
= not applicable
AUDIT= Alcohol Use Disorders Identification Test
DAST = Drug Abuse Screening Test
ARI = AIDS Risk Inventory
DALI = Dartmouth Assessment of Lifestyle Instrument for substance use assessment disorder for people with SMI
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17%
12%
-

1.5%
0.2%
1.4%
0.2%
66%
38%
13%

1.8%
0.6%
1.6%
0.2%
82%
33%
4%

4%
0.9%
1.1%
<0.1%
-

-

-

-

40%
-

3.4.2 Prevalence of STI and BBV infections in patients with SMI

Studies assessed only a few of the reportable infections for patients with SMI. As
such, data are only indicative of the degree of possible problems and not conclusive.
All STI, including HBV and HIV, as well as HCV exposures were reported at high
rates. Prevalence rate estimates for self-reported or tested STIs or BBVs are reported
in Table 3.2 and 3.3.

3.4.2.1 Prevalence of STIs and HCV

Only three studies explored the bacterial STIs of gonorrhoea, chlamydia or syphilis
in patients with SMI (Table 3.2). Infection rates were based on self-reported STI
history ever (Coverdale & Turbott, 2000), last 12 months medical record review
(Sitzman et al., 1995) and biological specimens assessing syphilis exposure ever
(Banger et al., 1995).

In the USA, Sitzman et al (1995) retrospectively reviewed the medical records of 426
patients with SMI. Half of the patients had previous STI tests with over 9% of all
patients having had an STI previously diagnosed. The researchers reported markedly
high rates for syphilis (9%) and gonorrhoea (32%) for those tested, and a calculated
incidence rate for syphilis at 4460 per 100,000 for all patients part of the study.
These rates are high compared to the cited USA population rate of 45 per 100,000
(Centres for Disease Control and Prevention, 1990) and even the high local New
Orleans’ rate of 192 per 100,000 (Lutz, Webb, Doucet, & et al, 1990). The second
New Zealand study interviewed 92 men (Coverdale & Turbott, 2000). Participants
provided self-reported history of previous STI treatment, as 5.4% for syphilis, 20%
for gonorrhoea and 8.7% for Chlamydia, statistically higher rates than their control
group. However, the third study, a German sero-prevalence review for syphilis that
screened 8915 patients (Banger et al., 1995), found a lower rate of syphilis (just over
1%), though this is higher than the prevalence rate of 0.03% of German blood donors
(Offergeld, Ritter, Faensen, & Hamouda, 2004). Overall, self-reported STIs ever
were reported by 9% to 44% of patients with SMI (see Table 3.2), and 18.5% of the
Australian population survey (Grulich, de Visser et al., 2003c).
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Table 3.2. Prevalence of STIs and HCV in patients with severe mental illness.

Author
Year
Country
Interview Tool
Schizophrenia/
Psychotic rate
Participation

Sitzman
1995
US
426
records

Coverdale
2000
NZ
92
self-report

Banger
1995
Germany
8915
Test

Rosenberg
2001
USA
931
Test

Klinkenberg
2003
USA
114
Test

Meyer Nakamura
2003
2004
USA
Japan
535
1193
Test
Test

Chang
1993
Taiwan
780
Test

Said Cividini
2001
1997
Jordan
Italy
192
1180
Test
Test

33%
50%

19%
96%

NA
100%

65%
87%

53%
86%

75%
95%

38%
100%

NA
95%

100%
100%

36%
100%

21%
88%

73%
24%

19.6%
8.7%
5.4%
40.0%

1.1%
-

23.4%

32.4%
29.8%
44.0%

24.7%
20.3%
-

9.1%
-

18.1%
6.8%
-

7.0%
-

6.7%
-

8.5%
-

19.4%
-

Gonorrhoea
3.5%12m
Chlamydia
0.7%12m
Syphilis
4.5%12m
HBV prior
HBV carrier
HCV
Past STI Diagnosis 9.4%12m

19.6%
28.4%
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Dinwiddie
2003
US
1556
Test

Lacey
2007
Aus
84
Test

HCV sero-prevalence rates often indicating chronic HCV exposure, were also
elevated with rates from 6.7% in an Italian study (Cividini et al., 1997) to 20%, from
the three US (Klinkenberg et al., 2003; Meyer, 2003; Rosenberg et al., 2001) and one
Australian study (Lacey et al., 2007).

In comparison, Australian data reports population prevalence rates from 0.5%, by
self-reported past HCV diagnosis (Grulich, de Visser et al., 2003c), to 1% (National
Centre in HIV Epidemiology and Clinical Research, 2010). In the US, general
population estimates for HCV are at 1.8% (Alter, Kruszon-Moran, Nainan,
McQuillan, Gao et al., 1999).

3.4.2.2 Prevalence of HIV

In contrast to STIs and other BBVs, many studies looked at HIV prevalence using
sero-prevalence data from biological specimens. Studies completed subsequent to the
Cournos and McKinnon review (1997), have had large sample sizes and been
conducted in other countries around the world, as well as the US. The 11 crosssectional-descriptive sero-prevalence studies that explored the rate of HIV in groups
with SMI are summarised in Table 3.3.

On average, high HIV prevalence rates were found for those with SMI, ranging from
0% to 24% dependent on geographical variations. The weighted mean for HIV
prevalence was 4.0%. Compared to population base rates for similar time-periods,
most of these studies reported HIV rates that were much higher for patients with
SMI.
3.4.3 The extent that patients with SMI are at risk for STIs and BBVs

The risk for patients with SMI was explored by examination of HCV, HBV and HIV
infections. These were the most prevalent infections identified as part of this review
and risk was assessed according to prevalence stratified by risk factors.
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Table 3.3. Prevalence of HIV infection in patients with severe mental illness
Author

AyusoMateos

Naber

Cournos

Chen

Chandra

Acuda

Hutchinson

Rosenberg

Tharyan

Klinkenberg

Meyer

Publication
Year

1994
1985-1993

1994
pre
1994

1996
19921995

1996

Study Time

1994
19891991

-

1997
19931994

2001
19971998

2003
19992000

2003
19962001

2003

Spain
477

1999
19911995
West
Indies
1227

Country
N=
Participation
rate
Schizophrenia
Study Sample
Drug History

Germany
623

USAa
962

Taiwan
843

India
2139

Zimbabwe
143

USAb
931

India
1160

USAc
204

USAd
535

5%
28%
Inpatient
34%

87%
51%
Inpatient
-

56%
Inpatient
rare

12%
Inpatient
29%

high
Inpatient
-

82%
40%
Inpatient
-

11%
Inpatient
-

87%
45%
In/outpatient
43%

80%
25%
Outpatient
6%

86%
48%
Homeless
63%

77%
76%
Inpatient
37%

SMI HIV rate

4.80%

5.20%

0.00%

3.40%

23.80%

5.10%

6.90%

3.10%

1.00%

6.20%

2.70%

1.2%f

0.0% e

0.4% e

17.4% e

0.6% e

0.9% e

0.7% e

0.5% e

0.5% e

2001

HIV weighted mean = 4%
Population HIV rate 0.1%e

Notes:
a = New York
b = Maryland, Connecticut, New Hampshire, North Carolina
c = Missouri
d = Oregon
e = Burton & Mertens (1998)
f = New York City Department of Health HIV Epidemiology Group & Thomas (2001)
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0.5% e

Only one study (Rosenberg et al., 2001), provided data on HCV and HBV prevalence
as well as IDU and four studies provided HIV and risk histories for IDU or MSM
allowing analysis (Ayuso-Mateos et al., 1997; Cournos et al., 1994; Rosenberg et al.,
2001; Susser, Valencia, & Conover, 1993).

3.4.3.1 Risk of HCV or HBV for patients with SMI stratified by IDU

HCV rates for patients with SMI and stratified by IDU history (Rosenberg et al.,
2001) are presented in Table 3.4. This study found that SMI patients, with an IDU
history, had HCV rates similar to US populations with IDU histories (Armstrong,
Wasley, Simard, McQuillan, Kuhnert et al., 2006). For patients with SMI but without
an IDU risk history, HCV rates were higher at 5% for patients with SMI (Rosenberg
et al., 2001) whereas US general population estimates are just under 2% for HCV
(Alter et al., 1999)

Table 3.4 Rates of HCV exposure stratified by IDU history and groups - patients with
SMI and the US population, from Rosenberg et al (2001)

HCV +ve %

SMI

USA population
(SMI –ve)

IDU +ve

62%

58%*

IDU -ve
5%
2%#
Note: *Armstrong et al (2006) # Alter et al (1999)

Likewise HBV rates for patients with SMI, reported by Rosenberg et al (2001), were
stratified by IDU history (Table 3.5). And similarly, the rate of HBV exposure for
SMI patients with an IDU history was similar to US population rates for those with
an IDU history (McQuillan, Coleman, Kruszon-Moran, Moyer, Lambert et al., 1999).
Patients with SMI but without an IDU risk history, had a much higher rate of 13%
(Rosenberg et al., 2001) than the US general population estimates at 5% for HBV
(McQuillan et al., 1999).
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Table 3.5 Rates of HBV exposure stratified by IDU history and groups - patients with
SMI and the US population, from Rosenberg et al (2001).

HBV +ve %

SMI

USA population
(SMI –ve)

IDU +ve

42%

50-80%*

IDU -ve
13%
Note *McQuillan et al (1999)

5%*

It seems that SMI patients with an IDU history had similar HCV and HBV exposure
prevalence rates to the others with an IDU history. The main problem identified is for
SMI patients without an IDU history, who were found to have higher rates of HCV
and HBV exposure than the general population without IDU histories.

3.4.3.2 Risk of HIV for patients with SMI stratified by IDU and MSM

There were four studies where it was possible to analyse the rate of HIV infection
stratified by risk behaviour histories for IDU or MSM (Table 3.6), (Ayuso-Mateos et
al., 1997; Cournos et al., 1994; Rosenberg et al., 2001; Susser et al., 1993). Weighted
means were calculated for both risk behaviours and the outcome factor of HIV
infection, as part of this analysis. The overall HIV prevalence rate was 4.6%.

A history of IDU was reported by 12% on average, and for this IDU subgroup 17%
were HIV positive. US rates of HIV infection for those that report IDU is similar at
15% (Aceijas, Stimson, Hickman, & Rhodes, 2004 ; Centers for Disease Control and
Prevention, 1999). Rate of MSM activity for the four studies, was close to 13% on
average, and 11% were HIV positive. HIV rates for MSM, in the US, is higher, at
19% (Centers for Disease Control and Prevention, 2006a). HIV rates for patients
with SMI and risk behaviour history were similar or slightly lower compared to US
populations with risk behaviour histories. Of note is that risk behaviours of IDU and
MSM activities, for patients with SMI were reported at elevated rates compared with
population data (Table 3.6).
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Table 3.6 Risk of HIV according to Risk Behaviours for patients with SMI

Author
Year
Country
N=
Schizophrenia Diagnosis

Susser
1993
USA
61
65%

HIV +ve % total

19%

IDU% Total
IDU HIV +ve%
Study p-value
Probability Ratio
Confidence Interval

Cournos
1994
USA
563
51%

Ayuso-Mateos
1997
Spain
390
40%

Rosenberg
2001
USA
930
45%

5%

5%

3%

= 4.6%

= 0.5-1.2% a

20%
42%
RR = 2.92*
(1.12-7.61)

10%
15%
p = 0.002*
OR = 2.04*
(1.31-3.17)

7%
48%
p<0.000001*
OR = 55.2*
(18.6-163.7)

17%
9%
OR = 5.49*
(2.89-14.58)

= 12%
= 17%

=1.5% b
= 15% c

MSM% Total
MSM HIV +ve%
Study p-value
Probability Ratio
Confidence Interval

18%
45%
RR = 3.25*
(1.26-8.34)

7%
13%
p = 0.04*
OR = 1.76*
(1.04-2.98)

4%
38%
p = 0.007*
OR = 12.7*
(2.7-60.9)

21%
6%
OR = 2.6
(0.97-6.96)

= 13%
= 11%

= 2% d
= 19% e

Population HIV ratesa

0.5%

1.2%

0.6%

0.5%

Notes: * Significance p <0.05 aBurton & Mertens (1998) bNHSDA (2001) cCDC (1999) dCDC (2012) eCDC (2006a).
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Weighted Means
x 4 studies

Population
Data

N = 1944

Some of the studies reported the HIV rates for some patients with SMI that did not
report the risk factors of IDU or MSM (Ayuso-Mateos et al., 1997; Cournos et al.,
1994; Rosenberg et al., 2001; Susser et al., 1993). Patients in Spain (Ayuso-Mateos
et al., 1997) without a risk history, had an HIV rate similar to the community rate of
0.6%. However, US patients without risk histories, had an HIV prevalence rate of
1.8% (Cournos et al., 1994) and 0.7% (Rosenberg et al., 2001). Although this was
lower than the rate for patients with risk histories, it was higher than the estimated
community rate of 0.5% (Burton & Mertens, 1998), (Centers for Disease Control and
Prevention, 1999).

All studies found statistically significant differences in HIV rates analysed by IDU
history. Male-to-male sexual activity was statistically associated with HIV infection
for all studies except one, Rosenberg et al (2001). The only study to report multiple
regression data identified that IDU and “homosexual” behaviour contributed
independently to the likelihood of being HIV positive (Cournos et al., 1994).

Together these findings indicate that patients with risk factor histories had prevalence
rates for HIV at least double the study groups’ rate and very much higher than
community rates. Findings also suggest that patients without risk history may also be
at risk. Previous studies have reported elevated risk behaviours for patients with
SMI. When analysis is made according to reported risk history, the rates of HIV,
HCV or HBV are not too different to the general population with risk histories.
Elevated rates of infection may be a problem for patients that do not report risk factor
histories.

3.5 FINDINGS - HEALTHCARE WORKERS RISK ASSESSMENT OF STIs
AND BBVs
The ten studies identified assessed “Knowledge” predominantly, as well as
“Attitudes” and “Behaviours” regarding STIs and BBVs, by healthcare workers. Key
areas of Knowledge identified were: (i) Epidemiology that covers natural history,
transmission risks and referral situations (ii) Management (iii) and Clinical
Symptoms. Research on Attitudes covered (i) attitudes to patients and (ii) attitudes to
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history taking. Behaviour included (i) behaviour regarding aspects of history taking
(ii) aspects of preparatory discussion for investigations (iii) and reported behaviours
when faced with a complex clinical problem.

The studies reveal misconceptions about treatment and transmission, especially for
hepatitis C. Overall medical practitioners have good knowledge generally and are
more knowledgeable than other healthcare workers (Richmond et al., 2007).

Knowledge on the epidemiology of HCV covers the natural history of HCV
exposure. In general, GPs overestimate the effects of HCV exposure regarding the
proportion of patients with HCV that would develop cirrhosis and hepatocelluar
carcinoma (Dev & Sievert, 2002). In the French study, lay persons were uncertain
whether HCV exposure results in carcinoma or death (Munoz Sastre et al., 2002),
whereas most patients with SMI (81%) correctly reported that HCV can cause death
(Goldberg et al., 2009).

Transmission risk knowledge, another component of HCV epidemiology revealed
mixed findings. A study of 267 Pakistani medical students’ that assessed knowledge
of BBVs, found that students overestimated risk from “sexual intercourse” and
underestimated transmission risk from “sharing razors, “needle stick injuries” and
“tattooing” (Anjum et al., 2005). Unfortunately, this study did not assess knowledge
regarding the risk behaviour of injecting drug use. Goldberg et al (2009) found that
88% of the 236 patients with SMI they surveyed correctly identified the risk of
“sharing needles” but were uncertain regarding “sharing razors” (68% correct).
A French study surveyed 431 adults from the general population and 9 HCV experts
(Munoz Sastre et al., 2002). The experts comprised, 6 liver disease specialists and 3
infectious diseases specialists (Munoz Sastre et al., 2002). The survey revealed that
lay persons were uncertain whether injecting drug users were most at risk for HCV.
Both the French laypersons and French medical experts were uncertain regarding
HCV being spread by using someone else’s personal belongings, such as
toothbrushes and nail clippers (possibly contaminated with blood). Laypersons
generally disagreed with the statement that HCV can be spread by possibly
contaminated personal belongings with a lower mean, and experts tended to agree.
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HCV risk from female genital secretions was another uncertainty, with the public
uncertain and the experts disagreeing that transmission occurred from infected
genital secretions (Munoz Sastre et al., 2002). The authors clarified as part of their
results that HCV virus may be isolated from genital secretions, “but the transmission
rate is at most very low” (Munoz Sastre et al., 2002, p. 597). Of note is that the
sexual HCV risk related to HIV +ve MSM was not described until about 2010 (Jin et
al., 2010)

GPs did not fare well regarding knowledge of STI and BBV epidemiology, such as
risks of acquisition and natural history (Anjum et al., 2005; Dev & Sievert, 2002;
Mulvey et al., 1997; Munoz Sastre et al., 2002). STI and BBV Knowledge on
asymptomatic/clinical disease features were well recognised by 444 GPs in the study
by Mulvey et al (1997).

Knowledge regarding HCV Management by doctors was not ideal. Australian
doctors (Dev & Sievert, 2002) and US Primary Care Trainees (Coppola et al., 2004)
showed variable and erroneous responses regarding treatments. Although no vaccine
is available for HCV, many groups, such as laypersons (Munoz Sastre et al., 2002),
75% of patients with SMI (Goldberg et al., 2009) and even 66% of doctors (Coppola
et al., 2004), incorrectly believed that HCV can be prevented by vaccine. Drinking
alcohol is not safe for patients with HCV which was correctly recognised by 77% of
Australian GPs (Dev & Sievert, 2002) and by 70% of patients with SMI (Goldberg et
al., 2009). In the French study both the lay population and medical experts were not
completely certain whether alcohol enhanced the risk associated with HCV and lay
persons tended toward believing that alcohol was not harmful while the medical
experts tended to believe that it was harmful (Munoz Sastre et al., 2002).

A study by Richmond et al (2007) examined attitudes by healthcare workers to
patients with HCV and found that some healthcare workers “displayed intolerant
attitudes toward people infected with HCV” especially if they had contracted
infection because of IDU activities (Richmond et al., 2007, p. 629). In contrast, 95%
felt compassion when hepatitis C was acquired through a blood transfusion,
compared with 63% when it was contracted through IDU.
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Fewer studies have been undertaken on the behaviours relating to STI or BBV testing
and all research has been by Australian research groups (Mulvey et al., 1997;
Richmond et al., 2007; Temple-Smith et al., 1999). Behaviours examined included
history taking, pre and post-test discussion regarding STIs and BBVs and the
meaning of results, as well as level of consultation. GPs reported behaviours such as
asking about safe sex, especially if the patient had a related presentation, but failed to
enquire with other presentations to the GP.

3.6

DISCUSSION

This review adds to prior reports (Cournos & McKinnon, 1997; Meade & Sikkema,
2005) by identifying that patients with severe mental illness, at least in the US,
continue to be at risk for HIV. The risk is particularly highlighted by comparing the
prevalence rates of risk factors and infections for patients with SMI with available
population data. Other STIs and BBVs, particularly HCV, are probably prevalent for
patients with SMI but the evidence for this is weaker as fewer studies have been
conducted.

Patients with SMI for the most part have elevated rates of risk behaviours and risk
partners that explain the high infection rates. Encouragingly some protective
behaviours, such as condom use at last sexual exposure, seem to be more often
reported. The untested dilemma here may be that patients with SMI, more frequently
report sex with casual partners at their last sexual encounter, which explains better
condom use. Having a severe mental illness appears to be an identifiable risk marker
or attribute indicating higher risk with higher prevalence rates for STI or BBV
infections.

Australia, and many other countries in the world, lack studies examining the
prevalence of STIs and BBVs for patients with SMI. In Australia, levels of risk
behaviour among patients with SMI are similar to their American counterparts and
warrant further evaluation. At this point in time, the Australian picture can only be
approximated from the mostly North American studies reviewed. From an
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epidemiological perspective, HIV infection in the general Australian population is
relatively low, at 0.07%, compared to USA rates of 0.5%. In Australia most HIV
infections are amongst MSM, with an HIV prevalence of 9 - 20% (Madeddu,
Grulich, Richters, Ferris, Grierson et al., 2006). Australian injecting drug users have
a 1-2% HIV prevalence and heterosexuals less than 0.07%. Australia has different
patterns than is seen in other countries where HIV is more prevalent in IDU and
heterosexual groups (Beyrer, 2007; National Centre in HIV Epidemiology and
Clinical Research, 2007). These differences highlight the need for research to
provide to “local” data for evaluation purposes (Hercus et al., 2005). Greater research
efforts are needed to better identify why these risk factors are so elevated amongst
this population with SMI.

It may be that Australia's current priority groups, are the subgroups also important in
the epidemiology of STIs and BBVs for patients with SMI. For example, HIV
infection may occur predominately among homosexual male patients with SMI, but
HCV and chlamydia are more likely to be concerns for the majority of patients with
onset of psychiatric illness in adolescence or early adulthood. These presumptions
are based on high drug use by patients with SMI coupled with injecting drug use as
the main vehicle for HCV transmission (Osher, Goldberg, McNary, Swartz, Essock
et al., 2003). In the general population up to 70% of long term injecting drug users in
Australia may have HCV whereas as stated few have HIV (National Centre in HIV
Epidemiology and Clinical Research, 2010). Such findings could be expected for
patients with SMI and IDU histories. Likewise the “likelihood of risky behaviour”
among young people is increased by psychiatric co-morbidity making infections such
as chlamydia, which is more common in young people, a threat (Kosunen, KatialaHeino, Rimpela, & Laippala, 2003; Ramrakha, Caspi, Dickson, Moffitt, & Paul,
2000).

In addition to the behaviours identified, patients with SMI are at risk because they
have greater difficulty in developing and maintaining intimate sexual relationships.
Sexual experiences for patients with SMI were noted to more often be casual,
unprotected, involve multiple partners and often occurred in the context of alcohol
and other drug use (Cooper, 2002; Kalichman et al., 1994). Alcohol is connected
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with sexual risk behaviours (Cooper, 2002) and this probably a similar picture for
patients with SMI. Kalichman et al, (1994) found that often patients with SMI,
socialised with other patients with SMI. It was postulated that sex and drug activities
(Kalichman et al., 1994) may be occurring within a subculture involving a small
network or core group of other patients in the close confines of a hospital, and may
add to the likelihood of sexual activity amongst patients with SMI and the related
risks of STI and BBV transmission. Research outside of specific mental health
contexts indicates that STIs and BBVs are often maintained by means of core groups.
The core group concept needs to be more fully evaluated for patients with SMI.

There is also a need to review the extent of drug paraphernalia sharing and not just
needle-sharing for patients with SMI, as this widens the transmission opportunities
for BBV (Kelly & Conigrave, 2002). Preventative facets of sexual health care are
important contributions to minimising the morbidity and mortality of BBV
communicable infections and future research might focus on these issues, such as
uptake of harm minimisation techniques.

Future research needs to improve on study methods. Better measurements, such as
infection rates based on biological specimens and standardised measurement
strategies for assessing risk behaviours as well as prospective cohort study design of
risk behaviours and infection rates, should be considered.

Prior research on the approach of healthcare workers is not very extensive. Doctors
seem well versed regarding most knowledge areas, except for aspects of
management. Overall they may be more knowledge but may not be applied in the
clinical assessment of patients. An understanding of this interplay will add to the
recognition of risk for patients. Doctors caring for patients with SMI who are also at
risk for STIs and BBVs, must recognise this risk. The doctors have a role to detect
and amend this risk when possible to minimise new infections. There have been no
studies that assess psychiatrists approach to STI/BBV infections, with populations
that have SMI. As such, a survey assessing psychiatrists and identifying strengths,
weaknesses and possible strategies to aid in detecting the potential risk to patients is
needed.
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3.7 CONCLUSION
The heightened risk for STIs and BBVs may be related to some of the highlighted
risks factors from this review, such as injecting drug use, and need to be addressed in
future research. Such issues to consider include incorporating STI and BBV research
with HIV research. There is strong evidence that STIs and HCV facilitate HIV
transmission and that early STI management should be part of a comprehensive HIV
prevention strategy (Fleming & Wasserheit, 1999). Of importance is the possible
higher risk of BBV infections for patients with SMI that do not report any risk
factors. This risk is intensified because it is not readily recognised nor detected by
healthcare workers. Poor attitudes to patients, as well as lack knowledge regarding
STIs and BBVs may add to the lack of assessment

This thesis has two studies that attempt to progress the understanding of risks for
patients with SMI. Study One attempts to provide a picture of risks and infections for
Australian patients with SMI. Study Two targets the psychiatrists themselves to
assess the extent that STIs and BBVs, particularly HCV, are recognised and assessed
for patients.
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CHAPTER FOUR

Study One: The risk of sexually transmitted infections and blood-borne
viruses for patients with severe mental illness2

4.1

OVERVIEW OF STUDY ONE

This thesis explores the risk of sexually transmitted infections (STI) and blood borne
viruses (BBV) for inpatients with severe mental illness (SMI) in Australia. Risk is
examined in the two studies that compromise this thesis and from the systematic
literature review of the previous chapter identifying potential risk factors for patients
with SMI. In Study One, the risk factors and rates of STIs and BBVs are presented.
Issues, such as screening and assessment for STIs and BBVs, particularly HCV, by
attending psychiatrists, are discussed in the next chapter, as Study Two.

Study One, as a cross-sectional-analytic study, aimed at identifying the level of risk
regarding STIs and BBVs for inpatients with SMI in the western suburbs of Sydney,
Australia. It is recognised that there is risk for patients with SMI regarding STI or
BBV infections. In particular, US studies describe high levels of HIV, and probable
HCV infection (Cournos & McKinnon, 1997; Rosenberg et al., 2001). Risk factors
considered for this study had been identified from the literature and presented in
Chapter 3 of this thesis. The extent that risk factors, such as unsafe sexual and drug
behaviours, are present was explored as Part 1 of the study protocol, and the
prevalence of STI and BBV infections as Part 2. This study attempts to elucidate the
role of the many risk factors and the role a diagnosis of SMI may contribute to risk of
infection.

For Study One the risk factors explored include those at the individual level; sexual
behaviours, substance use behaviours and “other” risk factors, such as healthcare
behaviours and incarceration. Risks at the partner level were also assessed, reviewing
2

Parts of this chapter were published as a letter - Lagios & Deane (2006)
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sex with partners at risk and possible sexual networks. The primary outcome factor
for Study One was the risk of an STI or BBV infection assessed by biological
specimen testing, as well as self-reported STI/BBV history.
Findings reported include the sample’s descriptive statistics of: (a) study factors;
demographic, medical and psychiatric variables, risk behaviours, risk partners,
“other” risk factors, testing rates and (b) outcome factors; prevalence of BBV and
STI infections. Statistical analyses involved (i) bivariate analysis of risk factors with
STI or BBV infections; (ii) comparison and statistical analysis of risk factors and
infections with the Australian population; and (iii) stratification of study participants,
permitting statistical analyses of infection risk for patients with and without risk
histories; and (iv) multivariate analysis predicting STI or BBV infection risk.

For this thesis the depth and breadth of risk factor identification, is extensive
compared to the approach of previous studies described in the literature review in
Chapter 3. Factors considered take into account an understanding of the local
demographics, as the area has a large multicultural population with immigrants from
countries with high STI or BBV prevalences. Another dimension is the exploration
of sexual networks for patients with SMI, with assessing partner choices and the
partners’ risks. Substance use risks, including drug use paraphernalia, are explored at
the individual level and through the risks of their partners. Comparisons with the
Australian population stratified by risk history, help define the context and the
magnitude of findings.

4.2 AIMS, OBJECTIVES AND HYPOTHESES

The aims of this research were:

1. Identify the levels of risk for STIs and BBVs for inpatients with SMI in western
Sydney.
2. To explore if a diagnosis of SMI could be associated with risk when compared to
the Australian population.
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The objectives of this research were:

1. To determine the prevalence and extent of risk factors for inpatients with SMI in
Western Sydney and compare with the Australian population
2. To determine prevalence of STI/BBV infections for inpatients with SMI in
Western Sydney, and compare with the Australian population
3. To assess the relationships of risk factor histories with STI/BBV infections
4. To assess the contribution of SMI diagnosis to STI/BBV infections

It was hypothesised that:

1. Patients with SMI engage in a wider range of risk behaviours (e.g., injecting drug
use or unprotected sexual intercourse) and do so more frequently, than the general
population.
2. Patients with risk factor histories are at a higher risk for STI and BBV acquisition
compared to patients without risk factor histories.
3. Patients with SMI compared to the Australian population with comparable risk
factor histories are at a higher risk for STIs and BBVs.
4. It is hypothesised that the nature of having an illness such as SMI, identifies and
places patients at risk for both risk behaviours and acquiring infection.

4.3 METHOD

This section provides a descriptive overview of the method used for Study One. It
presents a description of the study participants, descriptions of the measures and
procedures used in the study. Measurements are discussed at length with particular
attention to measuring individual risk behaviours, risk partners and networks as well
as means to measure STIs and BBVs. This section also presents the ethical and
potential research bias issues posed by the study.
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4.3.1 Ethical Issues

The Human Ethics review committees, of the University of Wollongong and Sydney
West Area Health Service (SWAHS), reviewed and approved all protocols
(Appendix 1). The protocol was created with reference to ethics, privacy and legal
issues given that both research on patients with psychiatric illnesses and research
exploring sex and drug behaviours are highly sensitive. In preparing the ethical
review, documents examined included the Royal Australian and New Zealand
College of Psychiatrists Code of Ethics (RANZCP, 2010; RANZCP., 1998),
Australian Injecting and Illicit Drug Users League (AIVL) Statement on Ethical
Issues for Research Involving Injecting/Illicit Drug Users (AIVL, 2002), NHMRC
Psychiatric Research, Human Research Ethics Handbook Commentary on the
National Statement on Ethical Conduct in Research Involving Humans (NHMRC &
Commonwealth of Australia, 2001), NSW Health Privacy Manual (NSW Department
of Health, 2005) and Public Health Act (NSW Consolidated Acts, 1991).

Consideration of issues such as respect, capacity to provide consent, confidentiality
as well as potential risks and conflicts of interest must be taken into account to obtain
informed consent and valid participation in research, for patients with psychiatric
illness (RANZCP, 2010). Various steps were taken in the study design to minimise
any pressures that may jeopardise the voluntary nature of consent and these steps
were explained in the participant information sheet (See Appendix 2). Attempts to
minimise coercion were addressed by ensuring the researchers were not involved in
the primary care of the patient, and by having the initial approach to participate
addressed only by the treating psychiatrist, who was not an investigator in the
research. The study required that patients be referred to the study, and that prior to
referral, assessment of rational decision-making, capacity and emotional stability be
made by the participant’s attending psychiatrist. Participants’ information sheets
were distributed once referred and the researcher reviewed the information package
with the participant and reinforced the voluntary nature of participation and
confidentiality. Once all of the above were satisfied then participants provided full
informed consent.
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Confidentiality and privacy for patients with psychiatric illness was very important
and incorporated into the study design. Study participants were advised that all
aspects of this study would be strictly confidential and only the researchers would
have access to personal information. Any publication of the results from this study
would use de-identified group data. Confidentiality was maintained at all levels of
the study by using codes instead of participant’s names, for all non-routine data
collected. Routine clinical tests for patients, utilising biological specimens, were not
de-identified and used patient details, in keeping with institutional practices. This
occurred for those patients who had testing completed as part of their routine care
and provided permission for these results to be used as part of the research. Patients
with research related biological specimen testing had de-identified coding.

Limits to confidentiality and privacy were discussed with study participants. Study
participants were informed that notifiable STI and BBV infections were reported by
the laboratory to NSW Health Department using a de-identified format and in
accordance with the Public Health Act 1991 (NSW Parliament, 1991), (see Chapter
2, section 2.2.2). Patients were advised that any information indicating a danger to
the participant or others would be referred to the treating staff. The interview
questions only asked about sex between adults and about previous drug use, to
minimise inadvertent disclosure of illegal activity. Study participants were
counselled that information provided about illegal activities such as dealing drugs or
sex with minors would need to be reported. An identified contagious STI or BBV
infection would require contact tracing by the participant with the help from an
appropriate healthcare worker.

Interviews were conducted in private, in a consultation room available on the ward.
Copies of the interview questionnaire, with sensitive risk behaviour information,
were not available in the patients' medical record but patients were advised that their
attending psychiatrist would be consulted on risk behaviours that required medical or
psychiatric care. Paper copies of biological specimen results, which were part of
routine care and had patient names, were filed in the patients' medical record. Results
of research only tests with de-identified codes were not part of the patient’s medical
record.
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4.3.2 Procedure

All individuals admitted as inpatients to the acute care wards of Cumberland
Hospital, Western Sydney, Australia, during the study period of May 2007 to August
2008 were potentially eligible to participate in Study One. Cumberland Hospital is
the largest psychiatric hospital in the region, and is about 20 kilometres west of the
centre of Sydney, see Figure 4.1 (Google, 2012). During the study period there were
1791 admissions. Patients were not approached directly but were first assessed by
their attending psychiatrist before being referred to the study and needed to be both
clinically stable and have the capacity to provide informed consent to be recruited
(see 4.3.1 Ethical Issues). Participant flow for the project is illustrated in Figure 4.1,
at the end of this section, showing the total potential population admitted to
Cumberland Hospital over the study period, numbers of referred, numbers deemed
ineligible, numbers and reasons of excluded patients and final number of study
participants included.

Cumberland Hospital

Figure 4.1 Map Cumberland Hospital, Western Sydney, Australia
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All healthcare workers on the ward, including psychiatrists, had education regarding
the study prior to commencement. Recruitment though was slow, despite weekly
reminders at ward meetings and monthly update-letters to the ward staff regarding
numbers recruited to the study. Given very slow recruitment, an amendment was
submitted to the Human Research Ethics committees, seeking a revision to the
protocol to approach potential study participants directly, however this was not
approved. Recruited patients participating in this study had provided informed
consent to both Part 1 and Part 2 of Study One.

Part 1 was designed to assess risk factors with information collected by a semistructured interview questionnaire and from review of the patient medical record.
Part 2 assessed BBV and STI rates, from test results of biological specimens and
from history of self-reported STIs/BBVs, provided at the time of the interview.
Patients, who had recent Cumberland Hospital screening tests, within the last 3
months, or who had a previous infection, were identified from the interview. If there
was a history of previous testing then medical records were reviewed to allow
verification and recording of results. Recent tests could have been serology for
syphilis, HBV, HCV or HIV and urine or cervical specimens for gonorrhoea and/or
chlamydia. Patients that had not had a particular BBV or STI test in the last 3 months
were invited to provide a biological specimen for testing, as part of Study One.

Study participants had pre-test discussion and information provided for BBVs and
STIs prior to provision of samples for testing. The aims of pre-test (and post-test)
discussions, prior to screening, are “to provide information and support around the
testing procedure, to minimise the personal impact of diagnosis, to change healthrelated behaviour and to reduce anxiety of the person being tested (ASHM, 2004, p.
90). SWAHS current practice was for completion of an area health service consent
form for HIV antibody testing (see Appendix 2), providing evidence to the hospital
venipuncture nurses of pre-test discussion. Samples of both blood and urine were
processed by the hospital nurses and sent to the hospital’s laboratory for testing.
Results were available within a week.
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Testing for BBVs and STIs was performed at ICPMR, Westmead Hospital, which is
a testing reference laboratory in New South Wales. Serology tests assessed for HCV,
HIV, HBV and Syphilis exposure. Urine, or recent cervical specimens were tested
for Chlamydia trachomatis and Neisseria gonorrhoeae infections. If the initial HBV
test was positive then automatically the laboratory would assess for chronic HBV
infection. Chronicity of HCV exposure, though more likely than for HBV, was not
determined immediately if a positive HCV test occurred, as repeat venipuncture is a
requirement for further assessment.

Interviews were conducted in private and took ten to twenty minutes, according to
the extent of risk behaviours elucidated. A paper interview record form was used to
store all information from the interview (see Appendix 3). The paper interview
record form was stored separately and not available in the patients' medical record.
Biological specimen results could have been from tests that were part of routine care
and ordered by the attending psychiatrists, or from tests that were part of Study One.
Routine care biological specimen results with patient details were filed in the
patients' medical record in accordance with current medical record practice. Study
test results with de-identified patient details and the paper interview forms were
stored in locked filing cabinets in the researcher’s office, initially at Parramatta
Sexual Health Clinic and then at Cumberland Hospital with the researcher’s
relocation. Paper and electronic data are to be securely stored for a period of seven
years after the study’s completion.

Data was entered into a specifically developed Microsoft Office Access database and
then read into Predictive Analytics SoftWare for windows version 18 PASW
Graduate Pack 18 for statistical analyses (SPSS Inc, an IBM Company, Chicago,
2000) with appropriate variable and value labels. Integrity checks were conducted on
the data for inconsistencies and extreme values using the SPSS query language.
The researcher provided post-test discussion to the participant and counselled
regarding risk behaviours, positive test results, harm minimisation techniques,
contact tracing requirements and further testing requirements at the time of result
provision. Study participants had been advised that the attending psychiatrist would
be consulted on risk behaviours and biological specimen results that required further
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follow-up and management. The psychiatrist also organised follow-up for patients
who were discharged including results being sent to the patient’s GP.

Some study participants did not respond to every item on the questionnaire and did
not choose to have every STI and BBV screening test. Provision of substance use
behaviour history and participation in BBV screening had the best responses.
Completion of these components was the post-hoc criterion for inclusion in the
study.

Cumberland patient demographic and serologic STI/BBV aggregate data was
available for all patients admitted during the study period. This was used to review
the extent of participation, representativeness of participant sample and to gauge the
extent of STI/BBV infections for all Cumberland Hospital inpatients.

The study findings of risk factors and infection prevalence were compared to the
Australian population data from the recent “Sex in Australia: Australian Study of
Health and Relationships (ASHR)” (Smith et al., 2003b), with nearly 20,000
participants. The ASHR survey provided details of sexual, substance use risk and
“other” risk factors such as incarceration history. It is presumed that the ASHR
survey would have a negligible number of participants with SMI. The ASHR survey
is broadly representative of the Australian population (Smith et al., 2003b) and it
could be expected that 1% (about 200) of the ASHR telephone survey potential
participants may have SMI. Patients with SMI are more likely to not have ready
access to a telephone, as described by Jablensky et al (1999, p. 29), whose research
project found that 12% of patients with SMI were homeless or in institutional care.
The ASHR study did state that “...Households without a telephone line were outside
the scope of the study” (Smith et al., 2003b, p. 109) and as such persons with SMI
were probably underrepresented and few in number.

4.3.3 Study Participants

Ninety-five participants provided some data for both Part 1 and Part 2 of Study One,
from the potential pool of 1791 consecutive patients with SMI, admitted to the acute
59

care wards of Cumberland Hospital, Sydney Australia. Patients were aged over 18
and admitted between May 2007 and August 2008. To be considered for inclusion in
Study One, patients had been referred by their treating psychiatrists. This identified
the 95 study participants, with the participants being a referred sample and identified
at “risk sample” by the psychiatrists see Figure 4.2.

Inclusion, as discussed in the procedure section, was post-hoc based on provision of
substance use behaviour history and BBV screening. The overall referral rate was
low, estimated at 8% (141/1791), but the participation rate for those referred was
satisfactory with 77% (108/141) participating in any part of the study, and 68%
(95/141) for those participating in both Part 1 and Part 2.

Enrolment

Cumberland Patients
n = 1791

Referred by Psychiatrists
n = 141

Allocation

Excluded n = 33
- Not available for interview n = 27
- Declined to participate n = 6

Participated in either Part 1 or Part 2 of Study One
n = 108

Final Analysis

.

Excluded n = 13
- Not in both Part 1 & Part2

Total Sample
N = 95
Cohort participated in
Part 1: Risk Factors AND Part 2: BBV and STI prevalence

Figure 4.2 Participant Flow Chart for Participant Involvement in Study One
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The referred study sample of 95 had 57% (54/95) males and 43% (41/95) females.
The mean age of the group was 35 years. There were more older groups of patients,
with only 13% aged less than 24 years and 23% aged 25 to 29 years. The largest
group at 30%, was the age group of 30-39 years and 35% were in the two age groups
of 40-49 years, or older than 50 years. Most were born in Australia (72%), with the
next most prevalent groups born in the Middle East (9%) and Pacific Islands (7%).
Despite most being born in Australia, only 50% described their cultural background
as Australian. Other cultural groups identified were Middle Eastern (11%), Pacific
Islander, including New Zealand (9%), European (4%), and Indigenous (3%). The
majority of study participants were single (88%). Sixty-seven percent had never been
married, 16% were currently divorced or separated and only 12% were married or in
a defacto relationship. Twenty three percent did not have a known or fixed address.

Diagnoses, including psychiatric diagnoses, were self-reported, and verified from
medical records review. Schizophrenia was the most commonly diagnosed mental
disorder (67%) then bipolar disorder (15%) and major depression (6%). Secondary
diagnoses for study participants were personality disorder (20%), alcohol disorder
(37%), and other drug disorders (59%). The mean number of years since diagnosis
was 10.7 years with a range of 1-31years. The mean number of admissions ever for
participants was 6.4 with a range of 1-25. Other significant health problems included
cardiovascular disease (6.3%), diabetes (6.3%), asthma (9.5%), epilepsy (12.6%),
thyroid (2.1%) and systemic lupus erythematosus (1.1%).
4.3.4 Measures

Study One, a cross-sectional-analytic study, was also a descriptive surveillance
study, aiming to simultaneously measure and describe the prevalence of risk factors
as well as prevalence of STIs and BBVs for patients with SMI and assess for
associations. This choice of study type was based on World Health Organisation
(WHO) advice, that a surveillance study is appropriate to research the question of
prevalence of health issues (Grimes & Schulz, 2002; WHO, 1999). Concerns in such
studies, include considering validity and reliability of measurements and possible
bias.
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Measurements included risk factors, assessed in Part 1, utilising a standardised
interview questionnaire, with questions compiled from previous studies. BBV or STI
infection measurements in Part 2, were by self-reported STI/BBV history, as used in
previous studies, and by testing biological specimens. In addition, there was analysis
of demographic and serology data available for all patients admitted to Cumberland
Hospital during the study period.

Measurements of Study One included:
Part 1 Standardised Interview Questions assessing Risk Factors
a. Demographic: age, country and region of birth, cultural background, marital
status.
b. Medical History: condition and details.
c. Psychiatric History: diagnosis, secondary diagnosis, years since diagnosis,
number of admissions.
d. Sexual Behaviours: sexual identity, sexual experiences with opposite and
same sex partners, sexual activity, number of sexual partners, sex after drug
or alcohol use and condom use.
e. Sexual Risk Partners: regular relationships, last sexual encounter, sexual
contact with partners at risk, sources of sexual contacts, sex for favours or
payment including sex work, sex with partners with drug or alcohol issues
and sexual coercion.
f. Substance Use Behaviours: illicit drug use, IDU and behaviours associated
with injecting; needle sharing, exposure to shared paraphernalia or exposure
to others’ blood.
g. “Other” Risk Factors: screening, vaccinations, tattoos, piercings and
incarceration history.

Part 2 Prevalence of STIs or BBVs
a. Self-Reported STI/BBV diagnosis.
b. Biological Specimen Results:
(i) Serology
HCV exposure - Bio-Rad Monolisa HCV Ag/Ab ULTRA assay enzyme
immunoassay.
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HIV exposure - Abbott HIV Ag/Ab Combo Architect Analyser.
HBV exposure - Abbott Anti-HBc II Architect Analyser (positive HBV core
antibody results tested automatically for HBV surface antigen to identify
chronic infection).
Syphilis exposure - Abbott Syphilis TP Architect System.
(ii) Genital Specimens - Urine or cervical swab.
Chlamydia trachomatis and Neisseria gonorrhoeae - Roche Polymerase
Chain Reaction (PCR) Cobas Amplicor assay, nucleic acid amplification
tests.
Other available measures for Study One
Cumberland patients’ demographic data for this study period
Cumberland patients’ serology results for this study period
4.3.4.1 Bias in Risk Factor Measurements

Measurements in research studies attempt to gauge a true value and if the gauged
measure of interest differs from the true value, then bias or measurement error occurs
(Irwig & Cumming, 1993). Measuring behaviour is a difficult process, as Catania et
al (1990 ) have written, because “gold standard tests” readily identifying the true
values are lacking. Bias in research can occur at any level from the literature review
of the study question, to study sample selection, to data analysis and presentation of
results. Measurements may be affected by selection, information or confounding bias
(Fenton, Johnson, McManu, & Erens, 2001). With proper techniques and
considerations regarding design, data collection and analysis, bias can be prevented
or minimised.

Of particular concern for Study One is selection or sampling bias which can lead to a
non-representative sample, with either underrepresentation or overrepresentation.
Sampling patients with SMI is more difficult than for a general population. Inclusion
of patients with SMI for research can be controversial, but overall it is feasible. It has
been shown that patients with schizophrenia can elect to participate in research, that
they have been evaluated as having “…strengths in the research consent process...”
(Roberts, Warner, Brody, Roberts, Lauriello et al., 2002, p. 573) and that they are
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keen and willing to participate (Roberts, Warner, & Brody, 2000). Patients and
psychiatrist have “substantial congruence…regarding their views of research
procedure risks” as both psychiatrists and patients felt that research procedures, such
as questionnaires and blood tests, were less risky than the usual daily risks for
patients (Roberts, Warner, Hammond, & Dunn, 2006, p. 1629). Conversely, patients
with SMI may be non-participatory or be excluded because of the effects of their
illness, such as lack of coherence, paranoia and poor literacy, leading to selection
bias. Even if patients are included and potentially representative, non-responsiveness
can still occur during the research because of their illness, or because questions are
perceived as intrusive or too sensitive. Some patients can have trouble with research
questions that do not have any immediate relevance, or do not provide clinical utility
and thus fail to participate comprehensively leading to selection bias (Dunn, Palmer,
Keehan, Jeste, & Appelbaum, 2006; Fulford & Howse, 1993). Attempts in the design
phase of Study One to minimise selection bias include selecting all subjects from one
hospital, widely educating all healthcare workers as well as the psychiatrists
regarding referral of patients to the study, and assessment of sample
representativeness with comparison, in the results section, of study participants with
non-participants.

Confounding bias, occurring with confounding variables may be controlled by
random selection of the study participants, or statistical methods such as stratification
and multivariable analysis (McNamee, 2005). Careful consideration of questions
used to attain data that are based on knowledge of the subject area, also helps to
minimise confounding errors. One example is recognition that prison is a risk for
HCV infection because of the confounding effects of injecting drug use activities
whilst incarcerated (Butler, Boonwaat, Hailstone, Falconer, Lems et al., 2007).

Information bias, be it subject, instrument or researcher, can be addressed, to some
extent, by the validity and reliability of measures. Validity generally relates to the
extent that the test measures, what it is purported to measure. If it is difficult to
assess validity, then a surrogate measurement reliability, the consistency of the
measurement, can be used. Information bias is a significant problem with psychiatric
research because of missing data, “…no matter how careful and committed the
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psychiatric researcher, there invariably will be subjects with one or more missing
measurements...” (Gibbons, Hedeker, Elkin, Waternaux, Kraemer et al., 1993, p.
741). The design of Study One implemented the following steps to minimise
information bias: (i) “binding” of the interviewer with respect to the study hypothesis
(ii) use of only one interviewer who was trained and experienced (iii) careful
wording to avoid leading questions (iv) offering categorised values for subjects to
select instead of requesting specific values (v) when possible checking answers
against records (Vermooten, 2006).

4.3.4.2 Measuring Risk Factors

A risk factor questionnaire should consider inclusion of sexual behaviours, a past
history of STIs or BBVs, as well as covering substance use and other risk factor
histories (Centers for Disease Control and Prevention, 2006b; Huffam, Haber,
Wallace, & Bradford, 2004). Measurements of behaviours are used as surrogates for
risk of infection acquisition. Although behaviour is clearly associated with STIs and
BBVs it is important to remember that acquisition requires contact with an infected
person (Aral, 2004; Peterman, 2002). Thus the risk in risky behaviours such as anal
intercourse without condoms or injecting of drugs with an unclean syringe is
embedded in the infection status of the source, and if uninfected, there will not be
transmission despite risky behaviour. When asking behaviour questions, the extent
and circumstances that risk behaviours occur, affect results, as has been illustrated,
with some studies finding that “people tend to have safe sex with risky partners and
risky sex with safe partners” (Peterman, 2002). Thus research questions that do not
explore circumstances and extent of the behaviour and partners’ risk inappropriately
dilute associations.

The approach taken in Study One was to utilise previous questionnaire tools, such as
the Australian Study of Health and Relationships (ASHR) questionnaire (De Visser,
Smith et al., 2003b). The Australian survey used and adapted questions from large
overseas British (Johnson, Wadsworth, Wellings, Bradshaw, & Field, 1992) and
French studies (Anonymous, 1992a; Anonymous, 1992b). The ASHR researchers did
not strictly perform their own validity tests (Smith et al., 2003b) , but stated that
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“..self-reports of sexual behaviour can be argued to be of sufficient reliability and
validity”. They relied on comparison with other data sources to evaluate reliability
and validity (Hubert, Bajos, & Sandfort, 1998; Johnson, Wadsworth, Wellings, &
Field, 1994; Laumann, Gagnon, Michael, & Michaels, 1994). Use of slightly
modified ASHR questionnaires by Sydney Vietnamese men (O’Connor, Wen, Rissel,
& Shaw, 2007; O’Connor, Wen, Rissel, Shaw, & Quine, 2007) and NSW prisoners
(Richters, Butler, Yap, Kirkwood, Grant et al., 2008) adds to the questionnaires’
validity, as well as feasibility and acceptability by participants.

There have been assessments of reliability specifically for patients with SMI.
McKinnon et al (1993) wrote “high test-retest reliability was found for; number of
sexual partners, frequency of (sexual) episodes, and proportions of episodes
involving vaginal intercourse and use of condoms” and has been confirmed by other
groups (Weinhardt, Carey, Maisto, Carey, Cohen et al., 1998). Good reliability has
been described for self-reports of substance use behaviours generally (McElrath,
Chitwood, Griffin, & Comerford, 1994) and for reports of substance use behaviour
by patients with SMI, particularly for alcohol (Maisto, Carey, Carey, Gordon, &
Gleason, 2000).

Part 1 interview questions were mostly from the published large Australian survey
(ASHR) (173 items) (Smith et al., 2003b, p. 106). Some questions were from AIDS
Risk Inventory (2 items) (Chawarski, Pakes, & Schottenfeld, 1998; Rosenberg et al.,
2001), from the Sexual History/HIV risk assessment (6 items) (Carmen & Brady,
1990; Thompson et al., 1997) and Risk Behaviour Questions from Body and Mind
Project Questionnaire (2 items) (Davidson et al., 2001; Volavka, Convit, O'Donell,
Douyon, Evagelista et al., 1992). Study One’s procedure differed from the ASHR
survey, as data collection involved face-to-face interviews. This was the most
feasible method, as patients were currently in a hospital setting. Face-to-face
interviewing allows for a good level of responses (Smith et al., 2003b, p. 109) and
has similar acceptance rates as telephone surveys (Anonymous, 1992b).
The AHSR based interview schedule asked about risk factors that were “recent” in
the “last 12 months”, and “ever” during the respondent’s lifetime, providing
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quantitative and qualitative information. The questionnaire data variables were
mostly dichotomous or categorical and set out with opening questions to enable
prompt cessation of inapplicable sections (see Appendix 3). The utility and
attractiveness of the ASHR questionnaire is that the interview length could be
filtered and tailored to the level of activities reported. This important element
enhances participant involvement and efficient risk factor measurements. The
question format utilised closed ended-responses with categorical answer options,
providing quantitative data for most questions. Use of questions from the ASHR
interview allowed some comparability, validity, reproducibility to the large
Australian data available.

4.3.4.3 Measuring Partners and Networks

Partner network characteristics play a major role in sexual and substance risk
behaviour, determining the progression or regression of infections. Researchers have
developed methods to understand partner connections and network characteristics
and their crucial role in STI and BBV epidemiology. Questions on sexual partnerings
in this study, took an egocentric approach which can “obtain an in-depth
characterization of the nature of individual personal networks in specific
populations” (Doherty, Padian, Marlow, & Aral, 2005, p. S44). The other option is a
sociometric or whole network study approach, which tries to enroll all members of a
network and define interrelationships and transmission risk. Information is built up to
identify all the network components. Such research uses network analysis but can be
expensive and difficult to implement, especially for hospital patients (Doherty,
2011).

Egocentric surveys obtain self-reported data of recent risk activities of the participant
only. Questions ascertaining sexual risk; such as number and type of partner, type of
contact, protective behaviours and partners’ risk histories, attempt to identify risk in
the network (Doherty, 2011). Questions that assess drug networks and risk can
likewise be asked, such as the extent and details of drug sharing contacts. This
approach is a conventional survey approach, cost-effective and well trialed (Doherty,
2011). As contacts do not need to be identified it is postulated that more honest
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reporting of partners and their risk is possible with egocentric study design (Doherty
et al., 2005). This thesis has incorporated an egocentric approach to understand
network risks, particularly for sexual risks. There were 10 items, that assessed sexual
risk partner contact “ever”, and 10 items that assessed for risk contacts in the “last 12
months”. Four items for risk contacts were from (Thompson et al., 1997), and the
other six developed by the researchers based on current risk assessment from the
literature and policies (Cooper, 2002; Kalichman et al., 1994; NSW Department of
Health, 2006a, 2007; NSW Department of Health Sydney, 2006; UNAIDS, 2009).

4.3.4.4 Measuring STIs and BBVs

Study One aimed to simultaneously measure the prevalence of risk factors as well as
prevalence of STIs and BBVs for patients with SMI. STI and BBV prevalence are
also outcome variables, part of the analytical statistics. Tools to measure STI and
BBV rates include testing of biological specimens and assessment by structured
interview to gauge history of self-reported STIs/BBVs. Current concepts in assessing
for STIs and BBVs, such as screening and performance measures of tests are
important in understanding Study One’s measurements.

Testing of biological specimens identifies both infections that may be causing
disease and infections that may be asymptomatic but present in an otherwise healthy
person. Services that target early asymptomatic infection detection are part of
secondary prevention measures and termed “screening” (Wald, 2001, p. 1).
Screening can be a risk reduction programme at the community-level. Many people
view screening as a check to prove that “no infection” is present and may participate
because of such reasoning. Part of this thesis will consider how extensive screening
should be for patients with SMI.

Many of the STI and BBV biological specimen tests, particularly serological tests,
have excellent sensitivity and specificity (Centers for Disease Control and
Prevention, 2009). Genital specimens can differ in their capabilities to truly detect
infection because of sample site. For example, chlamydia infection may not be
identified for women when a urine test is used for screening, instead of a cervical
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swab specimen. The test performance is balanced by the fact that urine tests have
better patient acceptability and cost utility (Serlin, Shafer, Tebb, Gyamfi, Moncada et
al., 2002; Watson, Templeton, Russell, Paavonen, Mardh et al., 2002). In Study One,
both urine and cervical specimens are used to test for chlamydia and gonorrhoea
according to the clinical requirements and acceptability and choice of female
patients.

The other component of STI and BBV prevalence rates is measuring STI and BBV
by self-report. Though this is a less satisfactory approach it is often taken in research
because most studies are unable to collect biological specimens (Dariotis, Pleck,
Sonenstein, Astone, & Sifakis, 2009). Assessing rates in this manner is an
underestimate of true levels (Dariotis et al., 2009; Harrington, DiClemente,
Wingood, Crosby, Person et al., 2001; Van Duynhoven, Nagelkerke, & Van De Laar,
1999). Self-reports asking for all specific STIs or BBV and not as a general question
provide the best responses and is the approach taken in this thesis and the approach
taken by the ASHR researchers (Grulich, de Visser et al., 2003c).

4.3.5 Statistical Issues

The data collected from the study was analysed using Predictive Analytics SoftWare
for windows version 18 (PASW Graduate Pack 18) for statistical analyses (SPSS Inc,
an IBM Company, Chicago, 2000).

Sample size estimates and power were determined to allow comparison of this
study’s findings with Australian population estimates. Calculations of sample size,
were based on statistical power set at .80 and p = .05 (Brant, 2010; Pezzullo, 2009)
and were used to estimate the required sample sizes for a range of possible outcome
factors of HCV exposure, HBV exposure, chlamydia infection, as well as the selfreported STI diagnosis.

To compare HCV exposure findings of this study to the Australian population, it was
calculated that a sample with 40 patients with SMI was required. Calculations were
based on the Australian rate being 1.0% (National Centre in HIV Epidemiology and
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Clinical Research, 2007) and the previous published rates of HCV in patients with
SMI close to 20% (Lacey et al., 2007; Rosenberg et al., 2001).

Patients with SMI may have rates as high as 23% for HBV exposure (Rosenberg et
al., 2001) and comparison with the Australian population with rates less than 1%,
(National Centre in HIV Epidemiology and Clinical Research, 2004) (Grulich, de
Visser et al., 2003c) would require 26 SMI patients to have sufficient power.
The variable, self-reported STI, incorporating all infections apart from HCV, HBV
and HIV, was considered in assessing a suitable sample size, given statistical power.
If the rate of self-reported STIs, in patients with SMI, is as high as reported by
Klinkenberg et al (2003) at 44%, and the Australian population rate is 19% (Grulich,
de Visser et al., 2003c), then we would require at least 61 patients with SMI to be
able to compare findings to the Australian population.

Calculations for assessing infections such as chlamydia would require a sample of
162 patients with SMI and infections such as gonorrhoea, HIV, or syphilis would
need over 1000 participants with SMI, to be compared to the Australian population.

Demographic and STI/BBV serology testing data, as discussed, was available
describing the admitted patients for the period of May 2007 to August 2008, from
Cumberland Hospital medical records and from the ICPMR Laboratories Information
Technology department. Demographic information was provided as summary data.
Data for BBV testing and results was available as an independent dataset. The results
section covers descriptions of the Cumberland Hospital population during the study
period, including total STI and BBV prevalence rates, as well as comparison of the
study participant sample representativeness.

Statistical tests for Study One included univariate descriptive statistics, such as
frequencies. Sexual behaviour is reported for males and females as well as overall
totals. For the “other” risk factors and prevalence rates, totals are more often
reported, due to low frequencies and less gender discrepancy. Bivariate analyses
using chi-square statistics and ensuing odds ratios and confidence intervals were used
to examine the relationship of risk factors with the prevalent STI or BBV infections
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and self-reported STIs/BBVs dependent variables. Logistic regression analysis,
because of categorical variables, was performed to identify the contribution of
significant risk factors to prevalent infections.

Chi-square testing, with stratification by risk, was also used to statistically compare
the findings from this study with the Australian population data from the “Sex in
Australia: Australian Study of Health and Relationships (ASHR)” (Smith et al.,
2003b) and provide a broad perspective on the extent of possible problems.

Statistically significant results were recognised when the p-value was less than the
significance level α of 0.05. The Bonferroni correction method was used, to
counteract the problem of multiple comparisons and minimise the risk of Type I
errors, i.e. findings of false "significance", (Bland & Altman, 1995). The Bonferroni
adjustment is the revised p-value, at a statistical significance level of 1/n times the
number of comparisons assessed. Each group and table of analyses reported the
appropriate statistically significant p-value.

Methods for handling missing data included review of representativeness of
participants. For univariate analysis, case-wise deletion was undertaken to maximise
the number of responses able to be included. For logistic regression analysis, pairwise deletion, which is the default method for PASW Graduate Pack 18 (SPSS Inc,
an IBM Company, Chicago, 2000) took place.
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4.4

RESULTS

The results section has missing data for many of the variables. The missing data
reflects that participants for this study were patients with severe mental illness, in an
acute care psychiatric hospital. As previously discussed, this is a problem often seen
in psychiatric research (Gibbons et al., 1993) and is due to study participants ’
inability, or refusal, to provide a response to every item. All results are provided with
information related to the number of total responses as the denominator.

4.4.1 Comparison and representativeness of study participants

During the study period there were 1791 patient admissions in total to Cumberland
Hospital, 989 men (55%) and 802 women (45%). Demographic and BBV testing
data was available describing the 1791 admitted patients for the study period. A
review of the representativeness of the study participant population of 95, with the
1791 total number of Cumberland patients admitted during the study period, was
undertaken. Assessment of the overall representativeness of the sample, required a
comparison of the 1696 non-participating Cumberland patients (N = 1791 total minus
95 study participants) admitted during the one year study period with the study
participant sample of 95, along a limited number of available characteristics.
Comparisons were also undertaken with the study sample of 95 and the Australian
population. The study participants had various age groups comparisons determined to
match the categories used by Cumberland Hospital Medical Records and by AHSR
survey.

Chi-squared analyses indicated that study participants were slightly younger, less
likely to be currently in a relationship (married or defacto) and more likely to have
never been married, or divorced, than either the non-participant Cumberland patient
group or the Australian population (data not shown). There were no significant
differences between study participants, Cumberland patient non-participants and the
Australian population regarding region of birth, considered as Australia or outside
Australia.
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4.4.2 Sexual Risk Behaviours
Sexual behaviours explored sexual identity, experience, activity. The many different
variables reflect the “complexities of human sexuality” (Smith, Rissel, Richters,
Grulich, & de Visser, 2003a, p. 144). As expected from the ASHR survey (Smith et
al., 2003a), the reporting of identity and experience did not match. Other sexual risk
behaviours explored included number of sexual partners, sex after drug and alcohol
use and condom use.

4.4.2.1 Sexual Identity and Experiences

Males mostly reported heterosexual identity whereas females reported a wider range
of sexual identity but with heterosexual still the most common (Table 4.1)

Table 4.1 Comparison of Sexual Identity and Experiences
2
Males
SMI
ASHR
N=9729
p- value
OR
CI
N = 49
n
%
n
%
lower
Sexual Identity
Heterosexual
46 93.9%
9476
97.40%
2.37
0.120
0.41
0.13
Homosexual
0
0.0%
156
1.60%
0.80
0.370
Bisexual
0
0.0%
88
0.90%
0.45
0.500
63.39 16.89
Uncertain
3
6.1%
10
0.10% 133.06
0.000*
Sexual Experiences
with women only
42 85.7%
8338
92.90%
0.00
0.998
1.00
0.45
with men only
0
0.0%
58
0.60%
0.29
0.588
with men & women
5 10.2%
992
6.20%
0.00
0.999
1.00
0.40
never had sex
2
4.1%
399
0.20%
0.00
0.995
1.00
0.24
2
Females
SMI
ASHR
N=9578
p- value
OR
CI
N = 39
n
%
n
%
lower
Sexual Identity
Heterosexual
0.08
0.04
30 76.9%
9358
97.70%
72.15
0.000*
Homosexual
1
2.6%
77
0.80%
1.5
0.220
3.25
0.44
Bisexual
5.87
1.79
3
7.7%
134
1.40%
10.96
0.001*
Uncertain
5 12.8%
10
0.10%
403.3
0.000* 140.71 45.68
Sexual Experiences
with women only
0
0.0%
19
0.20%
0.08
0.780
0.35
0.18
with men only
27 69.2%
8285
86.50%
9.88
0.000*
with men & women
10 25.6%
1207
12.60%
5.98
0.015
2.39
1.16
9.03
2.13
never had sex
2
5.1%
57
0.60%
13.09
0.000*
Notes: n = number responding N = total Number assessed *Significance p<0.003 with Bonferroni
adjustment
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upper
1.33
237.83
2.23
2.53
4.11
upper
0.17
23.95
19.31
433.43

0.70
4.92
38.36

Although identifying as heterosexual, fewer men (85.7%) and fewer women (69.2%)
reported having sex exclusively with the opposite sex. No-one reported exclusive
sexual experience with a same-sex partner.
In comparison to the Australian population data from ASHR (De Visser, Rissel,
Richters, & Grulich, 2003; Smith et al., 2003a), the study participants of male
patients were fairly similar in their sexual experiences but differed regarding sexual
identity with more patients with SMI being uncertain regarding their sexual identity,
albeit with small numbers.

Women with SMI and participants of this study differed from the women in the
national ASHR survey. The study women with SMI, though a small group, were less
likely to be heterosexual and more likely to be bisexual or uncertain regarding their
sexual identity. Women with SMI differed in their sexual experiences, as they were
less likely to have sex with men only and more likely to have never had sex.
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4.4.2.2 Sexual Activities
Ninety-six percent of all study participants had previously engaged in sex “ever”,
rates similar to the Australian population (Table 4.2). Both men and women with
SMI differed from the general population in that they were less likely to report Oral
Intercourse (OI) “ever”.
Fewer males reported sex in the “last 12 months” (54%), compared to Australian
males (88%). Women with SMI did not differ in their reported rates of sex in the last
12 months compared to the Australia population.

Table 4.2 Comparison of Sexual Activities
Males

SMI
n

%

ASHR

N=9729

n

%

2

p-value

OR

CI
lower

upper

Sex ever N = 54

52

93.6%

3.53

0.060

3.56

0.87

14.61

28

96.3%
53.8%

9106

Sex in the last 12 m N=52

8552

87.9%

55.69

0.000*

0.16

0.09

0.28

Sexual Activities ever N=49
VI ever
OI ever
Anal ever

47
29
16

95.9%
59.2%
32.7%

8970
7657
2033

92.2%
78.7%
20.9%

0.94
10.75
4.07

0.332
0.001*
0.044

1.99
0.4
1.84

0.48
0.22
1.01

9.20
0.70
3.34

ASHR

N=9578

OR

CI

n

%

Females

SMI
n

p-value

lower

upper

0.43
0.31

22.62
1.60

VI ever
37 94.9%
8840
92.3%
0.36
0.550
1.54
0.37
OI ever
16 41.0%
6389
66.7%
11.52
0.001* 0.35
0.18
Anal ever
3
7.7%
1446
15.1%
1.66
0.200
0.47
0.14
Notes: VI = vaginal intercourse, OI = oral intercourse, AI = anal intercourse
n = number responding N = total Number assessed *Significance p<0.008 with Bonferroni adjustment

6.42
0.66
1.52

Sex ever N=41
Sex in the last 12m N=40

40
33

%

2

97.6%
82.5%

8888
8333

92.8%
87.0%

1.39
0.71

0.238
0.398

3.11
0.7

Sexual Activities ever N=39
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4.4.2.3 Number of Sexual Partners Ever
There were no differences in the number of partners “ever”, reported by men
compared to the ASHR male population (see Table 4.3). Men reported a mean of
15.5 female sexual partners “ever”, slightly lower than ASHR, but with a higher
median of 20 partners.

Women, despite excluding accounts of sex work, were more likely to report 50 or
more partners and reported a higher mean of 9 and median of 8 than women in the
Australian survey (De Visser, Rissel et al., 2003) as displayed in Table 4.3.
Table 4.3 Comparison of Number of Opposite-Sex Partners “Ever” (excludes sex
work)
Males
ever
0
1
2
3 to 9
10 to 49

SMI

N=44

ASHR

N=9,469

n

%

n

%

p-value

OR

CI
lower

upper

2
3
3
10
23

4.6%
6.8%
6.8%
22.7%
52.3%

549
975
578
3125
3627

5.8%
10.3%
6.1%
33.0%
38.3%

1.26
0.58
0.04
2.09
3.61

0.723
0.448
0.844
0.148
0.057

0.77
0.64
1.13
0.60
1.76

0.19
0.20
0.35
0.30
0.98

3.21
2.06
3.65
1.21
3.19

3

6.8%
15.5
20
100

625

6.6%
16.7
8
3202

0.00

0.954

1.04

0.32

3.35

SMI

N=37

ASHR

N=9,340

n

%

n

%

50+
Mean
Median
Maximum
Females

2

2

p-value

OR

CI
lower

upper

ever
0
1
2
3 to 9
10 to 49

2
4
3
11
12

5.4%
10.8%
8.1%
29.7%
32.4%

663
2186
1065
3727
1625

7.1%
23.4%
11.4%
39.9%
17.4%

0.16
3.27
0.4
1.59
5.78

0.689
0.071
0.529
0.207
0.016

0.75
0.4
0.69
0.64
2.28

0.18
0.14
0.21
0.31
1.14

3.12
1.12
2.24
1.29
4.55

50+
Mean
Median

5
9
8

13.5%

84

0.9%
6.5
3

62.38

0.000*

17.22

6.55

45.27

Maximum
40
909
Note: n = number responding N = total Number assessed * Significance p<0.004 with Bonferroni
adjustment
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4.4.2.4 Number of Sexual Partners in the last 12 months

Overall patients with SMI were more likely to report the sexual risk behaviour of >2
partners in the “last 12 months” (18.8%),

2

(1, N = 89) = 29.80, p = .000 and with

an odds ratio of 3.81 and 95% CI (2.27, 6.39) than the Australian population survey
(5.8%).
Men with SMI were less likely to have sex in the “last 12 months” (Table 4.4), and
more likely to report zero sexual contacts. For those men that did have sex in the
“last 12 months”, there was a higher rate of reporting 3 to 9 partners than Australian
men.

Women with SMI were less likely to report one partner only and more likely to
report “2 partners” or “10 to 49 partners” in the “last 12 months” compared to
women part of the ASHR survey
Table 4.4 Comparison of Number of Opposite-Sex Partners - “last 12m” (excludes
sex work)
2
SMI
N=52
ASHR
N=9,469
p-value
OR
CI
n
%
n
%
lower upper
0
24
46.20%
985
10.40% 69.77 0.000*
7.38
4.26
12.79
1
15
28.90%
7215
76.20% 63.46 0.000*
0.13
0.07
0.23
2
1
1.90%
492
5.20%
1.13
0.288
0.36
0.05
2.59
3 to 9
12
23.10%
625
6.60% 22.49 0.000*
4.25
2.22
8.13
10 to 49
0
0.00%
133
1.40%
0.74
0.389
1.01
1
1.01
50+
0
0.00%
9
0.10%
0.05
0.824
1.01
1
1.01
Mean
1.3
1.5
Median
1
1
Maximum
6
260
Females
SMI
N=37
ASHR
N=9,340
p-value
OR
CI
n
%
n
%
lower upper
0
7
17.5%
1205
12.9%
0.75
0.387
1.43
0.63
3.24
1
22
55.00%
7491
80.20% 15.87 0.000*
0.3
0.16
0.56
2
6
15.00%
374
4.00% 12.39 0.000*
4.23
1.77
10.14
3 to 9
1
2.50%
262
2.80%
0.01
0.907
0.89
0.12
6.49
10 to 49
4
10.00%
9
0.10% 282.3 0.000* 115.2 33.93 391.14
50+
0
0.00%
9
0.10% 0.030
0.853
1.00
1.00
1.01
Mean
2.7
1
Median
1
1
Maximum
25
102
Note: n = number responding N = total Number assessed * Significance p<0.004 with Bonferroni adjustment

Males
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4.4.2.5 Sex after Drug or Alcohol Use
Over 70% (46/65) patients reported being high or drunk “ever” and over a third,
35.9% (23/64), reported being high or drunk in the “last 12 months”, when they had
sex. Australian population data regarding this risk behaviour, being high or drunk
ever, has not been published. This behaviour for patients with SMI differed when
compared to 58% of 1,234 young people aged 18-24, reporting the behaviour of
drunk/high during sex “ever”, that were part of an internet survey (McFarlane, Bull,
& Rietmeijer, 2002),

2

(1, N = 1299) = 4.14, p = .042. This risk also differed when

compared to only 27% of 9,515 US college students reporting being high or drunk in
the “last 30 days” (Schwartz, Waterman, Vazsonyi, Zamboanga, Whitbourne et al.,
2011),

2

(1, N = 9580) = 62.32, p = .000.

4.4.2.6 Sex and Condom Use
Patients with SMI were less likely to have used condoms “ever” (Table 4.5), but
reported better condom use at the last sexual encounter than the Australian
population.

Table 4.5 Comparison of Rates of Condom Use with an Australian Population
SMI
ASHR
p-value OR
CI
2
N = 91
N = 18951
lower
no condom use ever
23.5%
11.14% 13.73 0.000* 2.40
1.49
no condom use last12m
52.9%
60.90%
2.71 0.100
0.71
0.48
LSE condom use
35.8%
20.62% 13.25 0.000* 2.15
1.41
Note: n = number responding N = total Number assessed LSE = last sexual encounter
*Significance p<0.02 with Bonferroni adjustment

upper
3.88
1.07
3.27

4.4.3 Sexual Risk Partners

Sexual risk partners covered review of relationships, partner choices at last sexual
contact, sex with partner(s) with risk, settings for meeting sexual contacts,
exchanging sex for payment (sex work) or favours, or by coercion, as well as sex
with a partner with drug or alcohol risks.

78

Specifically sex partners with risk included; sexual contacts that had ever injected
drugs, had HIV, were bisexual, were sex workers, had multiple simultaneous
partners, were from an overseas country (NSW Department of Health, 2006a; NSW
Department of Health Sydney, 2006; UNAIDS, 2009), or had ever been in gaol
(NSW Department of Health, 2007), as described in Chapter 2. The risk of male-tomale sex had been covered in sexual experiences, section 4.4.2.1 and there had not
been any disclosures. In addition, risk partners included those with postulated risks
for patients with SMI, such as sex with partner(s) that also had an SMI diagnosis
(Kalichman et al., 1994).

4.4.3.1 Sex and Regular Relationships

More women, than men, reported having a regular partner but rates were
significantly lower than for Australians in general. Patients with SMI were less likely
to be in a longer-term stable relationship compared to the Australian public and the
duration of the relationship was less than one year for many (Table 4.6).

Table 4.6 Comparison of Regular Relationships
SMI
N

n

%

ASHR
N

n

%

2

p-value

OR

CI
low
er

upper

Males
regular partner 47
11
23.4%
9716
7235 74.5% 63.73 0.000* 0.11 0.05 0.21
duration <1 year 11
6
54.5%
7154
630
8.8% 28.41 0.000* 12.4 3.78 40.83
3
Females
regular partner 39
20
51.3%
9569
7435 77.7% 14.42 0.000* 0.32 0.17 0.59
duration <1 year 20
6
30.0%
7374
701
9.5% 9.687 0.000* 4.08 1.56 10.65
Note: n = number responding N = total Number assessed * Significance p<0.01 with Bonferroni
adjustment

4.4.3.2 Sex and Partner at Last Sexual Encounter

At the last sex encounter, men with SMI most frequently reported the option of sex
with a regular sexual partner, though this was not always deemed a “regular
relationship”. All men who reported a “regular relationship” also reported sex with a
“regular partner”, but 18 men who did not report a “regular relationship” reported
sex with a “regular sexual partner”. At the last sexual encounter, men and women
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with SMI were more likely to have had sex with a casual partner and less likely to
have sex with a regular partner, than the Australian survey (Table 4.7).

Table 4.7 Comparison of Partner at Last Sexual Encounter
Males

SMI

N=47

ASHR

CI

N=7923
2

n
%
n
%
p-value
OR
lower upper
9
19.1%
380
4.8%
20.73
0.000*
4.70
2.26
9.79
9
19.1%
29
61.7%
7471
94.3%
89.44
0.000*
0.10
0.05
0.18
SMI
N=36
ASHR N=7698
CI
2
Females
n+ve
%
n+ve
%
p-value
OR
lower upper
casual
16
44.4%
139
1.8% 331.70
0.000* 43.51
22.07 85.74
regular
19
52.8%
7513
97.6% 282.97
0.000*
0.03
0.01
0.05
Note: n = number responding N = total Number assessed * Significance p<0.01 with Bonferroni
adjustment
casual
sex worker
regular

Women with SMI more often reported sex with a casual partner at their last sexual
encounter than men with SMI, (44.4%),

2

(1, N = 36) = 5.601, p = .018. Slightly

more women, than men with SMI, had sex with their regular partner, with whom
they mostly also reported a regular relationship.

4.4.3.3 Sex with Partners at Risk
Most men and women reported sexual contact with partners at risk “ever” (see Table
4.8). A large number (38%), reported sexual contact with partners at risk in the “last
12 months”. Men reported more frequently, having sex “ever” with sex workers,
others with SMI diagnosis, overseas contact and others with IDU history. Women
had sex “ever” with partners whose risk included IDU history, incarceration history,
others with SMI diagnosis and those with multiple partners.
Men with SMI were much more likely to have had sex with sex worker “ever”
(60.9%),

2

(1, N = 9381) = 70.52, p = .000, compared to ASHR reports at 15.6%.

This held for risk in the “last 12 months” for men with SMI (21.7%),

2

(1, N =

7969) = 92.28, p = .000, compared to ASHR reports at 1.9%. The ASHR survey did
not provide further data regarding risk partners for comparison.
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Table 4.8 Description of Risk History of Sexual Contacts “ever”
Sex contact risk

Men

n

%

Women

Partner with risk history
37 54 68.5%
29
IDU History
15 45 33.3%
15
HIV positive
1 46
2.2%
3
Bisexual
0 46
0.0%
9
Sex worker
28 46 60.9%
0
Multiple partners
11 44 25.0%
9
Overseas contact
15 37 40.5%
4
Incarceration history
8 42 19.1%
13
SMI diagnosis
20 46 43.5%
13
Note: n = number responding N = total Number assessed

n

%

41
35
34
33
35
29
29
31
35

70.7%
42.9%
8.8%
27.3%
0.0%
31.0%
13.8%
41.9%
37.1%

Total

n

%

66
30
4
9
28
20
19
21
33

95
80
80
79
81
73
66
73
81

69.5%
37.5%
5.0%
11.4%
34.6%
27.4%
28.8%
28.8%
40.7%

4.4.3.4 Sources of Sexual Contacts

Patients also provided information regarding how they met the sexual contact with
whom they last had sex. Most people, 43.2% of men (22/47), and 48.3% of women,
(17/36) had met “socially”. The next most common means of meeting their last
sexual partner was at the “hospital”, reported by 27.0% of men, (13/49) and 20.7% of
women, (8/36). Other less frequent sources included police station, whilst in
detention and at employment locations.

4.4.3.5 Sex for Favours or Payment
Sex for favours “ever”, was reported by 35.7% (10/28) women, and sex for favours
in the “last 12 months”, by 18.8% (3/16) women. Fifteen percent of men (4/26),
reported sex for favours “ever”, and 6.7% (1/15), provided sex for favours in the
“last 12 months”.

Women with SMI were much more likely, than Australian women, to have been
involved in sex work, i.e. sex for payment, “ever” and in the “last 12 months” (Table
4.9). None of the men reported having ever been involved in sex work.
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Table 4.9 Comparison of Experiences of Sex Work for Women
SMI

N=34

ASHR

N=9134

%

n

%

n

sex work ever

17.6%

6

0.5%

45.67

176.52

0.000*

sex work last 12m

5.9%

2

0.1%

9.134

94.56

0.000*

2

p-value

OR

CI
lower

upper

42.34

16.74

107.1

63.37

13.17

304.89

Females

Note: n = number responding N = total Number assessed * Significance p<0.008 with Bonferroni
adjustment

4.4.3.6 Sexual Partner with Drug or Alcohol Issues
Over 65% (41/63) of study participants reported that their sexual partner had “ever”
been “high or drunk” during sexual activity. Twenty-eight percent (17/61) of
participants reported that their sexual partner had been high or drunk during sex in
the “last 12 months”. Fifty-five percent (32/58) reported a partner with a drug or
alcohol problem and 29.3% (17/58) reported such a partner in the “last 12 months”.
Australian data was not available for comparison.

4.4.3.7 Sexual Coercion
More women (64%), than men (21%), reported being coerced into having sex “ever”
(Table 4.10). Both men and women with SMI were much more likely to have
experienced sexual coercion than the Australian public. There were no differences
between those patients that had been coerced to have sex and the Australian public,
regarding the event occurring prior to the age of 16, or on more than one occasion.
Sixty-three percent of women and 30% of men had spoken to a healthcare worker
regarding the assault.
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Table 4.10 Comparison of Experiences of Sexual Coercion “ever”
SMI

ASHR

%

n

N

2

N

n

p-value

%

OR

CI
lower

Males
sex force ever 20.5%
9 44
9373
450
4.8% 23.14
0.000* 5.10
2.44
sex force age <16
6.8%
3
9
453
260
57.3% 2.084
0.149 0.37
0.09
sex force >2 16.7%
2
9
453
222
49.1% 2.535
1.111 0.30
0.06
Females
sex force ever 63.6% 21 33
9218
1945 21.1% 35.55
0.000* 6.54
3.21
sex force age <16 27.3%
9 21
1939
952
49.1% 0.324
0.569 0.78
0.33
sex force >2 40.9%
9 21
1939
1206 62.2% 3.298
0.069 0.46
0.19
Note: n = number responding N = total Number assessed * Significance p<0.008 with Bonferroni
adjustment

4.4.4 Substance Use Risk Behaviours

Substance use risk covers illicit drug use, injecting drug use, which included blood
exposure situations such as needle sharing, other drug paraphernalia sharing, or other
contact situations with “touching blood”.

4.4.4.1 Illicit drug use

All 95 patients responded to questions on illicit drug use. Many study participants
reported illicit drug use (74%) and specifically IDU (31%), at some point “ever” in
their life. Over 50% reported illicit drug use and 13% IDU in the “last 12 months”
see Table 4.11.
Table 4.11 Description of Drug Usage “ever” and in the “last 12 months”
Drug use
illicit - any
marijuana
amphetamine
heroin
cocaine
methadone
ecstasy

‘ever’
n
70
63

N
95
89

% of N
73.7%
70.8%

47
34
32
13
27

90
89
88
87
88

52.2%
38.2%
36.4%
14.9%
30.7%

‘12months’
n
52
37

N
95
89

% of N
54.7%
41.6%

13
12
7
6
5

90
89
88
87
88

14.4%
13.5%
8.0%
6.9%
5.7%

LSD/Hallucinogen
21
88
23.9%
2
88
2.3%
IDU
29
94
30.9%
12
90
13.3%
Note: n = number responding N = total Number assessed IDU=injecting drug use
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upper
10.67
1.50
1.45
13.32
1.85
1.09

Study participants reported high rates of marijuana and amphetamine use “ever” and
in the “last 12 months”. Comparisons were not possible with the ASHR survey.
4.4.4.2. Injecting Drug Use and Blood Exposures

Of the 31% (29/95) of patients that reported an injecting drug use history, 24 from
the 29, provided information regarding needles and syringe attainment. Health
settings were the most frequently reported source for injecting equipment supplies
(54.1%, 13/24 respondents). Sharing of needles with needle re-use was reported by
31% of IDU “ever” respondents. Sharing of injecting paraphernalia was reported by
35% of respondents. All behaviours were more frequent for patients with SMI
compared to the whole Australian population survey (Table 4.12).
The behaviour of “having touched others’ blood in sharing situations”, was reported
by 13%, 12 of the whole group of 95. The twelve that reported this behaviour
included 24%, (7/29), from the group that had an IDU history and 8% (5/66) from
those that did not report injecting.

Table 4.12 Comparison of IDU and Sharing Activities
SMI
N
95
95
95

n
29
12
9

%
30.9%
13.7%
9.9%

ASHR
N
19307
19307
19307

p-value
n
571
167
183

OR

%
3.0%
0.9%
0.3%

CI
lower
9.24
8.88
5.42

IDU ever
239.75 0.000* 14.42
IDU 12m
143.19 0.000* 16.57
shared needles ever
70.13 0.000* 10.94
shared paraphernalia
ever 95 10 10.3% 19307 292
0.5%
50.13 0.000*
7.66
3.39
Note: n = number responding N = total Number assessed * Significance p<0.007 with Bonferroni
adjustment

4.4.5 “Other” Risk Factors – Screening, Vaccinations, Tattoos and
Incarceration

Many had participated in protective healthcare behaviours with 72% (57/79)
reporting previous HIV testing, a rate much higher than the 40% of the Australian
population survey,

2

(1, N = 19032) = 73.58, p = .000. Sixty-four percent had

previously been screened for the other BBVs and STIs. Vaccination for HAV was
84

upper
22.49
30.93
22.07
14.90

reported by 25% (16/66), and for HBV by 38% (25/66), rates similar to the ASHR
survey (Grulich, de Visser et al., 2003a).
Table 4.13 Comparison of “Other” Risk Factors – Tattoos, Body Piercing &Incarceration
SMI
ASHR
p-value
OR
CI
2
N
n
%
N
n
%
lower
tattoo ever
76 27 35.5% 19306 2433 12.6%
35.90
0.000*
3.82
2.38
body piercing ever
71
6
8.5% 19306 1158
6.0%
0.75
0.385
1.45
0.63
incarceration history
79 24 30.4% 19306
425
2.2% 276.11
0.000* 19.39 11.89
Note: n = number responding N = total Number assessed * Significance p<0.02 with Bonferroni adjustment

“Other” risk factors for STIs and BBVs disclosed included previous tattoos, body
piercings and incarceration (Table 4.13). More patients with SMI than the Australian
population reported the risk behaviours of previous tattooing or incarceration. More
men 36.2% (17/47), than women 21.9% (7/32) reported incarceration risk, but this
was not significantly different.

4.4.6 Prevalence of STIs and BBVs

Part 2 results describe the prevalence of STIs and BBVs, assessed by testing of
biological specimens and by self-reported STI/BBV history. In this section, results of
all serological tests for all patients at Cumberland Hospital during the study period
are also presented and compared, providing a context for the whole population of
SMI inpatients at Cumberland Hospital.

4.4.6.1 STI and BBV Prevalence from Self-reported STI/BBV History

Results displayed followed the Australian survey style (Grulich, de Visser et al.,
2003c). Many advised of having a self-reported STI or BBV and nearly 50%
reported a previous STI/HBV (which included HBV but not candidiasis), and 46%
reported a previous STI (excluding HCV, HBV and candidiasis) see Table 4.14,
(Grulich, de Visser et al., 2003c, p. 236). Self-reported STI or BBVs were more
frequent for patients with SMI. Patients with SMI were more likely to report HCV,
genital warts, chlamydia and herpes compared to the Australian population survey.

85

upper
6.12
3.35
31.61

Table 4.14 Comparison of Self-reported STI/BBV rates
SMI
N
n
self-reported STI or BBV# 85 50
self-reported STI/HBV# 85 42
self-reported STI# 85 39
self-reported HCV
self-reported HBV
self-reported HIV
self-reported chlamydia
self-reported gonorrhoea
self-reported syphilis
self-reported genital herpes
self-reported genital warts
self-reported pubic lice

84
83
93
82
84
84
83
84
85

15
3
2
6
1
1
6
14
7

%
58.8%
49.4%
45.9%

ASHR
n
3681
3584
3449

17.9%
3.6%
2.2%
7.3%
1.2%
1.2%
7.2%
16.7%
8.2%

97
135
462
272
71
444
811
1356

N=19307
%
19.1%
18.6%
17.9%

86.09
52.98
45.04

0.000*
0.000*
0.000*

6.06
4.29
3.90

0.5%
0.7%
2.5%
1.5%
0.4%
2.4%
4.4%
7.3%

438.66
9.94
8.41
0.03
1.53
8.86
31.91
0.19

0.000*
0.002*
0.004*
0.865
0.216
0.003*
0.000*
0.663

43.05
5.33
3.22
0.84
3.26
3.31
4.56
1.19

2

p-value

OR

CI
lower
3.93
2.80
2.54

upper
9.36
6.57
5.98

23.80
1.66
1.40
0.12
0.45
1.44
2.56
0.55

77.89
17.07
7.43
6.08
23.77
7.64
8.13
2.58

self-reported candidiasis 84 18 21.4% 6159
31.9%
4.23
0.040
0.58
0.35
Note: n = number responding N = total Number assessed *Significance p<0.004 with Bonferroni adjustment
# less Candida

0.98

4.4.6.2 STI and BBV Prevalence from Biological Sample Tests

All study participants had provided at least one biological sample to be tested for STI
or BBV infections, with this study or previously, as part of screening when newly
admitted. Table 4.15 shows results for STIs and BBVs by males, females and total
number. The uptake rates for testing were high for the 95 participating in the study,
with 95.8%, (91) participants assessed for HCV, 94.7% (90) assessed for HBV,
85.3% (81) for HIV, 82.1% (78) for Syphilis, 61.1% (58) for Chlamydia and 60.0%
(57) for Gonorrhoea.

Of all the STIs and BBVs assessed, BBV infections were the most prevalent for this
group. HCV antibody was present for 26.4%. Sixteen percent had been exposed to
HBV (with one person, 1.1% identified as chronically infected). Only 2.5% were
HIV positive and all were male. Current STI infections were uncommon and only
one person of 58 tested (1.7%), was diagnosed with chlamydia and no-one had
syphilis or gonorrhoea.

86

Table 4.15 Description of Biological Sample - BBV and STI rates for study sample
Males
n

n
15
7
0
0
1

%
39.5%
18.4%
0.0%
0.0%
3.7%

N
91
90
81
78
58

n
24
14
2
0
1

%
26.4%
15.6%
2.5%
0.0%
1.7%

Gonorrhoea
30
0
0.0%
27
Note: n = number testing positive N = total Number tested

0

0.0%

57

0

0.0%

9
7
2
0
0

%
17.0%
13.5%
4.7%
0.0%
0.0%

Total

N
38
38
38
32
27

HCV
HBV
HIV
Syphilis
Chlamydia

N
53
52
43
46
31

Females

Six percent (5/90) patients had both HCV and HBV exposure. One person from 76
(1.7%) was positive for both HIV and HBV exposure and no-one had both HIV and
HCV positive results. Females were more likely to be HCV positive than males,

2

(1, N = 91) = 5.77, p = .02, odds ratio = 3.2, CI 95% (1.2, 8.4).

Biological testing indicates that self-reported STIs or BBVs may be underestimates.
Of this group, all were aware of a previous diagnosis of HIV, 63% knew of their
HCV results (15/24), but only 21% (3/14) were aware of previous HBV exposure.
4.4.6.3 STI and BBV results of all Cumberland Hospital Patients

Data regarding STI/BBV serology results was available for all Cumberland Hospital
patients admitted during the study period allowing an assessment of overall STI and
BBV prevalence and representative rates. Five-hundred and thirty patients of the
total Cumberland Hospital population of 1791 had BBV or STI assessment involving
2397 tests during the study period.

Overall HCV antibody positive prevalence, for all 1791 Cumberland hospital
patients, was 4.6%, see Table 4.16. HCV testing occurred for 25% (456/1791) of all
patients, with 18% (83/456) of those testing HCV antibody positive. HBV exposure
prevalence was 5.8% for all patients. HBV was assessed for 28% (504/1791) and
20% of those patients (103/504) tested positive. Of those 103 positive, 3% (13/103)
had chronic HBV infection. HIV antibody prevalence was low at 0.2%. HIV testing
occurred for only 4% (78/1791) of all inpatients, with 4% (4/78) of those tested,
having a positive result. Syphilis positivity overall was also low at 0.3%. Syphilis
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testing occurred for 18% of patients (320/1791) with less than 2% (5/320) having
positive results and none were acute infections.

A review was done to identify if Study One serology results were representative of
Cumberland Hospital serology results. The review compared non-participant
Cumberland Hospital patients that had screening tests as inpatients only, with the
results of patients participating in Study One. From the 530 Cumberland patients and
2397 tests, it could be determined that 54 patients had HCV and HBV testing as
inpatients and as participants for Study One. Dual HIV testing occurred for 31
patients and dual syphilis testing for 34 patients. From all 530 Cumberland patients,
the number of patient tests performed only as non-participant Cumberland hospital
patients, and thus non-participating for Study One, included 402 HCV tests ( = 456 54), 450 HBV tests ( = 504 - 54), 47 HIV tests ( = 78 - 31) and 286 syphilis tests
( = 320 - 34).

From the group that had both testing as an inpatient as part of Cumberland screening,
and as a study participant part of Study One, 14.8% (8/54) were positive for HCV,
13.0% (7/54) positive for HBV exposure and 3.2% positive for HIV (1/31).

Analysis of test results of patients that had testing only done as non-participant
Cumberland patients, with the test results of Study One participants was undertaken,
see Table 4.16. There was no significant difference in the prevalence of any positive
test result for the study participants when compared to the positive results for nonparticipant Cumberland patients: HCV
= 450) = 1.54 p = .21; HIV

2

2

(1, N = 402) = 2.75, p = .10; HBV

(1, N = 47) = 1.21, p = .27; syphilis

1.38 p = .24.
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2

2

(1, N

(1, N = 286) =

Table 4.16 Description of BBV and STI rates for study sample compared to
Cumberland Hospital
All
Tests

Cumberland
nonparticipants

% +ve
% +ve
n
N
tested
N=1791
n
HCV
83 456
18.2%
4.6%
75
HBV
103 504
20.4%
5.8%
96
HIV
4
78
5.1%
0.2%
3
Syphilis
5 320
1.6%
0.3%
5
n = number tested positive N = total Number tested

N
402
450
47
286

% +ve
tested
18.7%
21.3%
6.4%
1.8%

SMI Study
Tests
% +ve
N=1791
4.3%
5.5%
0.2%
0.3%

% +ve
n
24
14
2
0

N
91
90
81
78

26.4%
15.6%
2.5%
0.0%

All patient groups with SMI were more likely to be HCV positive than the Australian
population (Grulich, de Visser et al., 2003c). This held with comparison of HCV
exposure serology for all 1791 patients at Cumberland Hospital, and for the nonparticipant Cumberland Hospital patients, and for SMI study participants, based on
comparison of self-reported HCV (data not shown).
4.4.7 Stratification Analysis: Risk for HCV stratified by IDU risk history
To assess the possible role that SMI plays in HCV exposure, stratification by
injecting drug use history was undertaken comparing the study sample with the
Australian population (see section 4.3.2 Procedure).

Comparisons of the whole SMI study participant group, with the ASHR general
Australian population, reveals that in general both “IDU ever” and HCV exposure
rates are higher for patients with SMI. Thirty-one percent of patients with SMI
reported, having injected “ever” compared to 3.4% of the Australian population
survey. HCV was identified for patients with SMI at 26% by biological testing and
18% by self-reported HCV history, whereas the population rates are significantly
lower at 0.5% (Grulich, de Visser et al., 2003c) and up to 1.4% (National Centre in
HIV Epidemiology and Clinical Research, 2010).

Some initial assessments to review the role of IDU included looking at injecting drug
use of only those that had ever injected (both patients with SMI and the Australian
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population). We see that patients differed only in their use of heroin and methadone
in the last 12 months (Table 4.17).
Table 4.17 Comparison of Drug Use in the “last 12 months” by Injecting Drug Users
SMI
N n

%

ASHR
N
n

p value

OR

%

CI
lower

upper

Substance Use Behaviour
heroin 12m 12 11 91.7% 167
54 32.4% 17.04 0.000* 23.02
2.90 182.90
methadone 12m 12
6 50.0% 167
11
6.6% 24.55 0.000* 14.18
3.92
51.33
amphetamine 12m 12 11 91.7% 167 146 87.4%
0.19
0.666
1.58
0.19
12.89
cocaine 12m 12
7 58.7% 167
52 31.1%
3.75
0.053
3.10
0.94
10.21
LSD 12m 12
2 16.9% 167
25 15.0%
0.03
0.874
1.14
0.24
5.50
ecstasy 12m 12
5 41.8% 167
54 32.3%
0.44
0.507
1.50
0.45
4.93
Note: n = number responding N = total Number assessed * Significance p<0.008 with Bonferroni adjustment

As previous described, comparison of patients with SMI with the whole Australian
population showed that patients were much more likely to report the risks of
injecting and sharing. When this analysis was restricted to SMI patients and
Australians with IDU histories we see that there is no difference regarding recent
injecting or sharing risks (Table 4.18).

Table 4.18 Comparison of HCV risk by IDU Risk Activities for Injecting Drug Users
SMI
N
n

%

ASHR
N
n

p-value
%

OR

CI
lower

upper

Injecting Drug Users
IDU 12m 29 12 41.4% 571 167 29.2% 1.941
0.164
1.71
0.80
3.65
shared needles ever 29
9 31.0% 571 183 32.0% 0.013
0.909
0.95
0.43
2.14
shared paraphernalia ever 29 10 34.5% 571 292 51.1% 3.063
0.080
0.50
0.23
1.10
Note: n = number responding N = total Number assessed *Significance p < .02 with Bonferroni adjustment

Continuing analysis controlling for IDU history, showed that of SMI patients with
IDU history, 50% provided a self-report of HCV and 69% had positive HCV test
results, whereas only 11% of the general Australian population with IDU history
stated that they had HCV (see Table 4.19). A crosstabs review with Pearson’s chisquare test of contingencies, (with

= .05), showed that the difference in proportions

was statistically significant, with SMI patients being more likely to have HCV
exposure.
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Even patients with SMI that did not report IDU risk histories had a higher risk for
HCV exposure than the general population without IDU risk history. A crosstabs
review with Pearson’s chi-square test of contingencies, (with

= .05), was

undertaken and showed a statistically significant difference for SMI patients without
an injecting history with 3% self-report for HCV or 9% positive HCV tests compared
to only 0.2% of the Australian population. Patients with SMI were 50 times more
likely than the Australian population to have HCV exposure despite not providing an
injecting history.

Table 4.19 Risk for HCV stratified by IDU History and SMI
SMI
N

n

% HCV
+ve

ASHR
N

69.2%
50.0%

562
562

2

n

% HCV
test +ve

63
63

11.2%
11.2%

70.43
33.22

p-value

OR

CI
lower

upper

IDU +ve
HCV test
self-report

26
26

18
13

0.000*
0.000*

17.82
33.22

7.44
3.52

42.67
17.84

IDU -ve
64
6
9.4% 18534
38
0.2% 227.23 0.000*
Note: n = number responding N = total Number assessed * Significance p <0.05

50.35

20.45

123.69

4.4.8 Bivariate Analysis: Prevalence of STIs and BBVs for patients according to
risk history

In order to determine if risk factors and STI/BBV infections are associated, bivariate
analysis was undertaken. This was accomplished by comparing the prevalence rates
of the three frequently occurring outcome factors: (i) HCV exposure by biological
testing (ii) HBV exposure by biological testing and of (iii) self-reported STI with risk
factors from Study One. Specifically a subgroup of 25 risk factors for patients with
SMI that had been previously described from published research (Lagios & Deane,
2007), were included in the analyses. The bivariate associations were explored using
chi-square analyses and the results displayed in tables. A Bonferroni adjusted p-value
of .002 was used to control for the multiple comparisons.
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HCV exposure is explored in Table 4.20. HCV exposure was statistically associated
with lifetime “ever” use of heroin, methadone, IDU and a history of incarceration.
Table 4.20 Bivariate Associations between HCV rates and Risk Factors
n/N
Substance Use Risk Behaviour
illicit ever

HCV %

2

p-value

OR

CI
Upper

Lower

3.42

0.92

12.72

21/66

32.8%

3.67

0.550

heroin ever

15/32

46.9%

10.21

0.001*

4.96

1.78

13.80

methadone ever
amphetamine ever
marijuana ever
cocaine ever

10/12
17/44
19/60
11/31

83.3%
38.6%
31.7%
35.5%

23.26
5.16
2.20
2.20

0.000*
0.023
0.139
0.138

24.58
3.15
2.43
2.10

4.77
1.14
0.73
0.78

126.75
8.67
8.08
5.66

8/50
18/26

16.0%
69.2%

7.07
33.87

0.008
0.000*

0.23
21.75

0.07
6.66

0.71
71.01

15/54
6/24
15/45

27.8%
25.0%
33.3%

0.50
0.00
0.97

0.479
1.000
0.326

0.68
1.00
1.88

0.23
0.27
0.53

1.99
3.69
6.64

2/16
7/33
9/28
8/28
3/29

12.5%
21.2%
32.1%
28.6%
10.3%

1.79
0.84
5.35
0.01
6.72

0.181
0.360
0.020
0.911
0.010

0.35
0.62
10.56
0.94
0.19

0.07
0.22
1.07
0.34
0.05

1.71
1.75
104.1
2.64
0.73

12/29
5/14
6/19
7/31
4/23
8/20

41.4%
35.7%
31.6%
22.6%
17.4%
40.0%

4.67
0.55
0.12
0.80
1.26
2.99

0.031
0.460
0.734
0.370
0.262
0.084

3.06
1.59
1.22
0.62
0.50
2.67

1.09
0.46
0.39
0.22
0.15
0.86

8.61
5.51
3.84
1.76
1.70
8.27

14/44
17/54
12/27

31.8%
31.5%
44.4%

5.40
6.28
6.82

0.020
0.012
0.009

5.60
9.65
4.00

1.16
1.20
1.37

27.08
77.75
11.70

alcohol current
IDU ever
Sexual Risk Behaviour
having sex last 12m
condom use last sexual encounter
sex after drug and alcohol use ever
Sexual Risk Partners
2+ partners 12m
casual partners recent
sex for payment
sex forcing
sex with sex worker
sex with IDU ever
sex with bisexual
sex with multi-partnered
sex with SMI
sex with overseas contact
sex with incarceration history
Other Risk Factors
STI screen
past HIV tests ever
tattoo

incarceration
13/24
54.2%
13.08 0.000*
6.80
2.26 20.40
Note: n = number responding N = total Number assessed *Significance p < .002 with Bonferroni adjustment
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Table 4.21 assesses the associations between HBV status and risk factors. A history
of cocaine use, injecting drug use and recent casual partners were the most prominent
associations for HBV exposure but did not achieve statistical significance with the
Bonferroni adjustment.

Table 4.21 Bivariate Associations between HBV rates and Risk Factors
n/N
Substance Use Risk Behaviour
illicit ever
heroin ever
methadone ever
amphetamine ever

HBV %

2

p-value

OR

CI
Upper

Lower

12/65
8/32
4/12
9/43

18.5%
25.0%
33.3%
20.9%

1.50
3.58
3.22
2.13

0.220
0.058
0.073
0.144

2.60
3.13
3.39
2.52

0.54
0.92
0.85
0.71

12.58
10.62
13.60
8.91

12/59
8/31
9/50
7/25

20.3%
25.8%
18.0%
28.0%

3.58
3.85
0.94
3.95

0.058
0.050
0.333
0.047

6.13
3.27
2.20
3.17

0.75
0.96
0.43
0.98

49.96
11.12
11.12
10.24

7/54
4/24
11/45

13.0%
16.7%
24.4%

0.99
2.01
6.61

0.320
0.156
0.018

1.83
4.60
1.32

0.55
0.47
1.12

6.09
44.60
1.56

0/16

0.0%

3.47

0.063

0.82

0.73

0.92

casual partners recent
sex for payment
sex forcing
sex with sex worker
sex with IDU ever
sex with IDU 12m

2/33
5/28
6/28
5/29
7/29
2/14

6.1%
17.9%
21.4%
17.2%
24.1%
14.3%

3.82
.005
0.90
0.00
2.46
0.01

0.051
0.950
0.343
0.980
0.117
0.927

0.23
0.92
1.82
1.02
2.67
0.93

0.05
0.09
0.52
0.30
0.76
0.18

1.11
9.69
6.32
3.47
0.94
4.85

sex with HIV ever
sex with bisexual
sex with multi
sex with SMI
sex with overseas contact
sex with incarceration history

0/3
3/14
3/19
3/31
4/23
5/19

0.0%
21.4%
15.8%
9.7%
17.4%
26.3%

0.59
0.47
0.00
1.92
0.00
2.96

0.444
0.493
0.983
0.166
0.965
0.085

0.84
1.67
0.98
3.86
1.03
3.21

0.75
0.38
0.23
0.10
0.28
0.81

0.93
7.33
4.18
1.54
3.76
12.74

marijuana ever
cocaine ever
alcohol current
IDU ever
Sexual Risk Behaviour
having sex last 12m
condom use last sexual encounter
sex after drug and alcohol use ever
Sexual Risk Partners
2+ partners 12m

Other Risk Factors
STI screen
9/43
20.9%
2.12
0.145
3.18
0.63 16.03
past HIV tests ever
11/53
20.8%
1.48
0.224
2.62
0.53 12.95
tattoo
6/26
23.1%
2.14
0.144
2.58
0.70 9.47
incarceration
6/23
26.1%
2.75
0.097
2.82
0.80 9.95
Note: n = number responding N = total Number assessed *Significance p < .002 with Bonferroni adjustment
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Table 4.22 provides the associations for self-reported STIs (excluding HCV, HBV
and candidiasis) and risk factors and was related to illicit drug use “ever”, marijuana
“ever”, sex with a partner that had an IDU history ever, sex with a partner that had an
SMI diagnosis and sex after drug or alcohol use ever.

Table 4.22 Bivariate Associations between self-report STI Rates and Risk Factors
n/N

Self-report

2

p-value

OR

STI %

CI
Upper

lower

Substance Use Risk Behaviour
illicit ever
heroin ever
methadone ever
amphetamine ever

36/65
19/33
6/13
26/44

55.4%
57.6%
46.2%
59.1%

19.22
4.50
0.05
9.94

0.000*
0.034
0.826
0.003

2.24
2.63
1.14
4.33

1.71
1.07
0.35
1.70

2.94
6.51
3.57
11.03

marijuana ever
cocaine ever
alcohol current
IDU ever

34/58
18/32
25/51
16/27

58.6%
56.3%
49.0%
59.3%

17.43
3.52
1.847
4.63

0.000*
0.061
0.174
0.031

15.583
2.36
2.06
2.76

3.34
0.95
0.72
1.08

72.61
5.82
5.90
7.07

Sexual Risk Behaviour
having sex last 12m
condom use LSE
MSM

28/56
14/24
4/5

50.0%
58.3%
80.0%

2.27
2.83
2.72

0.132
0.093
0.099

0.47
2.64
5.75

0.18
0.84
0.59

1.27
8.31
56.35

26/45

57.8%

12.12

0.000*

11.63

2.40

56.48

2+ partners 12m
casual partners recent
sex for payment (women)
sex coercion
sex with sex worker
sex with IDU ever
sex with IDU 12m
sex with HIV ever
sex with bisexual
sex with multi

5/16
20/33
8/28
19/30
19/30
20/30
9/14
2/4
10/15
13/20

31.3%
60.6%
28.6%
63.3%
63.3%
66.7%
64.3%
50.0%
66.7%
65.0%

1.16
5.17
6.28
5.96
7.73
12.76
3.56
0.09
4.31
5.90

0.281
0.023
0.012
0.015
0.005
0.000*
0.059
0.767
0.038
0.015

0.53
2.89
12.50
3.24
3.80
5.83
3.11
1.36
3.43
3.71

0.17
1.14
1.26
1.24
1.45
2.14
0.93
0.18
1.03
1.25

1.70
7.28
124.5
8.45
9.94
15.91
10.46
10.15
11.39
11.02

sex with SMI
sex with overseas contact

21/32
13/24

65.6%
1.8%

9.45
1.82

0.002*
0.18

4.36
1.950

1.67
0.74

11.43
5.18

sex after drug and alcohol use ever
Sexual Risk Partners

sex with incarceration history
13/21
61.9%
6.30
0.012
3.79
1.30 11.04
Other Risk Factors
STI screen
23/46
50.0%
4.06
0.044
3.00
1.10 8.92
past HIV tests ever
28/55
50.9%
3.07
0.080
2.59
0.88 7.67
tattoo
14/27
51.9%
1.28
0.257
1.74
0.67 4.52
incarceration
14/23
39.1%
0.25
0.619
0.78
0.29 2.11
Note: n = number responding N = total Number assessed *Significance p < .002 with Bonferroni adjustment
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4.4.9 Multivariable Analysis: Risks for HCV exposure and Self-reported STIs

In order to clarify the degree of associations between the prevalence of HCV
exposure and self-reported STIs with risk factors, a multivariable analysis was
conducted, by logistic regression. Potential predictors included in the regression were
those that were significant risk factors and contributed to HCV or self-reported STIs
for patients with SMI.
HCV risk was assessed with the variables “incarceration history” and “injecting drug
use (IDU) ever”. “IDU ever” had the highest chi-square value of all potential
predictors and was chosen because it subsumes the risk behaviours of heroin and
methadone use and the small sample size allowed only a limited number of
instrumental variables. Table 4.23 provides information that the variable “IDU ever”
and “incarceration history” significantly predicted the outcome of HCV exposure.

Table 4.23 Logistic Regression To Assess Predictors of HCV exposure (n=78)
B

(SE)

Wald

p-value

OR

CI
Lower

Upper

Constant
0.34
(0.59)
IDU ever
2.55
(0.66)
15.17
0.000*
12.85 3.56
46.43
Incarceration history
1.34
(0.66)
4.11
0.043*
3.81
1.05
3.87
Note: * Significance p<0.05 B = Unstandardised regression co-efficient – indicates strength of the
relationship for predicting the dependent variable from the independent variable, in log-odds units,
SE = Standard error of B, Wald = test statistic to interpret significance of B, OR = Odds Ratio

A test of the full model against a constant only model was statistically significant
indicating that the predictors as a set reliably distinguished risk of HCV exposure
(chi-square = 29.26, p < .000 with df = 2). Nagelkerke’s R2 of .455 indicated a
moderate relationship between prediction and grouping. Prediction success overall
was 83% (87.7% for predicting HCV negative and 71.4% for HCV exposure
positive). The Wald criterion demonstrated that “IDU ever” made a significant
contribution to prediction (p = .000) and “incarceration history” was also a
significant predictor (p = .043). The Odds Ratio (SE) value, indicates that when
“IDU ever” is raised by one unit (one person), patients with SMI are 13 times more
likely and for “incarceration history”, 4 times more likely to have been exposed to
HCV.
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To estimate the proportion of self-reported STIs, that can be accounted for by the risk
behaviours of; (i) “marijuana use ever”, (ii) “sexual contact with IDU ever”, (iii)
“sexual contact with SMI ever” and (iv) “sex after drug and alcohol (D & A) use
ever”, a standard logistic regression analysis was performed. The variable “illicit
drug use ever” was not included, as this variable was captured by “marijuana use
ever” with 92% of “illicit drug use ever” also reporting “marijuana use ever”.
“Marijuana use ever”, also had a higher identification of risk with a higher odds
ratio. It can be seen that the variables, “marijuana use ever” by the study participant
and “sex with IDU ever”, that is sex with a person that had an IDU risk history,
significantly predicted the outcome variable of self-reported STI (Table 4.24).

Table 4.24 Logistic Regression to Assess Predictors Of Self-reported STI History
(n=59)
B

(SE)

Wald

p-value

OR

CI
Lower

Upper

Constant
2.969
-1
Marijuana ever
2.252 -0.92
5.92
0.015*
9.47
1.55 57.92
Sex with IDU ever
1.44 -0.69
4.32
0.038*
4.12
1.09 16.35
Sex with SMI ever
0.29 -0.71
0.16
0.689
1.33
0.33
5.39
Sex after D & A ever
0.66 -0.89
0.55
0.458
1.93
0.34 10.92
Note: * Significance p<0.05 B = Unstandardised regression co-efficient – indicates strength of
relationship for predicting the dependent variable from the independent variable, in log-odds units,
SE = Standard error of B, Wald = test statistic to interpret significance of B, OR = Odds Ratio

The model was statistically significant indicating that the predictors as a set reliably
distinguished risk of self-reported STI history (chi-square = 22.456 p < .000 with df
= 4). Nagelkerke’s R2 of .422 indicated a moderate relationship between prediction
and grouping. Prediction success overall was 73% (75.9% for predicting negative
self-reported STI history and 70.0% for predicting provision of a self-reported STI
history). The Wald criterion demonstrated that “marijuana ever” made a significant
contribution to prediction (p = .015) and that “sex with IDU ever” partner was also a
significant predictor (p = .038). The Odds Ratio (SE), value indicate that when
“marijuana use ever” is raised by one unit (one person) the odds ratio indicates that
patients with SMI are 9 times more likely, and for “sex with IDU ever” risk partner,
4 times more likely to provide a self-reported STI history.
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4.5 DISCUSSION

Study One explored if patients with SMI, in western Sydney, Australia, are at risk for
STIs and BBVs, as has been the situation in the USA and overseas. The results show
that Australian patients with SMI have elevated rates of risk factors, elevated rates of
infections and elevated risk for STIs and BBVs, and particularly HCV. This risk was
significantly higher when compared to the Australian population, even when analysis
was controlled for the associated risk factors.

Just about all risks (except for male-to-male sexual activity), for this risk network of
patients with SMI, were reported very frequently when compared to similar patient
groups with SMI (see literature review of Chapter 3, and with the Australian
population (Davidson et al., 2001; Kalichman et al., 1994; Rosenberg et al., 2001;
Thompson et al., 1997). Risks occurred for the individuals and for their reported
partners.

Sexual behaviour was risky. Women especially reported a wider repertoire of sexual
identity, experiences and more partners. Both males and females reported less
condom use “ever”. Even some positively reported behaviours, such as condom use
at last sexual contact, were not safe enough, as their last sexual contact was more
likely to have been with a casual partner. Patients proved the previous findings that
they “tend to have safe sex with risky partners and risky sex with safe partners”
(Peterman, 2002), but sex with safe partners happens less often. Substance use,
including injecting drug use, was elevated compared to the Australian population. Of
note, when only injecting drug users were compared, patients with SMI were more
likely to report heroin and methadone use but have similar rates of needle or other
paraphernalia risk activities, compared to IDU of part of the Australian population.
The other significant risk activity reported was a history of incarceration.

Patients had risk related to sex, substance use and incarceration but additional risks
were at the partner level. Patients with SMI reported sexual contact with others that
had sexual risks, such as multi-partnered, substance risk, particularly IDU, and their
own incarceration history.
97

Study One found high rates of HCV and HBV from biological sample testing, as well
as past self-reported STIs. These infection rates were significantly higher when
compared to the Australian population. HIV infection was not as prominent in
contrast to overseas findings. Nearly half of this group of patients with SMI provided
self-reported STI histories, as well as the high rates of HCV and HBV, which is an
important finding when contrasted with other groups. Findings indicated that
infections were mostly not recently acquired. The one positive chlamydia was
present for a young female, in keeping with infection being more prominent in young
persons.

The salient issue for patients with SMI is HCV exposure and infection. Over a
quarter of the participants had evidence of HCV exposure, comparable to other
research (Lacey et al., 2007; Rosenberg et al., 2001). Study One also identified a
high HCV rate for all patients tested at Cumberland Hospital with an overall elevated
HCV exposure prevalence of 5%, probably an underestimate, but much higher than
community values at around 1%. HCV risk for patients with SMI that injected was
higher than for the injecting general population. This research also found that the risk
for HCV was higher for patients with SMI that did not inject compared to the
Australian population that did not inject.

Risk factor histories did predict STI and BBV infections. Many risk behaviours were
associated with HCV, HBV or self-reported STIs. Multiple regression analysis
identified that HCV exposure was predicted by a history of “IDU ever” and
“incarceration ever”. Self-reported STIs were predicted, by “marijuana use ever” and
“sex ever with IDU risk partner”.

Patients with SMI have a greater risk for STI and BBV infections than the general
population. Risk is evident from the more pronounced risk factors, infection rates,
and higher likelihood of infection. As mentioned above patients seem to have risk
over and above what would be expected from a risk history. It may be that patients
with SMI have a heightened risk because of their severe mental illness. A diagnosis
of SMI does mark higher risk or a risk network, as seen by higher HCV rates for
patients compared to the Australian public when stratified by IDU risk history.
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4.6 OVERALL STRENGTHS AND LIMITATIONS

This is the first comprehensive review of risks and infections for patients with SMI
undertaken in Australia. It is unique in describing the sexual, substance use
behaviours and sexual partner choices for patients with SMI. It is unique in
recognising that patients with SMI are a unique network or risk group deserving
consideration as a priority group. Its strengths include information recognising high
rates of STIs or BBVs. HCV exposure in particular is a risk for all patients with SMI,
as seen with the over a quarter of the study group positive as well as the overall
Cumberland seroprevalence at five percent.
The study’s conclusions are valid as the required sample size was achieved with
results having statistical power support, even if the sample size was smaller than
anticipated. Findings hold for this patient population group, but may not be
applicable to all persons with SMI. Patient acceptance was very good as there was
93% participation rate for those patients referred and available and a final 83%
participation rate for those enrolled to both parts of Study One.

As such, the chief limitations included the failure to achieve a very large sample size
and the non-responsiveness of study participants to many of the questions, limiting
statistical power to assess for all the variables. Recruitment could have been broader
but was limited because of the reliance on psychiatrists to refer patients to the study.
Referral rates may have been low because psychiatrists were too busy, worried about
confidentiality or did not see the value of the research project, as assessed by other
groups (VanGeest, Johnson, & Welch, 2007), or did not believe that they had
patients at risk. Research projects, with direct recruitment of participants, have a
better participation rate than studies requiring referral by other healthcare providers
(Sullivan-Bolyai, Bova, Deatrick, Knafl, Grey et al., 2007).

The results may be limited by not attaining a large sample and selection bias may
have occurred. Specifically overrepresentation of persons at risk for STIs and BBVs,
if psychiatrists were more likely to refer those perceived at risk. This selection bias is
well known when hospitalised patients are researched and was described by Berkson
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(1946). Anecdotally some psychiatrists felt that this study should have patients
referred at risk for STIs and BBVs, or those patients that requested referral. Selection
bias has to be considered because some results, such as IDU activity at 31%, were
double the prevalence reported by some previous researchers for patients with SMI
(Davidson et al., 2001; Rosenberg et al., 2001; Thompson et al., 1997) but lower than
a recent survey of patients with SMI and 50% lifetime injection drug use (Lacey et
al., 2007). Balancing this potential problem is that the high rate of 26% for HCV
exposure though is similar to other groups that have examined HCV risk
(Klinkenberg et al., 2003; Lacey et al., 2007; Meyer, 2003; Rosenberg et al., 2001).
It may also be that the ASHR survey tool used in this study was better at eliciting an
injecting drug use history than tools used by previous researchers.

This study potentially suffered from other biases in addition to sampling. Information
bias, with missing data because of non-responsiveness and inaccurate recall
occurred. Poor response by patients with SMI may be an element of their illness with
an inability, or unwillingness, to focus on a lengthy questionnaire, requiring ten to
twenty minutes. Attempts were made minimise bias in the design process, but bias
may still have occurred. For example, the ASHR questionnaire was chosen because it
can be tailored to skip inapplicable sections. Study participants disclosed many risk
behaviours that led to a lengthier interview than anticipated.

4.7 CONCLUSION

Study One has identified that a patients diagnosed with SMI, appear to have unique
risks and vulnerable to risk activities and STI/BBV infections, in particular HCV
exposure. Risks for patients with SMI particularly involve substance use activities
and incarceration histories, as well as unsafe sexual behaviour. This study’s finding
has important implications for the content of harm reduction strategies, future
research and suggests that patients with SMI should be considered a priority, or risk
group or network.
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CHAPTER FIVE
Study Two: Psychiatrists’ knowledge, attitudes and behaviours in
assessment and management of STIs and BBVs for patients with
severe mental illness3

5.1

OVERVIEW OF STUDY TWO

A key finding from Study One of this thesis was that patients with severe mental
illness (SMI) were at a higher risk than the general community for sexually
transmitted infections (STIs) and blood borne viruses (BBVs), in keeping with
findings from the systematic literature review. Risk and rates of Hepatitis C virus
(HCV) for patients with SMI were particularly high, with HCV prevalence at 26%,
though HIV is less of an issue for Australian patients. Other researchers have
identified similarly high HCV rates ranging from 9% in Greece (Kakisi,
Grammatikos, Karageorgopoulos, Athanasoulia, Papadopoulou et al., 2009) to 19%
in Australia (Lacey et al., 2007) and 20% in the USA (Rosenberg et al., 2001).
Community rates of HCV antibody positivity are around only 1% (Grulich, de Visser
et al., 2003c; National Centre in HIV Epidemiology and Clinical Research, 2010).
This HCV risk for patients with SMI is related to injecting drug use (IDU) activities
and has been well-documented, particularly in the USA (Rosenberg et al., 2001).
Despite the prevalence of risk factors and infection for patients with SMI, the referral
of patients by psychiatrists into Study One, was extremely low. This raised questions
about the characteristics that may contribute to low assessment and referral rates, not
just in relation to Study One, but in general sexual health and medical care for
patients with SMI.

With HCV exposure a significant issue for patients, it was postulated that one reason
for the low referral rates may be psychiatrists’ low levels of awareness or knowledge
regarding the relative risk and implications for HCV amongst those with SMI.
3

Parts of this chapter were published as Lagios & Deane (2011)
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Thus, Study Two explores the self-reported Knowledge, Attitude and Behaviour
Practices (KAB) of psychiatrists in screening, assessment and management of
patients for STIs and BBVs, particularly HCV. The cross-sectional assessment of
KAB amongst psychiatrists was chosen as this has been a helpful format to guide
health programmes and is based on research indicating that behaviour is influenced
by attitudes (Ajzen, 1991, 2000) and to some extent knowledge (Kennedy, Regehr,
Rosenfield, Roberts, & Lingard, 2004). Inherent in screening is that healthcare
workers need knowledge to recognise risk factors and to conduct appropriate
assessments. Healthcare workers need positive attitudes that support and facilitate
behaviours, such as assessment for STIs and BBVs, and not negative attitudes toward
patients who may engage in risk behaviours, such as injecting drug use (Ampt,
Amoroso, Harris, McKenzie, Rose et al., 2009; O'Brien, Day, Black, & Dolan,
2008).

When assessing with a KAB survey the extent should be broad, (see Chapter 3).
From the review, KAB areas were categorised based on findings from a diverse
group of researched participants, such as doctors, medical students, patients with
SMI (Anjum et al., 2005; Coppola et al., 2004; Dev & Sievert, 2002; Goldberg et al.,
2009; Mulvey et al., 1997; Munoz Sastre et al., 2002; Richmond et al., 2007;
Temple-Smith et al., 1999). Knowledge of STIs and BBVs should cover
epidemiology, clinical features, such asymptomatic infection and management. In
Australia, GPs have available specialised guidance indicating that their knowledge
should include an understanding of the infective organism, natural history,
transmission, assessment, clinical presentations, treatment options and general
management such as vaccinations and lifestyle issues (ASHM, 2008). Attitudes
regarding STIs and BBVs may differ according to different healthcare situations.
Attitudes may be assessed in the approach or attitude to a health problem, or patient,
by a healthcare worker. Attitudes can also be assessed in acknowledgement of
discrimination issues for patients (ASHM, 2008). Behaviours regarding STIs and
BBVs can be explored in the extent that healthcare assessments or management
occurs, expanding on the behaviours of clinicians such as history taking, examination
and arranging investigative procedures.
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Other studies have attempted to examine different components that affect care such
as doctor characteristics associated with assessment for STIs and BBVs. Some have
found that younger, newly trained doctors fare better regarding STI knowledge
(Mulvey et al., 1997) and risk history elicitation (Haley, Maheux, Rivard, & Gervais,
2002). Whereas another study by Dev and Sievert (2002) reported that “years in
general practice” did not correlate with HCV knowledge. Study Two considers this
aspect to help understand psychiatrists approach to HCV.

Patients with SMI should ideally have a GP. The GP is best situated to provide
holistic patient care including screening for BBVs and STIs. Unfortunately, some
patients with SMI may not have a regular GP and most of their consistent healthcare
occurs once admitted to a psychiatric hospital (Millar, 2008). Many patients with
SMI spend a considerable amount of time in hospital as measured by frequency and
duration of admissions (Jablensky, McGrath, Herrman et al., 1999) which may
contribute to the lack of a GP and the need for psychiatrists to provide broader
healthcare.

It has been recognised that patients with SMI have an increased risk for many
physical health co-morbidities, including cardiovascular disease, diabetes and
chronic respiratory illnesses (Marder, Essock, Miller, & Buchanan, 2004; Millar,
2008; Osborn, Wright, Levy, King, Deo et al., 2008). As yet it is not widely
appreciated amongst medical practitioners that HCV exposure, and ensuing
morbidities, are also a significant problem for their patients with SMI (Lacey et al.,
2007) hence the need for any healthcare worker to provide broader healthcare.

Study Two was undertaken to explore reasons that might explain the low frequency
of screening found both in Study One and by other researchers in general (Goldberg
et al., 2009; Hercus et al., 2005; Lacey et al., 2007). Psychiatrists, particularly those
working in inpatient settings, are in a critical position to screen and assess the risk of
STIs, BBVs and especially HCV for patients, given their medical training and
leadership role in mental health treatment teams (Sims & Sims, 1993). Previous
studies’ findings related to STI and BBV screening have been based on GPs caring
for the general population and not samples with mental illness (Dev & Sievert, 2002;
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Mulvey et al., 1997; Richmond et al., 2007). As yet there have not been Australian
studies that explore the knowledge, attitudes and behaviour-practices of psychiatrists,
regarding STIs and BBVs, and the role of psychiatrists in screening assessment and
treatment for patients with SMI. If GPs, medical students and even HCV experts lack
knowledge on key areas of HCV, it may be that psychiatrists would have similar
challenges.

5.2

AIMS, OBJECTIVES AND HYPOTHESES

The aim of this research was to assess the knowledge, attitudes, and self-reported
behaviours of doctors working in psychiatry and caring for patients with SMI,
regarding STIs, BBVs and particularly HCV.

Specifically:

1. To describe the demographic and work situation characteristics of doctors
working in psychiatry and caring for inpatients with SMI.
2. To ascertain levels of knowledge, attitudes and self-reported behaviours
regarding STIs, BBVs and more specifically for HCV.
3. To compare the knowledge, attitudes and self-reported behaviours of
doctors working in psychiatry with other researched groups, such as GPs.
4. To determine the effect of doctor characteristics on knowledge, attitudes
and self- reported behaviours.
5. To determine the relationship of knowledge and attitude to behaviour
with regard to STIs and BBVs

It was hypothesised that:

1. Medical officers, particularly older doctors, will have lower levels of
knowledge regarding risk behaviours, risk groups, and management of STIs,
BBVs and HCV.
2. Knowledge will be correlated with attitudes and behaviours, such that
better knowledge will be related to more appropriate attitudes and behaviours.
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3. Knowledge and attitudes will predict self-reported behaviour practices such
as referral and screening.
4. Psychiatrists would have poorer knowledge than General Practitioners.
5.3

METHOD

The method section outlines procedure, study participants, measures and statistical
issues. As well the method section covers the issues considered in preparation for
KAB study assessing psychiatrists, such as bias and KAB design processes.

5.3.1 Procedure

An invitation to participate was extended to all doctors working in psychiatry in the
western Sydney region, called Sydney West Area Health Service (SWAHS). This
occurred in conjunction with an invitation to attend a planned “in-service education
session on sexual health” during 2007. For this study the terms “doctors working in
psychiatry” and “psychiatrists” are used interchangeably. Potential participants were
those who chose to attend the weekly education session that was advertised as “Sex
at Cumberland”. Cumberland Hospital is well-known as the largest psychiatric
hospital in the region and this session involved presenting data from Study One,
which had been conducted at Cumberland Hospital. Thus, it is likely to have
attracted personnel who had an interest in the content of the advertised session. All
doctors attending were invited to participate in the study at the beginning of the
session and attendees did not have prior knowledge that recruitment for research
participation would occur at these sessions.

All protocols had been reviewed and approved by the University of Wollongong and
the SWAHS Human Ethics review committees (Appendix 4). The information sheet
and questionnaire were supplied and collected immediately before the start of the
education talk. This was so that presentation of results from Study One did not
influence responses. The questionnaire was self-report and took approximately 15
minutes to complete. Participation was voluntary and informed consent was implied
by completion of the questionnaire. Identifying information was not collected, so that
the identity of each participant’s responses remained anonymous. The self-completed
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questionnaire data was entered into PASW 18 (SPSS IBM, 2009). The questionnaires
were then stored in locked filing cabinets in an office of the researcher at
Cumberland Hospital.

5.3.2 Study Participants

All 97 medical practitioners working in SWAHS Mental Health Care Services were
potential participants. This potential pool comprised 35% (34/97) senior consultant
psychiatrists and 65% (63/97) junior medical officers, of whom 46% (45/97) were
registrars and 19% (18/97), were career medical officers. However, only 52%
(50/97) of the potential pool attended the targeted weekly education sessions held at
three sites. Of the 50 attending the education sessions 35 completed and returned
questionnaires representing a response rate of 70% and the remaining 15 attendees
chose not to participate in the research (Figure 5.1).

Psychiatrist Population SWAHS
n = 97
Senior Staff = 34
Junior Staff = 63
- Registrars = 45
- CMOs =18
Number attending Education meeting
n = 50

Number Participating
n = 35
Senior Staff = 18
Junior Staff = 17 - Registrars = 13
- CMOs =4

.
Figure 5.1 Participant Flow Chart for Psychiatrist Involvement in Study Two
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Study participants were male (54%), greater than 35 years of age (80%), received
their medical degree in Australia (51%), had worked for less than ten years in
psychiatry (57%) and there was a slight majority of senior specialist consultant
psychiatrists (51%).

5.3.3 Measures
Study Two is a “Knowledge, Attitude and Behaviour practice (KAB)” study. The
attractiveness of KAB surveys to gain information on health-seeking or healthproviding practices is attributable to characteristics such as an easy design,
quantifiable data, ease of interpretation and concise presentation of results,
generalisability of small sample results to a wider population and speed of
implementation (Launiala, 2009). KAB surveys may have limitations in their
predictive capabilities, as they are typically cross-sectional surveys and may be
affected by issues, such as information bias (Cleland, 1973; Launiala, 2009).

The KAB survey of Study Two was implemented as a questionnaire to research
doctors working in psychiatry. Survey questions are from previous published studies
(Dev & Sievert, 2002; Mulvey et al., 1997) that had assessed KAB for STIs and
BBVs. Directly observable doctor characteristics were questions with categorised
options. Knowledge questions were in the format of “yes/no/uncertain”, a variation
of the true-false format, chosen because it is a simple, direct, and an efficient way to
assess knowledge about a subject (Downing, 1992). Attitude and behaviour are not
readily observable. Instead, these variables are studied as an inferred location on a
dimension, by observing ratings given to items on psychological inventories (Blanton
& Jaccard, 2006). For this KAB survey, attitude and behaviour are assessed with
psychometric summated scales, with multiple Likert-type items, to capture a domain.
Multiple items that measure a domain or scale potentially increase reliability and are
important in creating the KAB survey (Spector, 1992).

The questionnaire used in the present study consisted of four domains covering (1)
demographic and descriptive items, (2) knowledge, (3) attitudes and (4) self-reported
behaviours. The questionnaire had 105 items, was 5 pages in length and required
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most responses to be ticked (e.g., multiple-choice, categorical or Likert-type items).
The domains and items included were identified from previous research. The
questionnaire was comprised of 12 items asking demographic and descriptive
STI/BBV questions, 60 items covering five knowledge subscales, 12 items
comprising two attitude subscales, and 21 items assessing four behaviour subscales.
Items in each subscale of knowledge, attitude and self-reported behaviour were
grouped together in the questionnaire (See Appendix 6).

Measurements of Study Two included:
Domain 1: Demographic and Descriptive STI/BBV
Domain 2: Knowledge - Subscales:
(i)

STI/BBV Asymptomatic

(ii)

STI/BBV Epidemiology

(iii) HCV Epidemiology
(iv) HCV Referral
(v)

HCV Management

Domain 3: Attitude (toward) - Subscales
(i)

STI/BBV History Barriers

(ii)

Treating HCV patients

Domain 4: Behaviour - Subscales
(i)

STI/BBV History Taking

(ii)

Post-test STI/BBV Management

(iii) Pre-test HIV Screening
(iv) Pre-test HCV Screening
For the knowledge subscales, a sum of the number of “correct” items was used. For
the attitude and behaviour subscales, a mean of items in each subscale was used.
Scoring was organised such that higher scores for each subscale indicated better
knowledge, more positive attitudes or more appropriate behaviour. For the purposes
of this study, in order to define a “satisfactory” level of knowledge, attitude or
behaviours we used a value 70% or more of the maximum score. Although this value
is somewhat arbitrary for knowledge scales, it provides a standard point of reference
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for descriptive purposes and does represent the positive end of most 5 or 7-point
Likert-type item responses.

With the exception of the knowledge subscales, each subscale for attitude and
behaviour, had internal consistency (reliability) computed using Cronbach's alpha
coefficient. Values higher than 0.7, were considered to be sufficiently reliable for use
in group comparisons (Bland & Altman DG, 1997). Cronbach alphas for the scales
are provided in the Section 5.3.3.3 and 5.3.3.4 below. Cronbach alphas were not
calculated for the knowledge subscales since these were multi-dimensional covering
diverse knowledge domains and were not expected to yield high internal consistency
(Garson, 2011).

5.3.3.1 Demographics and Descriptive STI/BBV Domain

There were seven items measuring demographic characteristics in the first domain.
All questions were multiple-choice answers to a limited list of options. These
included gender, age group, if primary health care training was in Australia, years
since graduation, years in mental health and current position and hours of clinical
workload, and reported in section 5.3.3 Study participants. An additional five
descriptive questions asked respondents to: estimate HCV prevalence in the hospital
inpatient population, whether they felt well informed regarding HCV, the frequency
with which they ordered HCV tests, whether they had made any STI or BBV
diagnosis in the last year and how commonly they assessed their patients for STIs or
BBVs. The descriptive items were reported in results.

5.3.3.2 Measuring Knowledge

Domain two measured Knowledge over 5 key subscales. Two subscales assessed STI
and BBV Knowledge: STI/BBV Asymptomatic and STI/BBV Epidemiology and
three subscales assessed HCV knowledge only: HCV Epidemiology, HCV Referral,
HCV Management.
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Questions were mostly in the format of “yes/no/uncertain”. The “uncertain” response
option was used to minimise the tendency to guess when not sure (Aday &
Cornelius, 2006) and was also the method used in previous surveys (Dev & Sievert,
2002). Each item received a score of one for a correct answer, with “uncertain”
counted as incorrect. Two items regarding risk of HCV progression from the
subscale HCV Epidemiology and all items part of STI/BBVs Epidemiology subscale
differed, with study participants having to pick the correct answer from a list of
multiple choices. Knowledge level for each subscale was calculated as the sum of
correct answers for each item.

Knowledge STI/BBVs Asymptomatic
Eighteen questions assessed knowledge regarding the asymptomatic nature of STIs
and BBVs with respondents selecting from a list of nine STIs or BBVs that may be
present without causing symptoms in males and nine of the same STIs or BBVs that
may be present without causing symptoms in female patients. Ten questions were
from Mulvey et al (1997) the other eight questions in this subscale were included to
assess STIs and BBVs based on the current academic literature (e.g., asking if
chlamydia or HCV may be present without causing any symptoms). The maximum
score possible was 18 on this subscale.

Knowledge STI/BBVs Epidemiology
There were seven questions with six of the items from Mulvey et al (1997). These
items assessed the epidemiology of some STIs and BBVs, such as the most common
age groups for detecting chlamydia. An additional question regarding the
epidemiology of syphilis was added as there has been a recent syphilis resurgence
(National Centre in HIV Epidemiology and Clinical Research, 2008). Study
participants received a score only if they correctly identified all of the one or two risk
categories as requested. The maximum score possible for this subscale was 7.

Knowledge HCV Epidemiology
There were 16 items that had all been used in previous research by Dev and Sievert
(2002) that assessed knowledge of the transmission and disease progression risk. For
example, if “HCV can be spread through faecal contact, (Yes/No/Uncertain)” or
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picking the correct “percentage that progress to hepato-cellular carcinoma in 20 to 40
years, from the multiple choices of; “ < 10%, 10 - 40%, > 40%”. The maximum
score possible on this scale was 16.

Knowledge HCV Referral
There were 10 questions, all from Dev and Sievert (2002) that assessed knowledge
regarding situations for referring patients with HCV for specialist management, for
example, “Referral should occur as soon as a patient tests Hepatitis C antibody +ve”,
(Yes/No/Uncertain). The maximum possible score for the subscale was 10.

Knowledge HCV Management
This scale had nine items, with eight derived from previous research, that assessed
knowledge about choice of antivirals and advocacy of vaccinations (Dev & Sievert,
2002). One item was added by the authors, asking if “management of HCV includes
immunisation against HCV”, (Yes/No/Uncertain), as this was a common
misconception for patients and healthcare workers (Anjum et al., 2005; Munoz Sastre
et al., 2002). The maximum score was 9.

5.3.3.3 Measuring Attitude

There were two attitude subscales. One subscale assessed Attitudes towards
“STI/BBV History” with review of perceived barriers, and one subscale assessed
Attitudes towards “Treating HCV patients”.

Attitude Barriers to STI/BBV History
This subscale explored barriers to taking STI/BBV history and had nine attitude
statements that had all been used in previous research (Temple-Smith et al., 1999).
Study participants were asked to respond to each statement on 6-point rating scale
from “major barrier” to “not at all a barrier”. The subscale had a potential mean score
ranging from 1 to 6. An example of a barrier item in this subscale is “appreciable age
difference between doctor and patient”. The scale had an internal reliability with a
Cronbach alpha value of .80.
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Attitude Treating HCV Patients
The subscale of attitudes toward treating patients with HCV was assessed with three
items and evaluated such attitudes as “believing that psychiatry has a central role in
the treatment of patients with HCV”. All three questions were verbatim from past
research (Richmond et al., 2007, p. 626). Study participants were asked to indicate
their agreement on a 5-point Likert-type scale from (1) “never” to (5) “always”. The
maximum possible score for the subscale’s calculated mean was 5. The Cronbach
alpha value was unsatisfactory with a value of .32, indicating low internal
consistency and suggesting that the 3 items were measuring different attributes or
dimensions (Garson, 2011).

5.3.3.4 Measuring Behaviour

There were four behaviour subscales. Three subscales explored behaviour related to
STI/BBVs: STI/BBV History, Post-test STI/BBV Management and Pre-test HIV
Screening. The behaviour subscale Pre-test HCV Screening, assessed behaviour
practices related to HCV.

Behaviour STI/BBV History Taking
This subscale had seven statements used in previous research, asking respondents
about their behaviour of history taking they conducted as part of risk assessment for
STI/BBVs (Temple-Smith et al., 1999). Study participants were asked to indicate
their level of involvement in the behaviour on a 3-point rating scale, from “not at all
common” (1) to “very common (3)” (Temple-Smith et al., 1999). A mean of all items
was calculated and scores could range from 1 to 3. An example of an item from this
subscale asked respondents how commonly they assessed the gender of sexual
contacts during history taking. Cronbach alpha for this scale was .83.

Behaviour HIV Pre-test Screening
The extent to which respondents self-reported engagement in various aspects of HIV
pre-test screening discussion behaviour was assessed by four items from previous
research (Temple-Smith et al., 1999). Each item was rated on a 5-point Likert-type
scale from (1) “never” to (5) “always”. A mean score for all items was calculated
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with potential scores ranging from 1 to 5. This subscale attempted to gauge the
frequency that risks and implications of HIV testing were discussed. For example,
whether the implications of a negative HIV Antibody test result was discussed, if the
risk for HIV occurred in the recent, 2 to 3 month window period. Cronbach alpha for
the scale was .81.

Behaviour Post-test STI/BBV Management
There were four statements as part of this subscale assessing behaviours related to
Post-test STI/BBV Management. These items explored management after STI/BBV
testing, for example issues such as the frequency of recommending vaccinations
were investigated. All items were from previous research (Mulvey et al., 1997;
Temple-Smith et al., 1999). Each statement had 4 response options from “never” to
“always” (1 = never, 2 = sometimes, 3 = mostly, 4 = always). A mean score for the
scale could range from 1 to 4. Cronbach alpha reliability was .68.

Behaviour HCV Pre-test Screening
HCV Pre-test Screening behaviour had 6 statements. This subscale attempted to
identify the regularity that risks and implications of testing for HCV were discussed.
HCV and HIV pre-test discussions have a similar format and these HCV items were
created and included in this questionnaire because of the significance of HCV
prevalence for patients with SMI. Three items were based on the items exploring
HIV pre-test screening discussion (Temple-Smith et al., 1999) and three items were
developed for this study according to national guidelines (Australian Government
Department of Health and Ageing, 2007). Each item had a 5 point rating, from
“never” to “always”, (1 = never, 2 = rare, 3 = sometimes, 4 = mostly, 5 = always),
and a maximum possible item score of 5 and a mean score for the subscale ranging
from 1 to 5. Cronbach alpha was .91 for items in this subscale.

5.3.3.5 Bias In KAB Survey Assessing Psychiatrists

Bias in Study Two is also a potential problem. Bias could occur because of the
research tool, especially for surveys with poor validity or reliability, causing
information bias. Study Two may also potentially have selection bias. It is
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appropriate to use as research tools for new projects existing, psychometrically tested
questionnaires identified from the literature (Kelley, Clark, Brown, & Sitzia, 2003).
The questionnaires must demonstrate the psychometric properties of reliability
(consistency from one measurement to the next), validity (accurate measurement of
the concept).

The questionnaires utilised in Study Two have all been previously devised and used
in research and have had previous evaluation, (Dev & Sievert, 2002; Mulvey et al.,
1997; Richmond et al., 2007; Temple-Smith et al., 1999). Questions from Mulvey et
al (1997) and Temple-Smith (1999), had face validity assessed, with review and pilot
testing of the questionnaire by GPs, venereologists and epidemiologists. Two other
sources of questions were available from published studies (Dev & Sievert, 2002;
Richmond et al., 2007). The results by Richmond et al (2007, p. 627) demonstrated
aspects of construct validity as medical practitioners scored higher on knowledge
compared to pharmacists, who would not be expected to have as much coverage of
content regarding hepatitis C. The questions developed by Dev and Sievert (2002)
were knowledge questions, based on the comprehensive hepatitis C publication,
“Hepatitis C – A management guide for general practitioners”, produced by the
Australian National Council for AIDS, Hepatitis C and Related Diseases; the
Gastroenterological Society of Australia; and the Royal Australasian College of
General Practitioners (Puplick, Farrell, Dore, MacDonald, McCoy et al., 1999). This
publication had been distributed to every doctor in Australia in 2000. Dev and
Sievert’s study (2002) was conducted 6 months after the publication’s distribution
and presumed GPs had read this comprehensive HCV management publication and
thus have a valid knowledge basis.

The collated questionnaire used as the research tool for Study Two met validity and
reliability requirements. The knowledge, attitude and behaviour questions reviewing
STIs had, as stated, face validity assessed by the original researchers (Mulvey et al.,
1997; Temple-Smith et al., 1999). Though the study by Dev and Sievert (2002) did
not provide information regarding validity it is assumed that the creation of the
questions based on the recent publication for GPs would have validity. All the
subscales with corresponding items for Study Two had internal reliability formally
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assessed as part of this thesis. All the subscales, apart from one, had a Cronbach
alpha reliability coefficient of .70 or higher, which is considered acceptable and
indicative of satisfactory reliability for the KAB survey.

As well as potential weaknesses in the questionnaire there is also a risk of selection
bias. Studies with doctors as research participants, may suffer from selection bias as
it is not uncommon for doctors to decline to participate in surveys (Kellerman &
Herold, 2001).Doctors who are hesitant to participate may simply not be interested,
be too busy, worried about confidentiality or not see the value in the survey
(Sudman, 1985). What could be of concern, but difficult to identify, is if doctors with
poorer skills, or with conservative attitudes, choose not to participate in surveys.
Study Two’s techniques considered this issue and attempted to minimise poor
participation with the psychiatry attendees not having prior knowledge that
recruitment for research participation would occur and having participation as
voluntary and anonymous.

5.3.4 Statistical Issues

Data was analysed with PASW 18 (SPSS IBM, 2009). Frequencies were reported for
items part of the Demographic and Descriptive STI/BBV domain. Descriptive
statistics, including frequencies, were calculated for each item and for the subscales
for the other domains. Data was presented for the summarised subscales of each
domain in tables, with the number of items, mean, standard deviation, % index mean
for knowledge (mean/maximum score possible as a percentage), range and mean
rank for each subscale. Frequencies for some items are also presented.

Initial screening of data indicated many variables were not normally distributed and
did not meet the assumptions of the parametric tests. Thus non-parametric tests were
used to provide inferential statistics about the parameters of the distribution for the
summarised subscales. These included: Friedman’s ANOVA test to detect
differences in the means of two or more subscales; Wilcoxon signed-rank test to look
for differences between pairs of related subscale results; non-parametric Kruskal115

Wallis ANOVAs; Chi-square analyses to explore differences in subscale scores for
doctors of varying experience or qualifications; Spearman’s correlations performed
to determine significant correlations between subscales. Lastly standard multiple
linear regression analysis were performed to identify predictors of self-reported
behaviour. The major assumptions to permit multiple regression analyses were
assessed and addressed in the results.

Sample size estimates for Study Two took into consideration that the study was
assessing relationships, including regression. As a descriptive study, a sample of 200
would suffice.

5.4

RESULTS

Results of Study Two included descriptions of the domains, a comparison of KAB
items with other researched groups, correlation between subscales, as well as
multiple linear regression analyses discussing predictors of behaviour. Domain
portrayals included frequency descriptive statistics for the general Descriptive
STI/BBV domain and some interesting KAB items, as well as summarised data of all
the subscales in the KAB domains in tables. Comparisons of KAB results for these
doctors working in psychiatry with prior research were made and data provided in
tables. Other comparison groups included Australian GPs (Mulvey et al., 1997;
Temple-Smith et al., 1999), Pakistani medical students (Anjum et al., 2005), French
lay people and liver specialists (Munoz Sastre et al., 2002), Australian health
professionals (complementary therapists, dentists, pharmacists, nurses and medical
practitioners) (Richmond et al., 2007) and persons with SMI (Goldberg et al., 2009).

5.4.1 Descriptive STI/BBV Domain Results

Most medical officers (86%), who participated in this survey, incorrectly estimated
that the percentage of their patients with HCV was “less than 10%”. Only 29% felt
that they were “well informed regarding HCV”. Only 37% “mostly” or “always”
ordered a HCV antibody test. Most (60%), “never” or only “sometimes”, considered

116

assessing patients for STIs or BBVs and 68% had not diagnosed any STI or BBV in
the last year.

5.4.2 Knowledge Domain Results

Table 5.1 indicates that doctors were more knowledgeable regarding the
Asymptomatic nature of STIs and BBVs, than STI/BBV Epidemiology in
recognising risk groups. The doctors working in psychiatry had good knowledge
regarding HCV Epidemiology and HCV Referral but were less knowledgeable about
HCV Management.

Table 5.1 Summary of Knowledge Domain
Description of Subscales

No. of
items

Mean

SD

% Index
Mean*

Range

Mean Rank

STIs/BBVs Asymptomatic

18

11.85

5.29

66%

0-18

1.93

STIs/BBVs Epidemiology

7

2.83

1.34

40%

0-6

1.07

HCV Epidemiology

16

11.71

2.07

73%

7-15

2.93

HCV Referral

10

7.80

1.41

78%

5-10

2.07

HCV Management

9

3.29

2.20

37%

0-7

1.00

* % Index Mean = mean/max score possible, as percentage

5.4.2.1 Knowledge STI/BBVs Asymptomatic

The mean score for the Knowledge STI/BBVs Asymptomatic subscale was 11.85
from 18 items. The doctors recognised that many of the STI or BBV infections can
be asymptomatic including HCV exposure (82%).

5.4.2.2 Knowledge STI/BBVs Epidemiology

The Knowledge STI/BBVs Epidemiology subscale revealed low knowledge in this
area with a mean of 2.83 from 7 items. The doctors did not recognise all of the main
groups with prevalent infections or complications related to STI or BBV infections.
For example, that chlamydia was common in young age groups or that a woman is at
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risk of HIV if she has had sexual contact with someone that injects drugs or is
bisexual.

5.4.2.3 Knowledge HCV Epidemiology

The Knowledge of HCV Epidemiology subscale generally had high scores (M =
11.71, out of 16 items). For example, 94% recognized the risk associated with other
injecting paraphernalia as well as all recognising the HCV risk associated with direct
IDU. Some items, such as risk of progression to cirrhosis (10-40% over 20 to 40
years), were correctly recognized by only 59% of doctors and risk of progression to
hepato-cellular carcinoma (<10% over 20 to 40 years) by only 41%. Although
knowledge in this domain was good overall, almost 80% of respondents believed that
HCV is spread through sexual contact.

5.4.2.4 Knowledge HCV Referral

Respondents, with a subscale mean of 7.80 out of 10 items, correctly answered most
items on the Knowledge HCV Referral subscale. Seventy-nine percent of doctors
identified correct situations for an HCV antibody positive patient to be referred to a
specialist for further assessment of HCV treatment options (such as when abnormal
liver function tests occur or a patient is symptomatic). All doctors indicated they
would refer patients with SMI to a specialist and 91% indicated they would refer
patients with intravenous drug use. However, only a limited number (29%) reported
that patients with solitary raised ALT liver function tests should also be referred.

5.4.2.5 Knowledge HCV Management

Doctors had low scores on the Knowledge of HCV Management subscale, which had
a mean of 3.29 out of a possible 9 items. For example, 47% of doctors were not
aware that the current medical treatment for HCV is dual therapy interferon and
ribavirin. Other inaccuracies reported included 69% of doctors wrongly thinking that
HCV vaccination was a current option. Doctors did not adequately know that
vaccination for other hepatitis infections was beneficial, though this was the highest
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correct response provided in this knowledge subscale, with 68% recognising that
patients with HCV should be immunised against HBV, but only 41% also advised
HAV vaccination. Only thirty-five percent of doctors appreciated that abstinence
from alcohol was recommended.

5.4.2.6 Knowledge Domain Differences

The two subscales for Knowledge STI/BBVs varied significantly and were assessed
by pairwise comparisons with the Wilcoxon signed rank test and a Bonferroni
adjusted

of .025 (.05/2). The STI/BBVs Asymptomatic subscale scores (mean rank

1.93) were significantly higher than STI/BBVs Epidemiology subscale scores (mean
rank 1.07), T = 1, z = -5.00, N - Ties = 33, p < .0001. This effect can be considered
“large” (Cohen, 1986),with r = .88.

A Friedman two way ANOVA indicated that rankings of Knowledge HCV varied
significantly between the three subscales,

2

= 65.83, df = 2, N = 35, p < .0001.

Follow-up pairwise comparisons, using Wilcoxon signed rank test and a Bonferroni
adjusted

of .017 (.05/3), were undertaken. HCV Epidemiology (mean rank 2.93)

had better scores than the HCV Referral scores (mean rank 2.07), T = -7.00, z = 4.99, N - Ties = 34, p < .001, two tailed. This effect were considered “large” (Cohen,
1988), r = -.85. Both HCV Epidemiology (mean 2.93) T = 0, z = -5.18, N-Ties = 35,
p < .0001 and HCV Referral (mean rank 2.07) had T = 0, z = -5.18, N - Ties = 35, p <
.0001 had better scores than HCV Management (mean rank 1.00). The effect can be
considered “large” (Cohen, 1988), with r = -.88 for both.

5.4.3 Knowledge of Psychiatrists compared with other researched groups.
Table 5.2 provides a descriptive evaluation of psychiatrists’ knowledge regarding
STI/BBV and HCV, compared to other researched groups. The following narrative
provides an outline of the comparisons only and no formal statistical tests were
conducted. This was in part due to the large number of potential comparisons, but
also because the broad aim was to provide a reference points for appreciating
psychiatrists knowledge base. Psychiatrists were more knowledgeable regarding
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HCV epidemiology and referral than GPs and similar regarding STI/BBV knowledge
but both groups were weak in their knowledge of HCV management.

In keeping with the good scores overall regarding Knowledge of HCV
Epidemiology, psychiatrists had better knowledge regarding HCV epidemiology than
GPs despite reporting less confidence in their HCV knowledge than GPs (Dev &
Sievert, 2002). For example, more psychiatrists (97%) than GPs (32%) recognised
that HCV can spread through injecting paraphernalia (Dev & Sievert, 2002). More
psychiatrists (89%) compared to GPs (67%) (Dev & Sievert, 2002) recognised that
prison is risk factor.

Knowledge of HCV referral, was stronger for psychiatrists than for GPs (Dev &
Sievert, 2002). GPs less frequently reported correct situations for referring patients
for HCV specialist opinion and treatment. Nearly all psychiatrist would refer patients
with and injecting drug use history or with SMI, whereas only about 80% of GPs
would consider such referrals.

Knowledge regarding HCV therapy was similar for psychiatrists (55%), GPs (48%)
and primary care trainees (52%), with only about half of each group recognising that
combination interferon and ribavirin treatment as the most effective. Knowledge
regarding HCV vaccination, also part of HCV management was a misunderstood
issue. In this study 69% of psychiatrists wrongly thought that HCV vaccination was a
current option, as did primary care residents (66%), Pakistani medical students (48%)
(Anjum et al., 2005) and patients with SMI (75%). Only the study with French liver
or infectious diseases HCV experts had correct responses with all of the HCV experts
recognising that HCV vaccination does not exist (Munoz Sastre et al., 2002).

Scores on the Knowledge STI/BBV Asymptomatic subscale were similar for GPs
(63%) (Mulvey et al., 1997) and psychiatrists (70%). The knowledge of the
asymptomatic nature of HCV was well recognised by both psychiatrists (88%) and
SMI patients (92%) (Goldberg et al., 2009) but not assessed in the GP study.
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Table 5.2: Comparison of Knowledge Items with Correct Responses for different participant groups (%)
Knowledge Items (with correct answers)

% reporting that they were well informed regarding HCV
HCV Epidemiology
HCV re-infection can occur (T)
HCV Ab test does not differentiates b/w current and past (T)
HCV in adults is more chronic compared to HBV in adult (T)
HCV can be spread through shared needles in drug usage (T)
HCV can be spread through shared injecting paraphernalia (T)
HCV can be spread Blood products (T)
HCV can be spread by medical equipment/procedures (T)
HCV can be spread sexually (F)
HCV can spread vertically (T)
HCV can be spread contaminated food (F)
HCV can be spread oral faecal (F)
HCV can be spread poor hygiene (F)
HCV can spread with infected household members (F)
Prison is a risk marker for HCV (F)
HCV exposure has a 10-40% risk of cirrhosis (T)
HCV exposure has a <10% risk of hepatocellular carcinoma (T)
HCV Referral
Refer if HCV Antibody +ve (T)
Refer if abnormal LFT (T)
Refer if ALT >100 (T)
Refer if symptomatic (T)
Refer when patients requests (T)
Refer if IDU - as suitable (T)
Refer if with SMI - as suitable (T)
Refer even if not interested in treatment (T)

Psychiatrists
SWAHS

GPs
(Dev &
Sievert)

GPs
(Mulvey
et al)

Pakistani
medical
students
(Anjum et al.)

French
specialists
(Munoz
Sastre et al.)

SMI
patients
(Goldberg
et al.)

Primary
Care
Trainees
(Coppola
et al.)

29%

68%

-

-

-

-

-

71%
50%
71%
100%
94%
94%
97%
23%
69%
94%
80%
71%
71%
89%
60%
43%

52%
62%
42%
100%
32%
67%
45%
29%

-

84%
86%
66%
59%
-

75%
48%
-

88%
25%
-

75%
92%
46%
48%
72%
-

71%
65%
29%
79%
84%
94%
100%
100%

24%
35%
35%
3%
4%
85%
82%
68%

-

-

-

-

-
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Refer if Prisoner (T)
Refer - as no patient is unsuitable (T)
HCV Management
Best treatment Interferon and Ribavirin (T)
Best treatment Interferon (F)
Best treatment Ribavirin (F)
Best treatment Lamivudine (F)
Management includes Immunise HAV Vaccine (T)
Management includes Immunise HBV Vaccine (T)
Management includes Immunise HCV Vaccine (F)
Management includes - nil Vaccine (F)
Management includes avoiding alcohol (T)
STI/BBV Asymptomatic
Recognise STI can be asymptomatic
Recognise HCV can be asymptomatic
STI/BBV Epidemiology – common groups
Chlamydia age groups – 15-19 & 20-24
HIV risk groups –MSM & Overseas contact
Syphilis risk groups – MSM & Overseas contact
Gonorrhoea risk groups – MSM & Men Overseas sex
HIV risk groups for women – Bisexual male & IDU
STI associated with cervical cancer - HPV
STI associated with infertility - Chlamydia

97%
74%

8%
56%

-

-

-

-

-

55%
9%
18%
18%
41%
68%
31%
56%
43%

48%
76%
97%
75%
57%
67%
91%
77%

-

52%
-

-

25%
70%

52%
41%
65%
34%
-

70%
88%

-

63%
-

-

-

92%

-

35%
21%
12%
9%
53%
94%
53%

-

28%
30%
42%
83%
96%
92%

-

-

-

-

Note: % = proportion correct
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GPs overall scored better on the Knowledge STI/BBV Epidemiology items. The
correct age groups for chlamydia infection were similarly identified by 28% of GPs
(Mulvey et al., 1997) and 35% of psychiatrists. Other items had better responses
from GPs, for example 83% of GPs (Mulvey et al., 1997) correctly identified the two
main sources of HIV infection for women, as “injecting drug use” and “sexual
contact with bisexual men”, whereas only 53% of psychiatrists answered this
question correctly.

5.4.4 Attitude Domain Results

Attitude subscales were generally in the positive range of responses. Barriers to
STI/BBV History Taking had a mean of 3.76 from a possible score of 6. Attitudes
toward Treating Patients with HCV had a mean of 4.01, from a maximum possible
score of 5 (See Table 5.3).

5.4.4.1 Attitude Barriers STI/BBV History

Barriers to STI/BBV History subscale had most items favourably reported. There
appeared to be few significant barriers identified by the psychiatrists involved in this
survey. Nearly 40% believed that sexual history taking was an “appropriate part of a
psychiatric assessment” (M = 3.91 out of a score of 6). The strongest barrier (M =
2.91) was not having “enough time to take a sexual history” with 29% reporting this
as “a major barrier”.

5.4.4.2 Attitude Treating Patients with HCV

The 3 items in this subscale are all described with an overall subscale mean of 4.01
from 5. The 3 items are multidirectional and as such have a low Cronbach alpha
value. One item assessed the study participants “willingness to treat patients with
HCV”. This had a high item mean of 4.29/5, with 82% indicating that they “mostly”
or “always” agreed with this response. The second item assessing if psychiatrists “do
not like treating people with HCV” with reverse scaling order, had a mean of 4.49/5
and 89% “rarely” or “never” agreeing with the statement. Beliefs that “psychiatry
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should have a central role in HCV” were lower, but still favourable, (mean 3.26/5),
with 46% “mostly” or “always”, and 31% “sometimes”, agreeing with the statement.
Table 5.3 Summary of Attitude Domain
Description of Subscale

No. of
items

Mean

SD

Range

Mean Ranks

9
3

3.76
4.01

1.02
0.66

1.44-5.33
2.33-5.00

1.40
1.60

Barriers STI/BBV History
Treating HCV patients

5.4.4.3 Attitude Domain Differences

A Wilcoxon signed rank test with Bonferroni adjusted

of .025 (.05/2) indicated

that the attitudes towards barriers STI/BBV History (mean rank 1.40) and the
attitudes towards treating patients with HCV (mean rank 1.60), did not significantly
differ T = 192, z = -1.35, N – Ties = 32, p = .18, with a small effect of r = .24
(Cohen, 1988).

5.4.5 Attitudes of Psychiatrists compared with other researched groups.

Doctors working in psychiatry had positive attitudes towards patients on the subscale
Attitude towards Treating Patients with HCV. In Richmond’s study (2007), 13% of
GP doctors did not want to treat patients that injected drugs (and had HCV), whereas
none of the psychiatrists surveyed chose the response that they “never” want to treat,
for this item.

In surveying Barrier Attitudes to STI/BBV History (Table 5.4), it can be seen that in
general psychiatrists were less concerned about the “presence of a third person”,
“issues related to language” and “culture” as barriers than GPs (Temple-Smith et al.,
1999). Psychiatrists main “major barriers” to sexual history taking were “first
consultation” and “insufficient time”, but were considered as barriers at lower
frequencies, compared to GPs.
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Table 5.4 Comparison of Attitudes - Barriers to STI/BBV History (%)
Attitude Items

Psychiatrists
SWAHS

Barriers to STI/ BBV History
32.4%
sufficient
time
forpatient
consultation
28.6%
first
consult
with
language issues
17.6%
presence of a third party
14.7%
appropriateness for psychiatry
11.8%
significant age gap with patient
5.9%
patient is of the opposite sex
5.9%
cultural issues
3.0%
fear of uncovering a problem
2.9%
Note: % = proportion who perceived the item as a major barrier

GPs (Temple-Smith
et al., 1999).
42.0%
28.1%
56.4%
73.0%
10.2%
13.4%
35.6%
3.9%

5.4.6 Behaviour Domain Results

The subscales examining STI/BBV and HCV Behaviours (see Table 5.5) indicated
that psychiatrists reported appropriate behavioural practices. The most frequently
reported behaviours related to conducting Pre-test HIV Screening discussions and the
least for coverage of Pre-test HCV Screening discussion items and performing
STI/BBV History Taking.

5.4.6.1 Behaviour STI/BBV History Taking

The subscale assessing behaviours related to STI/BBV History Taking had a low
mean, (M = 2.00 out of a possible score of 3) indicating that this behaviour was not
frequently undertaken. For most of the items that assessed risk history behaviours,
less than a quarter of the psychiatrists reported eliciting the various components that
should be performed “very commonly”. The only exceptions were that 74% of study
participants indicated they conducted an IDU history “very commonly” (M = 2.7)
and 46% indicated that they asked about safe sex “very commonly” (M = 2.2).
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Table 5.5 Summary of Behaviour Domain
Description of Subscales

STI/BBV History Taking
HIV Pre-test Screening
STI/BBV Post-test Management
HCV Pre-test Screening

No. of
items

Mean

SD

Range

Mean
Ranks

7
4
4
6

2.00
4.13
3.20
2.87

0.56
0.86
0.64
0.9

1-3
1-5
2-4
1-5

1.23
3.80
2.60
2.37

5.4.6.2 Behaviour STI/BBV Post-test Management
The subscale assessing STI/BBV Post-test Management Behaviour (M = 3.2 out of
4) explored patient management after a test had been done. In this subscale more
than 70% indicated they “always” seek specialist advice about management for
abnormal syphilis serology (M = 3.69). But only 41%, “always” recommended
vaccination against hepatitis B for patients that had a negative test result (M = 2.8).

5.4.6.3 Behaviour HIV Pre-test Screening

Pre-test HIV Screening discussion was the most frequently reported behaviour, with
more than two thirds of the study participants reporting that they “mostly” or
“always” performed the listed behaviours (M = 4.13 out of 5). Examples of highly
endorsed behaviours included discussing the implications of a negative HIV test
result if testing occurred during the window period for HIV detection (M = 4.11) and
discussing safe sex (M = 4.03)

5.4.6.4 Behaviour HCV Pre-test Screening

Doctors did not conduct the components HCV Pre-test Screening discussion very
frequently (M = 2.87 out of 5 items) (see Table 5.5). Although most respondents
asked about IDU as part of Behaviour STI/BBV History Taking, only a third
“mostly” or “always” said they discussed the various components expected during
HCV Pre-test discussion.
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5.4.6.5 Behaviour Domain Differences

A Friedman two way ANOVA indicated that rankings of Behaviour varied
significantly across the subscales,

2

= 71.01, df = 3, N = 35, p < .0001.

Follow-up pairwise comparisons with the Wilcoxon Signed Rank test and a
Bonferroni adjusted

of .0125 (.05/4) indicated that the Behaviour HIV Pre-test

Screening scores (mean rank 3.80) were significantly higher than (i) Behaviour
STI/BBVs Post-test Management scores (mean rank 2.60), T = 29.50, z = -4.39, N –
Ties = 32 p < .0001 with a large effect of r = .78 (Cohen, 1988), than (ii) Behaviour
HCV Pre-Test Screening scores (mean rank 2.37), T = 5.00, z = -5.00, N – Ties = 34
p < .0001 with a large effect of r = .86 (Cohen, 1986) and (iii) Behaviour STI/BBV
History Taking scores (mean rank 1.23), T = 1.00, z = -5.14, N – Ties = 35 p < .0001
with a large effect of r = .87 (Cohen, 1988).

The Behaviour STI/BBV Post-Test Management scores (mean rank 2.60), were
significantly higher than Behaviour STI/BBVs History Taking scores (mean rank
1.23) T = 11.50, z = -4.97, N – Ties = 35 p < .0001 with a large effect of r = .84
(Cohen, 1986) but not significantly higher than Behaviour HCV Pre-Test Screening
scores (mean rank 2.37), T = 186.50, z = -1.90, N – Ties = 34 p < .058 with a
medium effect of r = .33 (Cohen, 1988).

Finally, the difference between Behaviour HCV Pre-Test Screening scores (mean
rank 2.37) were significantly higher than Behaviour STI/BBVs History Taking
(mean rank 1.23), T = 33.50, z = -4.61, N – Ties = 35, p < .001, with a large effect of
r = .78 (Cohen, 1988).

5.4.7 Behaviour of Psychiatrists compared with other researched groups
Table 5.6 provides descriptive comparison of psychiatrists’ behaviours compared to
other researched groups. The most common behaviour reported by GPs involved
asking about “safe sex” (79%) (Temple-Smith et al., 1999), whereas only 44% of
psychiatrists elicited this history. Psychiatrists more commonly asked about “IDU”
activities (77%) whereas only 60% of GPs questioned their patients on this issue
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(Temple-Smith et al., 1999). Similar proportions, 88% of GPs (Mulvey et al., 1997)
and 97% of psychiatrists “mostly” or “always” sought specialist advice regarding
abnormal syphilis, as part of Post-test Management of STI/BBVs.

Table 5.6 Comparison of Behaviours of Psychiatrists and GPs
Behaviour Items

Behaviour STI/BBV History Taking
number of sexual partners
having safe sex
gender of sexual partners
having sex with sex worker
involvement in sex work
recent overseas travel
injecting drug use

Psychiatrists
SWAHS
*not
common

medium

44.1%
25.7%
35.3%
44.1%
51.5%
50.0%
5.7%

26.5%
28.6%
32.4%
35.3%
27.3%
38.2%
20.0%

very
common
29.4%
45.7%
32.4%
20.6%
21.2%
11.8%
74.3%

GPs
(Temple-Smith et al., 1999)
not
very
common medium common
14.0%
9.0%
40.0%
18.0%
12.0%

23.0%
12.0%
29.0%
32.0%
28.0%

63.0%
79.0%
31.0%
50.0%
60.0%

Behaviour STI/BBV Post -Test
Management
seek specialist advice for abnormal
syphilis
97.1%
88.0%
counsel patients for HBV
immunisation
58.8%
62.0%
Note: % = proportion who asked or acted regarding study item for scale of 1 to 6 with * not common
= 1 or 2, medium = 3 or 4, and very common = 5 or 6.

5.4.8 Bivariate Analysis: The relationship between doctor characteristics and
Knowledge, Attitudes and self-reported Behaviours

An analysis was undertaken to explore the relationship of doctor characteristics with
the knowledge, attitude and behaviour subscale scores, with the use of nonparametric Kruskal-Wallis ANOVAs and chi-square analyses. The significant
findings occurred for HCV items only and not for items that were part of the
STI/BBV scales.

Doctors who had worked for less than 10 years in mental health had higher scores in
(i) HCV Knowledge Referral subscale ( χ 2 = 8.28, df = 1, p = 0.004) and (ii) HCV
Knowledge Management ( χ 2 = 5.42, df = 1, p = 0.02), than those who had greater
than 10 years working in mental health. Likewise assessment by junior versus senior
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doctors (specialist consultant psychiatrists) found that junior doctors were also more
knowledgeable with respect to HCV Referral Knowledge (χ 2 = 4.14, df = 1,
p = 0.04) and reported more frequent HCV Pre-test Screening Behaviour than the
senior consultants (χ 2 = 9.07, df = 1, p = 0.003). Doctors who felt that they were
well informed regarding HCV reported more frequent HCV Pre-test Screening
Behaviours (χ 2 = 10.76, df = 1, p = 0.001). Overall, it seems that younger or “newer”
doctors had more HCV Knowledge and “well informed” doctors reported better
HCV Screening Behaviours, in keeping with some of the hypotheses.

5.4.9 Multivariable Analysis: The Relationship of Knowledge and Attitude to
Behaviour

To explore the relationship between knowledge, attitude and behaviour for the HCV
and STI/BBV subscales, Spearman’s correlations were performed (because the
variables were not all normally distributed). Table 5.7 provides the correlations
specific for STIs/BBVs. Table 5.8 provides the summary of the analysis of
correlations specific for HCV. STI/BBV analyses (Table 5.7) did not show any
significant correlations except between behaviour subscales.

Only results from the analysis of HCV variables (Table 5.8) had statistically
significant correlations. Knowledge of HCV Referral correlated with both Attitude
Treating HCV patients (r = .45) and with Behaviours HCV Pre-test Screening (r =
.49).

To determine the predictors of behaviour, standard multiple linear regression analysis
was performed. The selected variables in the regression analysis were the subscales
with significant correlations between knowledge and behaviour or attitude and
behaviour.
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Table 5.7 Spearman’s Correlation coefficients and significance tests for STI/BBV subscales
Knowledge STI/BBV

Knowledge STI/BBV
Asymptomatic
Epidemiology
Attitude STI/BBV
Barriers to History

Attitude STI/BBV

Asymptomatic

Epidemiology

-

0.25
-

Barrier to History

Behaviour STI/BBV
History Taking

Pre-test HIV

-0.02
0.03

-0.04
0.09

0.13
0.17

-0.12
-0.12

-

0.05

0.18

-0.01

Note: * Significance p < 0.05 level (1-tailed) Listwise N = 34

Table 5.8 Spearman’s Correlation coefficients and significance tests for HCV subscales
Knowledge HCV
Epidemiology
Knowledge HCV
Epidemiology
Referral
Management
Attitude HCV
Treating HCV Patients

-

Referral

0.22
-

Management

Post-test STI/BBV

Attitude HCV
Treating HCV Patients

0.36*
0.19
-

0.05
0.45**
0.00
-

Note: *Significance p< 0.05 level (1-tailed) ** p< 0.01 level (1-tailed) Listwise N = 35
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Behaviour HCV
Pre-test HCV Screening

-0.08
0.49*
0.18
0.06

Multiple linear regression analyses requires that the assumptions regarding
normality, linearity and homoscedasticity of the standardised residuals are met, that
there are not any multivariate outliers and that there is no multicollinearity. Thus,
prior to conducting multiple linear regression analyses, these assumptions of these
selected variables were evaluated (Allen & Bennett, 2008, pp. 182-191). Inspection
of the normal probability plot of standardised residuals as well as the scatterplot of
standardised residuals against standardised predicted values indicated that the
assumptions of normality, linearity and homoscedasticity of the standardised
residuals were met. Second Mahalonobis distance did not exceed the critical

2

for df

= 2 (at a = .001) of 13.82 for any cases in the data file, indicating that multivariate
outliers were not of concern. Third, relatively high tolerances for both predictors in
the regression model indicated that multicollinearity would not interfere with the
ability to interpret the outcome of the multiple regression analyses.

Thus, the significant correlations for the related domains of HCV subscales were
combined in a model to evaluate the hypothesis that the behaviour of doctors
working in psychiatry in SWAHS, can be predicted by their knowledge and attitudes.
Specifically the hypothesis that if doctors had good Knowledge of HCV Referral and
positive Attitudes toward Treating Patients with HCV, then this would predict their
Behaviours for HCV Pre-test discussion.

Table 5.9 provides the regression co-efficients for predicting behaviours. The
likelihood of reporting appropriate behaviour as part of HCV Pre-test Screening
discussions was the dependent variable, and Knowledge of HCV Referral and
Attitude toward Treating Patients with HCV, as the independent variables.
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Table 5.9 Summary of standard multiple regression variables predicting self
reported Behaviour of HCV Pre-test Screening (n = 35)

Variable

sr2

B

M

SD

Knowledge HCV Referral

.46

.72

.41**

7.8

1.41

Attitude Treating HCV Patients

-.46

-.34

.09*

4.0

.66

Note: * Significance p < 0.05 level (1-tailed) ** p < 0.01 level
B= Unstandardised regression co-efficient & = Standardised co-efficient
sr2= the square of the semi-partial correlation between predictor and criterion (provides variance)
M = mean, SD = standard deviation

Both Knowledge of HCV Referral and Attitude toward Treating HCV patients are
important predictors and accounted for 41% of the variability of Behaviour HCV
Pre-test Screening, R2 = .41 adjusted R2 = .37, F (2, 32) = 10.96, p < .0001.
Unstandardised (B) and Standardised ( ) Regression Co-efficients, and squared
semi-partial (or ‘part’) correlations (sr2) for each predictor in the regression model
are reported in Table 5.9.

The most important predictor for the Behaviour of HCV Pre-test Screening is
Knowledge of HCV Referral as this variable alone still provided 41% of the
variance, as depicted by the sr2 value. By Cohen’s (1988) convention, the combined
effect of this magnitude, proportion of variance for HCV Pre-test Screening
Behaviour that can be accounted for by the predictors of HCV Referral Knowledge
and HCV Treating Patients Attitude, can be considered “large” (f 2 = .69).

5.5 DISCUSSION

Study Two surveyed doctors working in psychiatry and caring for patients with SMI
regarding their STI and BBV related knowledge, attitudes and behaviours, with
emphasis on HCV. This second study does explain the low referral of patients to
Study One for assessment of risk factors and infection. Overall, psychiatrists caring
for patients with SMI do not frequently screen patients and subsequently do not
detect STI or BBV infections, despite the high levels of HCV. The doctors that
participated in Study Two were mostly older than 35 years, senior specialists and less
than a third reported being well informed regarding HCV. This small KAB study
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found that psychiatry doctors did relatively well in all domains when compared to
GPs, even though more GPs reported that they were well informed regarding HCV.

Doctors working in psychiatry are knowledgeable about HCV, more so than other
STIs and BBVs, with the exception of current HCV treatment options. Psychiatrists
have good attitudes regarding history taking and dealing with HCV patients, though
they are less in agreement regarding the central role psychiatry should have.
Psychiatrists reported appropriate behaviours more so for referral and management
of STI and BBVs and for Pre-test HIV screening, than HCV screening provision.
Some discrepancies included the overestimation of HCV disease progression, the
underestimation of HCV prevalence, the high reporting of IDU risk history
questioning but the poorest rating behaviour being for HCV Pre-test Screening.

A contentious item was the role of HCV heterosexual transmission. Current
knowledge recognises the role of sexual transmission for MSM, but in 1999 (Puplick
et al., 1999) and for most of the proceeding decade, HCV by sexual transmission was
very rare, even for MSM. Prevalence has only been prominent in the last few years
(Centers for Disease Control and Prevention, 2011a) and if doctors were up to date,
their knowledge would reflect that HCV was not routinely sexually transmitted.

Study Two identified that one of the key elements in providing care for patients with
SMI, are behaviours required for HCV assessment. These behaviours were predicted
by knowledge and attitudes. In particular, Knowledge of HCV referral, that all
groups with HCV should be referred and assessed for treatment, and positive
Attitudes towards treating HCV patients, predicted the Behaviour of Pre-test HCV
Screening for patients. The findings are consistent with the theory-driven approaches
to understanding and modifying clinicians’ behaviour (Casper, 2007; Perkins,
Jensen, Jaccard, Gollwitzer, Oettingen et al., 2007).
Key findings for this small study are that psychiatrists’ knowledge, attitudes and
behaviours are relatively “good”. HCV Pre-test Screening behaviours are predicted
by appropriate knowledge and attitudes and “newer” doctors to psychiatry reported,
“better” HCV knowledge and behaviours.
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5.6 OVERALL STRENGTHS AND LIMITATIONS
This study’s strengths include researching psychiatrists and researching their
knowledge, attitudes and behaviours regarding STIs and BBVs for patients with
SMI. One strength is use of validated previous research tools that help provide a
context for the psychiatrists’ knowledge, attitudes and behaviours. The finding that
knowledge, and attitude to a lesser extent, predicts behaviour with a large effect is
reassuring that the research is useful despite the suboptimal sample size. Conclusions
though are limited in their application because of the small number of study
participants.

Another study strength is that the participation rate in this study was good at 70% for
those offered the opportunity, which is comparable to the participation rates amongst
GP samples (Mulvey et al., 1997). Poor response rates of doctors to surveys is often
reported (Kellerman & Herold, 2001). Low attendance for medical education
programmes is also common, which had been the planned “draw card” for
recruitment into the study (Smith, Singleton, & Hilton, 1998). Attendance at the
scheduled weekly meeting had been relatively low at 52%, and had there been better
attendance; a higher number of study participants might have been recruited.

Study Two potentially suffered from selection bias because of the low number of
doctors attending the education meeting, and from that group 30% of attendees
choosing not to complete the questionnaire. Study Two may also have information
bias as doctors may have provided, “socially acceptable answers”, particularly to the
attitudinal and behaviour components of the survey (Adams, Soumerai, Lomas, &
Ross-Degnan, 1999; Bowling, 2005). Comparison of psychiatrists to other doctors
can result in selection bias as has been described by Berkson (Berkson, 1946), that
arises when there is an ascertainment bias inherent in a study design (Westreich,
2012).

Other limitations include the very low Cronbach alpha, of .32, for the Attitude
toward Treating HCV patients. This could be problematic for results of multiple
linear regression, though the dependent variable “Behaviour of HCV Pre-test
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Screening” had an excellent alpha value (.91). Cronbach alpha will be low and even
unstable with small sample size and few and varied variables, as occurred for this
study (Torabi, 1988). Review and deletion of the poorest performing item in the
attitude scale improved Cronbach alpha to 0.6. Results with re-analysis of linear
regression were almost identical, as the main contributor to Behaviour was
Knowledge (data not shown).

5.7 CONCLUSION
Preliminary data from this small study highlights the risk from underestimating STI
and BBV prevalence, particularly HCV. Good knowledge about the role IDU
activities play in HCV epidemiology and referral options for those who are HCV
positive, suggests that appropriate clinical behaviours are achievable even if doctors
working in psychiatry fail to recognize the magnitude and significance of HCV
exposure for patients with SMI. Improving knowledge of HCV disease progression
and management options may facilitate better health care for patients with severe
mental illness.
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CHAPTER 6

Discussion

6.1. INTRODUCTION

This discussion chapter integrates the findings across the two studies and links the
aims, hypotheses and background literature of the thesis. Specifically this section
evaluates why patients with SMI are at risk for STIs and BBVs. Considered are
emerging patterns with attempts to gauge the mechanisms, and implications, for this
risk. Several concepts at the individual, partner and community level may be
important to understand the elevated risk for patients with SMI, and will be discussed
under key headings.

6.2 INTEGRATION OF STUDIES’ AIMS, HYPOTHESES and FINDINGS
Study One’s findings identified that the level of risk for STIs and BBVs for
inpatients with SMI, in western Sydney, Australia is prominent. Elevated risk is
determined by; the rates of risk factors, rates STI and BBV infections and by
comparison of these rates with the Australian population.

Patients had a higher risk for risk factor histories, STI or BBV infection being
present and a higher likelihood for STI or BBV infection acquisition. It was seen that
they engage in a wider range of risk behaviours and do so more frequently, than the
general population. The prevalence of STIs and BBVs for patients with SMI was
higher than the general population. Consistent with risk factor correlation, is the
finding that patients with risk factor histories are at a higher risk for STI and BBV
acquisition compared to patients without risk factor histories. Specifically HCV
exposure was predictable if patients reported “IDU ever” or “incarceration ever” and
self-reported STIs were predicted by “marijuana use ever” or “sex ever with IDU risk
partner”.
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Patients with SMI compared to the Australian population with comparable risk factor
histories had a higher risk for STIs and BBVs even when risk factors were controlled
in the analysis. It seems that the nature of having an illness such as SMI, identifies
and places patients at risk for both risk behaviours and acquiring infection, even in
the absence of reported risk factors.

Both studies identified that this risk for patients is not well appreciated. From Study
One it was seen that patients did not recognise the extent of risk for themselves.
Patients underestimated the extent of acquired BBV infections when compared to
current biological sample results. Study Two identified that doctors had reasonable
knowledge and attitudes regarding STIs and BBVs compared to GPs but doctors
working in psychiatry did not fully recognise the risk for their patients, as some
behaviours, such as assessment practices for patients with SMI, were suboptimal,
particularly for HCV.

Study Two could identify the influences on behaviours to assess for risk regarding
HCV. The doctor characteristics that suggested appropriate behaviours included
younger or “newer” doctors reporting better HCV knowledge, whereas “well
informed” doctors reported better HCV assessment behaviours. Analysis with linear
regression, demonstrated that HCV referral knowledge and genial attitudes to HCV
patients predicted the self-reported behaviour practices of screening for HCV.

From these results, the patterns of individual risk activities, partner risk activities,
inappropriate healthcare, in the context of SMI, help explain the elevated risks for
patients.

6.3 UNDERSTANDING WHY PATIENTS WITH SMI ARE AT RISK

The work that has been part of this thesis; the literature review and the two studies,
undoubtedly finds that patients with SMI are at risk. The two studies have displayed
the heightened risk, as first defined in the Chapter Two, of being infected,
encountering an infected partner and acquiring infection if exposed. Though not
explicitly evaluated there probably is also a heightened risk of exhibiting disease if
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infected and transmitting disease to others, because of low testing and poor treatment
uptake. Some facets of risks for patients with SMI are considered.

6.3.1 Risks for Patients with SMI at the Individual Level

Many risk factors were elevated and contributed to the risk of STI and BBV
infections for patients with SMI. Patients had more risky sex, with high numbers of
partners, casual sex and elevated rates of sex work, or sex with sex workers. In this
section the risks of sexual behaviours, substance use(particularly IDU), incarceration
and healthcare are discussed and evaluated against other priority risk groups. Lastly,
the possible role of SMI is considered in the extent of risk for patients.

6.3.1.1 Elevated Risk associated with Risk Factors

Sexual Behaviours
Study One portrayed a picture of patients with SMI not having good sexual health.
Patients are sexually active, but less often have mutually exclusive, safe and
supportive sexual partners. Many risk behaviours were reported at higher levels than
the Australian population survey. Some sexual behaviours are compared to risk
groups such as prisoners and injecting drug cohorts to provide a context for risk.

A comparison with sexual risk behaviour reported by 1317 prisoners, who had a
modified ASHR telephone survey, showed many analogous findings (Richters et al.,
2008). Patients with SMI and prisoners had similar reports for sexuality and number
of partners ever. Differences were that male prisoners were more likely to report 2 or
more partners in the last 12 months and patients with SMI more frequently reported
sex with sex workers and casual partners at last sexual contact, though again patients
reported more condom use. Comparable sexual behaviours of persons with an IDU
history seem to be less frequently studied or published. A large report of 902
injecting drug users, had only one variable that could be compared, and found just
over 50% of injecting drug users reported being single (Stafford & Burns, 2011),
whereas many more patients with SMI were likely to be single (88%).
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Other similarities were that up to 20% of prisoners had a mental illness that had
resulted in hospitalisation, hinting that it may have been an SMI. Future evaluation of
behaviours for prisoners and injecting drug users with and without SMI will be
useful to elucidate the risk for those with SMI.

IDU History
As seen in Study One, patients with SMI have risks related to injecting behaviours
for HCV exposure. A problem for patients with SMI that inject is that the likelihood
of HCV exposure is greater than for injectors part of the general population. Though
HCV was predicted by “IDU ever”, or “incarceration ever”, which is in keeping with
the ASHR correlates (Grulich, de Visser et al., 2003c, p. 240), the patients with an
IDU history, at least part of this study, seem to be different to the Australian
population with IDU history. Patients with SMI were more likely to inject heroin and
methadone, though, use of other injecting drug substances or sharing of needles and
other paraphernalia were not different. Though not explored in this study it may be
that patients have been injecting drugs for longer and with heavier drug abuse
problems, based on higher heroin and methadone use that explains their higher HCV
prevalence and risk. Another complicating factor is that in the state of NSW,
Australia, persons that inject are more likely to inject heroin (Stafford & Burns,
2011). NSW prisoners are also more likely to inject heroin and more likely to be
HCV positive than prisoners from other states (Butler et al., 2007). Perhaps NSW
SMI patients may represent NSW IDU users, but not other Australian injectors.
Patients with SMI have at least similar or higher risks than others who inject drugs,
but review with injectors in NSW would be useful.

Incarceration History
An important finding is the high incarceration rate for patients with SMI and part of
Study One along with high IDU activities and the predicted HCV infection. The
incarceration rate of 30% was much higher than for the Australian general population
at 2% (Grulich, de Visser et al., 2003a), and approaching rates for African-American
male patients with SMI of 58% (Ramsay, Goulding, Broussard, Cristofaro, Abedi et
al., 2011) and of other IDU cohorts at 50% (Stafford & Burns, 2011). Further work
can elaborate this association and risk, but some groups have reported that patients
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with SMI are more likely to have repeat incarcerations that may play a role in
causation (Baillargeon et al., 2009; Ramsay et al., 2011). Research could explore the
duration of incarceration, reasons for imprisonment, risk activities whilst
incarcerated and how these behaviours differ from, others with SMI and not
incarcerated, or those incarcerated but without a SMI.

Healthcare
Access and provision of appropriate healthcare helps minimise risks from STIs and
BBVs. These studies have highlighted that patients may not be receiving the correct
healthcare to identify and manage STIs and BBVs, as assessment may be inaccurate
or lacking. The KAB survey of psychiatrists, examining STIs and BBVs, and in
particular HCV, isolated some of the issues that may account for the suboptimal STI
and BBV management, despite patients’ increased risk.

Non-comprehensive healthcare for this patient group may be because the lead
psychiatry doctors are older and have been working for longer in the speciality of
psychiatry. Statistically it was seen that overall knowledge was better for “newer”
doctors working in psychiatry; those who had worked for less than 10 years in
psychiatry and for those that did not have specialist qualifications. This may be
related to “newer doctors” having had more up-to-date training or a broader scope of
practice prior to psychiatry, keeping in mind that the science of HCV is a relatively
new body of knowledge. Other groups such as Mulvey et al (1997) found that
younger doctors also had better knowledge scores for STIs, probably for similar
reasons, with the “…undergraduate medical training in STDs having undergone
improvement in recent years…” (Mulvey et al., 1997, p. 537). Doctors that have
been working for longer in a senior psychiatry role may feel that it is not appropriate
for psychiatrists to consider other health problems, exemplified by doctors having the
most ambivalence regarding the attitude that psychiatry should have “a central role in
the treatment of HCV”.

In this research, doctors working in psychiatry underestimated the extent of the
problem of HCV exposure for patients with SMI that they were caring for in hospital.
Actual rates of HCV for all Cumberland Hospital patients are close to 20% of those
140

tested, whereas the doctors estimated 10% of their patients would have HCV. The
underestimated response rates regarding the extent of HCV exposure may carry
through to insufficient screening and management for their patients with SMI.

From this study an uncertain area, that may influence healthcare and requires
clarification, was sexual transmission of HCV. The role of sexual transmission was
unclear to as many psychiatrists part of Study Two, as well as French
specialists(Munoz Sastre et al., 2002), Pakistani students (Anjum et al., 2005) and
patients with SMI (Goldberg et al., 2009). HCV may be transmitted with HIV coinfection, or with sexual practices that involve exposure to blood (Wyld, Robertson,
Brettle, Mellor, Prescott et al., 1997). Transmission to MSM (especially with HIV)
via anal sex, or to MSM because of needle sharing occurs; but transmission by
heterosexual sex is extremely rare (Bresters, Mauser-Bunschoten, Reesink,
Roosendaal, van der Poel et al., 1993; Chiaramonte, Stroffolini, Lorenzoni, Minniti,
Conti et al., 1996; Lauer & Walker, 2001; MacDonald & Wodak, 2003). The second
most frequent assessment behaviour reported for history taking was asking about safe
sex (46%). Perhaps there is a mistaken belief that needs further exploring, that if
patients with SMI report safe sex, then they may not be at risk for HCV and not
screened.

The misconceptions regarding HCV may follow through with the inconsistencies
identified in this study. Though there were many areas of HCV knowledge in which
psychiatrists fared better than previously surveyed GPs (Dev & Sievert, 2002),
appropriate clinical behaviours for HCV were reported at lower frequencies by the
psychiatrists in this study. Knowledge and attitudes predicted HCV pre-test related
behaviours, indicating screening of patients, but the reported HCV pre-test screening
behaviours had the lowest subscale score of all behaviour domains. For example,
almost all psychiatrists (100%) knew IDU was a risk for HCV infection and almost
all (94%) reported the behaviour of asking about IDU. But only a third of
psychiatrists reported testing for HCV and about a third stated that they provided the
behaviours related to HCV screening, whereas two thirds provided HIV screening
behaviours. An explanation may be related to SWAHS requirements. Pre-test HIV
Screening is mandatory prior to HIV testing, whereas this does not apply for HCV
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testing. Cumberland testing revealed that few HIV tests were performed with only
4% of all patients had HIV testing. It seems that those few psychiatrists that assess
for HIV are correctly performing all the necessary behaviours related to HIV
assessment. A quarter of all patients had HCV testing but fewer patients received the
appropriate non-mandatory pre-test discussion. Therefore, there may be a small
subgroup of psychiatrists who perform well, but low scores for many others may
translate into low and incorrect estimates of HCV, sub-optimal subsequent screening
and management.

Suboptimal healthcare is apparent from many patients reporting previous HIV
screening (72%), but less assessment for other individual STIs or BBVs. Patients,
and psychiatrists, underreported rates of HCV. The underreporting may be because
patients do not recall their results or it may be that patients have not been tested. The
psychiatrists reported that they did not assess for STIs and BBVs, with only about a
third frequently assessing for HCV. Their declaration can be verified from the
information regarding testing of all Cumberland Hospital clients. As stated in the
above paragraph, the largest group of testing was for HCV and HBV, with about a
quarter tested, and only a small group was tested for other STIs.

Another component to consider for suboptimal healthcare is that screening patients
based on history alone is not sufficient. The prevalence of infections such as HCV, at
26% for all study participants, 5% prevalence for the whole Cumberland patient
population and at 9% for patients without an IDU risk history requires serious
consideration. The discrepancy may be because of lack of recognition, or inability to
report involvement with injecting drug risk activities, by patients with SMI. There is
a need for a broader approach to screening patients with SMI, at least for HCV.

6.3.1.2 Elevated Risk associated with STI and BBV Infections

Heightened STI and BBV risk is evident, with HCV infection more common for both
patients that did and for patients that did not report injecting drug use. The extent of
STI and BBV risk compared to other risk priority groups is presented.

142

HCV rates were elevated for patients with SMI with high rates for HCV at 26%
overall and 69% for those that reported IDU. This study’s findings are in keeping
with previous research. One other Australian group identified a 20% overall
prevalence for patients with SMI (Lacey et al., 2007). National surveillance data
quote a 50% HCV prevalence for injecting drug users (National Centre in HIV
Epidemiology and Clinical Research, 2010). HCV prevalence for patients with SMI
is more similar to prison samples, who have an HCV prevalence rate of 34% (Butler
et al., 2007).

Nearly half of patients with SMI provided self-reported STI histories. Two groups
researching patients with SMI (part of the Literature Review in Chapter 3),
correspondingly identified past STI rates at 40% (Coverdale & Turbott, 2000;
Klinkenberg et al., 2003). A more recent Australian survey reported 27% (Lacey et
al., 2007), while the Australian population had lower self-reported STI rates at 18%
(Grulich, de Visser et al., 2003c). Other more current surveys such as one of
Vietnamese men in Sydney had a lower rate of self-reported STIs (12%) (O'Connor,
Shaw, Wen, & Quine, 2009), whereas prisoners reported comparable or lower levels
of past individual STI diagnoses than patients with SMI (Richters et al., 2008). The
prisoner study had a similar older-age group but differed in other demographics, as
one fifth was indigenous. Prisoners self-reported less genital herpes (2.5%) than
patients (7.2%), and less genital warts (7.5%) compared to patients (16.7%). The
prisoners self-reported similar previous chlamydia but higher gonorrhoea rates than
patients, which may be related to the larger indigenous group. Studies that have
looked at STI rates in injecting drug users have provided comparable rates for past
STIs at 48% (Kuyper, Collins, Kerr, Hogg, Li et al., 2005). A Melbourne study of
314 young street-based injecting drug users had similar STI and BBV results, with
high HCV and HBV, but low HIV and gonorrhoea, and negative syphilis. As a young
group, there was a 9% chlamydia prevalence (Bradshaw, Pierce, Tabrizi, Fairley, &
Garland, 2005), in keeping with the level of self-reported previous chlamydia rate for
patients with SMI and reflecting that chlamydia is present in young cohorts.

The particular self-reported STIs of patients with SMI part of Study One were those
more often diagnosed in the general community such as chlamydia, genital herpes
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and warts. The infections of gonorrhoea and syphilis were not common for patients
with SMI. These infections are more prevalent in men-who-have-sex-with-men
(MSM) in Australia, as described in Chapter 2, and this was not a reported behaviour
for this study group. Western Sydney, being twenty kilometres from the “high
visibility of inner city gay territories” (Hodge, 1995, p. 41), has a much smaller
MSM community, and less likelihood of representation in surveys.

In Study One the prevalence of HBV was also very high. There was a bigger
discrepancy between self-reported HBV at 4%, and biological sample results with
prevalence at 16%, with nearly eighty percent unaware of previous HBV exposure.
Though HBV infection is less likely to cause long term health effects if infection was
acquired as an adult, it should be assessed. HBV is preventable for those negative,
may require medical treatment for those positive and is a marker of potential risk for
those previously exposed. HIV rates were not as elevated as found in the USA. HIV
at 2.5% for patients with SMI is still significantly higher than community levels and
warrants vigilance to prevent escalating epidemics.

Even though this patient group with SMI did not comprise of MSM or indigenous
persons, the recognised risk groups for STIs and BBVs in Australia, there was
significantly raised STI and BBV infection prevalence. High infection rates add to
the risk picture for patients with SMI.

6.3.1.3 Elevated Risk associated with SMI

A diagnosis of SMI, as well as creating mental health problems and prolonged
hospitalisations, affects cognition and socialisation for patients. It is postulated that a
diagnosis of SMI may play a role in the existence of risk for STIs and BBVs. An
SMI diagnosis is associated with a myriad of effects, such as poor social skills, poor
housing, and limited social networks outside of hospitals, that all contribute to risk. It
is possible that patients with SMI are not socially proficient and this may explain
why they engage in (risky) sex and drug use activities, since these activities provide
ways to interact with others without the need for elaborate social skills. This has been
seen for marijuana use and socialisation for patients with psychosis and possibly
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applies to other activities (Schofield, Tennant, Nash, Degenhardt, Cornish et al.,
2006). Ethnographic USA research has depicted SMI as a risk network and has
described different substance-use socialisation patterns, with importance for the
individual based on different levels of involvement (Alverson, Alverson, & Drake,
2000).

It also is possible that the nature of a mental illness precludes safe decision-making
and even recollection of risks. For example, patients with SMI have an excessive risk
for HCV and this risk may be because they engage in injecting activities when
psychiatrically unwell and less likely to have a recollection of risk activity or be able
to provide a reliable history. In light of Study One’s findings the above consequences
related to a diagnosis of severe mental illness, may explain why patients that do not
provide a risk history still have a higher prevalence of HCV exposure.

6.3.2 Risks for Patients with SMI at the Partner and Community Level
Patients’ risks are compounded by risk factors related to their partners and their
position in society. Patients with SMI are a group with a mixed risk profile of
injecting drug users, prisoners and possibly other undifferentiated risks. The role that
SMI may contribute to this risk network is explored.

6.3.2.1 SMI Risk Network

Patients with a diagnosis of SMI, report at the individual level unsafe sexual
behaviours, high rates of substance use (including IDU) and incarceration histories.
Patients continue with risk at the partner level. Their sexual contacts were others that
reported unsafe sexual, substance use, incarceration and others with a diagnosis of
SMI (and often met in hospital). This studied group can be defined as a “network”.
According to Klovdahl (1985), “…a network is a set of nodes connected together by
links of one kind or another.” In this network, the nodes are persons with SMI and
the links are sexual or substance related relationships, with risks for STIs or BBVs.
This thesis explores sexual links but it is possible that the same individuals are also
part of a substance use network, fitting in with previous work identifying networks
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often with dual risks, “risky needle-sharing and sex norms” (Latkin et al., 2010, p.
1159; Shev et al., 1995).

Patients with SMI differ from the general community and even from other injecting
drug users. They have an enhanced risk, possibly because of their SMI diagnosis.
SMI provides a frequent hospitalisation framework within an encircling theme of
unsafe risk factors, of substance use, incarceration, or sexual contact with someone
else that has these risk factors. As inpatients, this group experienced an average of
six hospital admissions, and based on prior reports (Jablensky, 1999) an estimated
average length of stay of 13 weeks., This suggests that meeting and socialising with
others whilst in hospital may happen regularly and for sufficient durations to allow
development of relationships. In hospital, there is probably mixing with other risk
partners not currently hospitalised, who are able to attain access as visitors, in the
open psychiatric ward conditions (Lelliott, 2006), and a mixing of similar persons as
sexual partners and probably as substance use partners. In this small SMI network,
there is similar “associative mixing” by SMI diagnosis but possibly “dissociative”
mixing by risk activities. A situation similar to the risks African Americans
encounter (Hallfors et al., 2007). This risk network had been first recognised by
Kalichman et al (1994). Their study also identified that the “…use of illicit drugs,
meeting sex partners in psychiatric clinics, and meeting partners in bars…”
accounted for risk (Kalichman et al., 1994, p. 221), which is the situation for patients
with SMI part of this study. This newly recognised risk network should be part of the
recognised priority groups for health care and health promotion, with respect to
preventing STI and BBV infections. Data from two population studies support
mental illness as a risk or risk marker for HIV, but have not examined other
infections such as HCV (Blank, Mandell, Aiken, & Hadley, 2002; Hoff, BeamGoulet, & Rosenheck, 1997). The important findings from Study One support that
severe mental illness is a risk marker, at least for HCV exposure.

Such an SMI risk network for this patient group seems to be a closed network as
none of the STI and BBV infections, identified from biological samples, were new or
recent infections, apart from one new chlamydia diagnosis, in a young person and
possible externally acquired. The reporting of common but past STIs may reflect that
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there was an enhanced risk for STIs, for patients with SMI, when younger. This
hospitalised patient group may not currently have contacts outside of this network
and be relatively protected. There can be a degree of safety with an established but
closed network because new infections may be less likely to be introduced.

6.3.2.2 SMI in the Community

Throughout this thesis, the devastating impact of SMI has been described for persons
affected. This thesis has identified some of the social isolation issues for patients
such as poor relationships and the available socialisation being risky sexual contacts
or drug sharing. The high rates of incarceration and sex work hint that SMI limits
effective and safe means of income and creates protracted episodes of
institutionalisation. This adds to the theory of the unique SMI network, as
socialisation is limited to hospitals, custodial settings and possibly street-based, as
many patients with SMI lack a known or fixed address.

6.3.2.3 Patient Healthcare Provider Networks

The health system available to patients with SMI affects their level of risk.
Discussion has occurred for the issues at an individual level for patients, such as lack
of accurate screening. Inappropriate healthcare is an issue at the community level as
health centres, testing policies and healthcare workers are all determined on a larger
scale. Patients with SMI spend a lot of time in hospital and may not access healthcare
elsewhere. Part of the psychiatry’s lead care role is to ensure broad healthcare is
available for patients.

6.4 CONCLUSION

Patients with SMI are at risk because of their risk behaviours and risk partners. They
constitute a risk network with unique characteristics. They are at risk is for unsafe
behaviours and infections. SMI risk networks are akin and cumulative to risks that
prisoners and injecting drug users experience, but perhaps risk is exaggerated
because of the presence of an SMI.
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CHAPTER SEVEN

Conclusions and Recommendations

7.1 IMPORTANCE OF FINDINGS
As noted in the first chapters of this thesis “…sexual health requires a positive and
respectful approach to sexuality and sexual relationships…” (WHO, 2002, p. 5) and
is facilitated by good mental health. Many patients because of poor mental health,
due to severe mental illness, do not enjoy “good” sexual health. The subsequent
adverse effects of severe mental illness on mental health and on sexual health,
contribute to risk for sexually transmitted and blood borne virus infections at many
levels.

The two studies of this thesis have endorsed the literature review findings that
patients with SMI are at risk for STIs and BBVs. Their risky behaviour is associated
with increased rates of infections, such as HCV. Contributing to the ongoing risk is a
lack of appreciation of the extent of risk by patients and by psychiatrists caring for
them. Traditional assessment methods based on history alone may not be sufficient
for patients with SMI, possibly because of their mental illness. The findings from this
thesis indicate that STI and BBV infections probably happen for patients in their
earlier years. Infections may occur with initial SMI diagnosis, and sexual and drug
use debuts, and this early period should be the focus points for preventative
healthcare.

Patients have higher rates of risk factors, STI and BBV prevalence and likelihood for
infection than the Australian population. For this study, some of the key priority
groups for STIs, such as MSM, were not reported as present, yet STI and BBV rates
were high. Risk was compared to studies of other key risk groups of prisoners and
injecting drug users. Patients with SMI closely resembled these two groups but some
risks, such as less stable relationships, seemed more prominent for patients,
indicating additional or differing paths of risk.
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This thesis’ research has discovered a new risk network , defined by linkage of
patients’ sexual, substance use, and incarceration risks with similar partners. A
diagnosis of SMI marks risk for this newly recognised network. This studied group
may be a closed SMI risk network, as new infections were mostly not identified, and
somewhat safe. For other, particularly younger SMI risk networks, priority health
care and more research is warranted. Both doctors caring for patients and
government public authorities must take on recommendations, such as education,
harm minimisation strategies, broader screening and healthcare programmes for this
risk network.

7.2 PUBLIC HEALTH IMPLICATIONS

Both STI and BBV infections and SMI are significant public health problems, as
they affect physical, psychological, social and economic well-being. These health
problems affect the whole community creating public health and economic issues,
such as high health and social costs, for example from loss of employment. Both
fulfil the criteria requiring public health action, in that they occur frequently and
widely, can cause severe disability and suffering and both have effective methods of
prevention or management with mostly acceptable therapies.

The public health costs are often not well recognised, as the sequelae of an STI or
BBV infection, such as liver disease, can be delayed and the threat to society lags
with postponement of the risk of disease. Public health measures, such as mandatory
screening, strain individual rights and as risk from STI or BBV infections are not
immediately apparent, infections are tolerated rather than managed (WHO, 1992).
Sexually transmitted diseases have been called the "hidden epidemic" because "their
scope and consequences are under-recognized by public and healthcare
professionals" (Workowksi, William, & Wasserheit, 2002, pp. E-255). The findings
from Study Two appear to support these concerns. HCV is a problem for patients
with SMI, and “…even where liver complications have not developed, the burden of
disease is high. Fatigue, depression and decreased quality of life are common...”
(Seccull, Richmond, Thomas, & Herrman, 2006, p. 374). Seccull et al (2006, p. 377)
advise that, “Hepatitis C is a major issue of concern for both people with mental
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illness and health professionals...A considered, systematic approach to testing,
counselling and referral needs to be taken by every mental health service”.

Overall the impact of STIs and BBVs, and in particular HCV, must be alleviated for
patients with SMI. Patients are burdened because of their psychiatric illness with
many problems. They, have “…poor diet...little exercise and... high rates of
smoking” (Peet, 2004, p. s102). As well antipsychotic medications can cause
increased food intake, all which can contribute to metabolic syndrome, and
subsequent risk for cardiovascular disease and diabetes. Patients may be burdened
with associated substance abuse problems (Dixon, 1999). Measures to prevent
further adverse outcomes from HCV, must be implemented. Recognition of the
personal health costs for a patient with SMI, as well as the costs to society, show
benefit in early recognition and consideration of prevention strategies (Seccull et al.,
2006).

The morbidity and costs of STIs and BBVs for patients with SMI may be estimated,
with HCV as an example. If two percent of the Australian population has a severe
mental illness and 5% at minimum have HCV infection, then potentially another
15,000 patients will develop chronic hepatitis and be at risk for liver failure or
malignancy. Direct and indirect costs of SMI and STI and BBV infections to patients
and society are already significant without factoring further costs from HCV.
Projection of the extent of the combined problems of SMI and STI and BBV
infections would show an even grimmer situation. Australian estimates for HCV cost
in 1996/97 were $107.5 million (Lowe & Cotton, 1999). It has been estimated that
prevention of a single HCV case may save at least $6000 as direct costs (Shiell &
Law, 2001) and savings of much more with respect to indirect costs. Mental health
disorders, as lifelong problems for an individual and society, create the some of the
biggest costs in Australia. Schizophrenia has been assessed to be $1.85 billion, in
2001, costing nearly $50,000 per annum on average for each of more than 37,000
Australians with the illness (Carr, Hocking, Jablesnky, James, Leggatt et al., 2002;
Smark, 2006). Efforts to minimise unfavourable health outcomes for patients with
SMI, with removal of the hazards from preventable infections, such as HCV, is
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crucial. Elimination of problems from preventable infections promotes maintenance
of good health and savings of health dollars.

Another concern and public health impact for patients with SMI, as a unique risk
network with riskier behaviours, is the consequences of an infection such as HIV has
the potential to spread easily amongst network members. The extent of HIV infection
for many African patients with SMI is significant as risk is additive to the endemic
HIV levels (Collins, Berkmana, Mestryd, & Pillaia, 2009) The USA has higher STI
levels, such as HIV, gonorrhoea and syphilis, in general and for patients with SMI. It
would be expected that if a similar situation occurred in Australia and HIV infection
was introduced to this SMI network, the spread would be facilitated because of the
network and prevalent HCV infection (Polis et al., 2007; Renton et al., 1998).
Australia’s harm minimisation policy, with Needle and Syringe Programs and
substance abuse management, such as methadone prescribing, have prevented HIV
spread in IDU communities (Commonwealth Department of Health and Ageing,
2002). An understanding of the biological factor differences and interactions of STIs
and BBVs has allowed successful strategies to be in place when HIV was a new
infection and not yet introduced into IDU communities. HCV, a more efficient blood
borne viral infection regarding transmission, has been well established in IDU
communities for many decades, and is not as well controlled by Needle and Syringe
Programmes (NSP) strategies as is HIV (Commonwealth Department of Health and
Ageing, 2002). The USA did not adopt such measures and has a significant problem
with high HIV and HCV rates for IDU groups, including those with SMI (Rosenberg
et al., 2001). The USA was slow to realize the extent of HIV and HCV risk to
communities with IDU and is only now recognizing the additional risk for the
network of patients with SMI. Patients with SMI that inject drugs should
theoretically benefit from harm minimisation programmes. The elements of severe
mental illness though that create HCV risk without recognition or recollection of risk
activity, suggest that harm minimisation programmes may be less protective for this
unique risky IDU group with SMI and require tailoring.
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There has to be a consideration of the detriments as well as benefits of detecting STI
or BBV infections. An additional STI or BBV diagnosis has the potential to add to
the stigma and health burden for patients with SMI. HIV infection, substance abuse
and mental illness have already been labelled as the “triple diagnosis” (Douaihy, Jou,
Gorske, & Salloum, 2003) and pose a major challenge at both a clinical and public
health level. There will be some patients with four major health problems that need
attention - HIV care, drug and alcohol services, HCV hepatology services as well as
psychiatric services (Douaihy et al., 2003). It could be argued that the benefits of
better screening for these patients would clearly outweigh potential stigma concerns.
However in Australia and in other parts of the world, the risks, costs and benefits of
routine screening of all patients with severe mental illness have yet to be fully
investigated or debated.

Prevention of additional health burdens for patients with SMI requires a medical and
public health model. Ideally, a psychosocial component of improving patients’
lifestyles, with housing, jobs and enhanced social situations should be incorporated
to attain the best sexual and mental health.

7.3 RECOMMENDATIONS

Recommendations start off with key healthcare programme providers acknowledging
that patients are a unique SMI risk network. Patients with SMI need to be recognised
as a priority group with programmes and resources allocated accordingly.

Then, a comprehensive approach should be considered for patients with SMI,
incorporating clinical and public health measures, such as care for STIs and BBVs,
as well as addressing substance abuse and psychiatric illness requirements of their
patients (Rosenberg, Goldberg, Dixon, Wolford, Slade et al., 2010; Walkup,
Santriano, Barry, Sadler, & Cournos, 2002). Mental health policies need to include
and address the problem of risk networks, risk behaviours and resulting infections.
Recognising and understanding the different substance-use socialisation patterns and
the significance that this socialisation has in patient’s lives is important if healthcare
workers are to effectively support patients sobriety (Alverson et al., 2000).
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Strategies to minimise the number of new infections must use a combination of
approaches at primary preventative level, at a secondary level of detection and
treatment and a tertiary level to minimise morbidity and mortality. Expanded
Response Programmes (Stover, Walker, Garnett, Salomon, Stanecki et al., 2002), or
STIRR (Screening for HIV and HCV risk factors, Testing for HIV and hepatitis,
Immunization against hepatitis A and B, Risk reduction counselling, and
medical treatment Referral) (Rosenberg et al., 2010) may be useful models. These
programmes simultaneously address problems at a clinical, public health, political
and social level to alleviate the impact of HIV.

The New South Wales capacity-building framework to improve health (NSW Health,
2001) provides a useful model of the complex system changes that are needed for
effective change. There are five areas that need to be considered in order to
ensure that evidence from research can be effectively translated into action and can
be sustained. These five areas, are: workforce, development, organisational
development, resource allocation, partnerships and leadership. NSW Health
advocates for incorporation and sustainment “...of effective health promotion
programs into the routine work of services from across the whole health care
continuum…”(NSW Health, 2001, p. ii)
7.3.1 Primary Prevention – Education and Harm Minimisation

Primary prevention includes education to patients and healthcare workers as well as
harm minimisation such as Needle and Syringe Programmes and condom
availability. Patients would benefit with specific education and skill attainment.
Learning the risk of infection and means of minimising risk behaviours may prevent
new infections. Studies have shown that patients have sub-optimal knowledge, such
as with HIV transmission, with many reporting risk behaviours but not believing that
they are at risk (Davidson et al., 2001; Kalichman et al., 1994). Other studies from
the USA, show that patients have better HIV information than HCV (Goldberg et al.,
2009). Education programmes are new and still being evaluated regarding the most
effective means of delivery to achieve safer behaviours (Rosenberg et al., 2010). All
healthcare workers caring for patients with SMI require education regarding the
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clinical, epidemiological and psychosocial consequences of STIs and BBVs. With
good knowledge, and positive attitudes we can see that healthcare workers can
integrate STI and BBV prevention activities into routine care for patients, as
established in Study Two. This concept has been evaluated with others finding that
psychiatrists (Casper, 2007) and patients (Lacey et al., 2007) report better selfpredicted behaviours after appropriate education. Some previous studies have already
shown that patients with SMI receive lower levels of care for preventative and early
health interventions (Carney, Allen, & Doebbeling, 2002). Patients who were part of
our study, reported HBV and HAV vaccinations at rates similar to the Australian
population, indicating that preventative measures are happening, but can be
improved.

Ideally, a replication of the service provided by some clinical settings that
incorporates education and an opportunity for “appropriate” socialisation could be
considered. An example is the invitingly named “Coffee and Condoms” programme
in the USA (Woolf & Jackson, 1996). The programme consists of gender-specific
and mixed groups, a drop-in service and condom provision. The aim is to provide
knowledge and skills for safe-sex, HIV/AIDS and other STIs, including assertiveness
and condom use, for patients with SMI.

7.3.2 Secondary Prevention - Improved Patient Clinical Care

Improved clinical care may consist of comprehensive programmes for patients with
SMI, or be at the basic level of screening for infections. Screening is one of the most
important components of sexual health clinical care. The studies that are part of the
literature review in Chapter 3 indicated that screening and testing should be for those
with a risk history only, as is the practice for the general population. A contentious
issue is whether screening should be based on a risk assessment history, or should
involve biological specimen assessment for all patients. Findings from Study One, of
high HCV and high HBV rates, would suggest the need for screening with biological
specimens, for all patients with SMI. The Centers for Disease Control (CDC)
recommendation of population screening (for HIV), once the prevalence surpasses
1% (Bozette, 2005), needs serious consideration for the prevalent infections. In fact
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the most recent guidelines advocate for universal HIV testing in health care settings
(Centers for Disease Control and Prevention, Branson, Handsfield, Lampe, Janssen
et al., 2006), though most professionals advocate for improved voluntary testing
rather than mandatory testing (Walkup et al., 2002).

The CDC also advocates for prevention of HIV transmission related to HCV and
STIs (Renton et al., 1998; Workowksi et al., 2002). Reduced transmission of other
STIs and BBVs, and thus HIV, is achievable by a broad screening approach, adding
to the benefits of screening.

Education is also helpful for secondary prevention methods. Lacey et al (2007) found
that the background HCV testing level of 9% improved to 18% with the advent of
HCV education provided to patients. There is a potential for similar improvements at
Cumberland Hospital regarding HCV detection and management with similar
interventions.

7.3.3 Tertiary Prevention - Integrated Clinical Care Services

For many current patients prevention of infection, such as HCV, may be too late, but
optimising health despite chronic illnesses can be achieved. It has been noted that,
“Integration of services and co-management for mental health, substance use,
primary medical care and hepatology/ID treatment will become the standard of care
for ..populations (with SMI)...” (Freedman & Nathanson, 2009, p. 372). Freedman
and Nathanson even add that the above problems need to be co-managed with all the
other health issues for patients with SMI, such as diabetes and obesity that lead to
other metabolic disorders. The authors clearly argue that there should be a focus on
integrated services.

As already mentioned some psychiatric care settings have started, as already
mentioned, comprehensive sexual health programmes. An example is the STIRR
model (screening, testing, immunisation, risk reduction and referral) that reported
increased screening, vaccination and reduced alcohol abuse. Risky sex and needle
sharing did not improve but the researchers considered that patients with SMI
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benefited (Rosenberg et al., 2010). HIV risk reduction programmes have been
evaluated for cost-effectiveness. Programmes tailored to patients with SMI are more
resource intensive and more costly but can still be cost-effective (Pinkerton,
Johnson-Masotti, Otto-Salaj, Stevenson, & Hoffmann, 2001). The STIRR researchers
still felt that their intervention was “ …efficacious in providing a basic, best-practice
package of interventions for clients with co-occurring disorders” (Rosenberg et al.,
2010, p. 885). The results of this thesis lead to the recommendation that patients have
access to comprehensive healthcare programmes for sexual, physical and psychiatric
well-being.

HCV prevention and management will be key attention areas for patients with SMI
and should be integrated with general psychiatry care. Although there have not been
any descriptions of unique HCV risk-reduction strategies and cost benefit analysis
for patients with SMI, it may be that we can extrapolate from reviews of HCV
prevention in injecting drug users generally. HCV prevention strategies are multifaceted and focus on IDU activities as well as therapies for substance abuse
(Freedman & Nathanson, 2009). Transmission can be reduced by (i) preventing
uptake of any IDU activities, (ii) shortening IDU duration of use, (iii) vaccinations
against other hepatitis viruses, (iv) encouragement of NSP services, needle cleansing
with provision of bleach (v) referral for treatment such as methadone maintenance.
Prevention services would potentially provide the greatest benefit if they were
focused on younger persons or newer persons commencing IDU activities and for
those at risk of relapse, but not yet HCV infected.

There has been the successful development of other integrated services such as dual
diagnosis management of substance abuse and SMI, by psychiatrists. In the US triple
disease management with the inclusion of HIV has been developed (Douaihy et al.,
2003). So far most work, particularly for HCV therapy, has been limited to those
with severe depression and not illnesses such as schizophrenia (Freedman &
Nathanson, 2009). In Australia (Matthews, 2012), and in the USA (Mistler, Brunette,
Marsh, Vidaver, Luckoor et al., 2006; Mistler, Brunette, Rosenberg, Vidaver,
Luckoor et al., 2006), there have been patients with stable schizophrenia that have
been able to successfully complete HCV therapy. In the next few years HCV therapy
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will have interferon-free combinations of direct-acting antiviral regimens (Dore,
2012). The new regimes have enhanced tolerability, simplified dosing schedules and
monitoring protocols, which will make them an attractive option for patients with
SMI (Dore, 2012) and open up more options for integrated and holistic care for
patients with SMI.

7.4 FUTURE RESEARCH

Larger and more representative studies are needed to replicate the findings from
Study One and Study Two, This will increase generalisability and minimise potential
selection bias, as has been found from other studies of hospital patients (Berkson,
1946). Study One part of this thesis has provided a snapshot of risk for patients that
needs to be elaborated and Study Two has implied that appropriate clinician
behaviours are achievable. The problem of STI and BBV risks requires more
research to provide further insight into the direction and nature of associations in the
population of individuals with SMI. Future research should consider larger projects
across other health care settings and take into account research issues that limited the
current research of this thesis.

Research such as a prospective observational study of a young cohort, newly
diagnosed with SMI at inpatient and outpatient community health services, would be
ideal. Regular review of sexual, substance use, cognitive, psychiatric effects and the
associated life circumstance changes related to SMI should be observed. Future
research needs to be conducted in younger age groups because STI and BBV
epidemiology identifies that young persons are most at risk for all infections because
of new sexual and drug use activity. This study hints that the bulk of risk has already
happened for patients, probably when younger, as the initial years of an SMI
diagnosis may be the most chaotic.

The observational study could review doctors’ assessment behaviours, in line with
patients’ needs. Research that measures doctors’ behaviours before and after
education may help identify the most effective educational methods.
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One of the major implications for future research relates to the problem of sampling.
Ideally, incorporation of screening by all healthcare workers in psychiatry will allow
a better evaluation of the extent of the problem in similar future research projects.
Another measure to improve the sample is for patients to be enrolled directly for
inclusion in projects and best done with patient education and involvement.

Future research could consider a socio-metric or whole network study approach,
enrolling all members of the network and defining interrelationships and
transmission risk. Such an approach, though difficult would describe the risks for
patients with SMI, in this unique risk group, at risk as a substance and sexual
network. Network analysis of injecting behaviour exploring sources of drugs,
situations of drug use including drug-sharing partners would in particular provide
valuable knowledge for planned health programmes. Studies should review IDU
activity, such as frequency of injecting, duration of injecting, and drug preferences. If
possible deciphering the mix of drug and sexual partners would be very insightful.
Further information would help define if the risk of HCV is exacerbated because of
SMI.

Future work must incorporate education for patients, staff and the community of
heightened risk. Education will provide a useful tool for patients with knowledge of
the risk for themselves and their contacts, and a means of minimising risk of harm
(Woolf & Jackson, 1996).

7.5 CONCLUSION

Patients, part of this research, are a SMI risk network with mixed sexual, substance
and incarceration risks for themselves and their partners. Priority healthcare
programmes, are needed, as well as more research that is on a larger scale, in
community settings, with young people and with an emphasis on substance use
behaviours.

For now, programmes that implement prevention and detection as well as specialist
referral and integrated care, at least for HCV therapy, may lessen the health burden
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(Cohn & Sernyak, 2006b; Seccull et al., 2006). Vigilance is needed to recognise and
contain any new STI or BBV threats to this vulnerable population of patients with
SMI.

Psychiatrists can and should play an integral role. What has been described as,
“psychiatry’s unique emphasis on a therapeutic alliance based in a comprehensive
view of the patient” (Price & Goyette, 2003, p. 262) provides a strong starting point
for assessing both psychological and physical health including STIs, BBVs and
especially HCV.
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